
<html lang="en"     class="pb-page"  data-request-id="7df42205-30d9-4657-a0e8-0ab288a3cd80"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.8b01597;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-8"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies" /></meta><meta name="dc.Creator" content="Xuewu  Liang" /></meta><meta name="dc.Creator" content="Jie  Zang" /></meta><meta name="dc.Creator" content="Xiaoyang  Li" /></meta><meta name="dc.Creator" content="Shuai  Tang" /></meta><meta name="dc.Creator" content="Min  Huang" /></meta><meta name="dc.Creator" content="Meiyu  Geng" /></meta><meta name="dc.Creator" content="C. James  Chou" /></meta><meta name="dc.Creator" content="Chunpu  Li" /></meta><meta name="dc.Creator" content="Yichun  Cao" /></meta><meta name="dc.Creator" content="Wenfang  Xu" /></meta><meta name="dc.Creator" content="Hong  Liu" /></meta><meta name="dc.Creator" content="Yingjie  Zhang" /></meta><meta name="dc.Description" content="Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC ..." /></meta><meta name="Description" content="Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 22, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01597" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01597" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01597" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01597" /></link>
        
    
    

<title>Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01597" /></meta><meta property="og:title" content="Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0014.jpeg" /></meta><meta property="og:description" content="Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors. Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivatives as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which 8m possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concentration at the nanomolar level. 8m exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematological cell lines. Remarkably, 8m exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2V617F mutation. Pharmacokinetic studies in mice showed that 8m possessed good bioavailability after intraperitoneal administration. Finally, 8m showed antitumor efficacy with no significant toxicity in a HEL xenograft model. Collectively, the results confirm the therapeutic potential of JAK and HDAC dual inhibitors in hematological malignancies and provide valuable leads for further structural optimization and antitumor mechanism study." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01597"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01597">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01597&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01597&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01597&amp;href=/doi/10.1021/acs.jmedchem.8b01597" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3898-3923</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01288" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01827" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xuewu Liang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuewu Liang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Jiânan, Shandong 250012, P. R. China</div><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuewu++Liang">Xuewu Liang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jie Zang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jie Zang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Jiânan, Shandong 250012, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jie++Zang">Jie Zang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Xiaoyang Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoyang Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina 29425, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyang++Li">Xiaoyang Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3684-2106" title="Orcid link">http://orcid.org/0000-0003-3684-2106</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Shuai Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuai Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuai++Tang">Shuai Tang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Min Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Min Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Min++Huang">Min Huang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Meiyu Geng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Meiyu Geng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Meiyu++Geng">Meiyu Geng</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">C. James Chou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">C. James Chou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina 29425, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=C.+James++Chou">C. James Chou</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6808-9089" title="Orcid link">http://orcid.org/0000-0001-6808-9089</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Chunpu Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chunpu Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chunpu++Li">Chunpu Li</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yichun Cao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yichun Cao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Fudan University, 826 Zhanghen Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yichun++Cao">Yichun Cao</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Wenfang Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenfang Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Jiânan, Shandong 250012, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenfang++Xu">Wenfang Xu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Hong Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#2d454144586d404c4441035e454e434e034c4e034e43"><span class="__cf_email__" data-cfemail="791115100c3914181015570a111a171a57181a571a17">[emailÂ protected]</span></a>. Tel: +86 21 50807042 (H.L.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Liu">Hong Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0863-7853" title="Orcid link">http://orcid.org/0000-0002-0863-7853</a></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Yingjie Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingjie Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Jiânan, Shandong 250012, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#344e5c555a534d5d5a535e5d51744750411a5150411a575a"><span class="__cf_email__" data-cfemail="9ae0f2fbf4fde3f3f4fdf0f3ffdae9feefb4fffeefb4f9f4">[emailÂ protected]</span></a>. Tel: +86 531 88382009 (Y.Z.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingjie++Zhang">Yingjie Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6118-6695" title="Orcid link">http://orcid.org/0000-0001-6118-6695</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01597&amp;href=/doi/10.1021%2Facs.jmedchem.8b01597" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3898â3923</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 22, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 October 2018</li><li><span class="item_label"><b>Published</b> online</span>22 March 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 April 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01597" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01597</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3898%26pageCount%3D26%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXuewu%2BLiang%252C%2BJie%2BZang%252C%2BXiaoyang%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D8%26contentID%3Dacs.jmedchem.8b01597%26title%3DDiscovery%2Bof%2BNovel%2BJanus%2BKinase%2B%2528JAK%2529%2Band%2BHistone%2BDeacetylase%2B%2528HDAC%2529%2BDual%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BHematological%2BMalignancies%26numPages%3D26%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3923%26publicationDate%3DApril%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01597"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4629</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01597" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xuewu&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Jie&quot;,&quot;last_name&quot;:&quot;Zang&quot;},{&quot;first_name&quot;:&quot;Xiaoyang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Shuai&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Meiyu&quot;,&quot;last_name&quot;:&quot;Geng&quot;},{&quot;first_name&quot;:&quot;C.&quot;,&quot;last_name&quot;:&quot;James Chou&quot;},{&quot;first_name&quot;:&quot;Chunpu&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yichun&quot;,&quot;last_name&quot;:&quot;Cao&quot;},{&quot;first_name&quot;:&quot;Wenfang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yingjie&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;3898-3923&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01597&quot;},&quot;abstract&quot;:&quot;Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors. Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivatives as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which 8m possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concentration at the nanomolar level. 8m exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematological cell lines. Remarkably, 8m exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2V617F mutation. Pharmacokinetic studies in mice showed that 8m possessed good bioavailability after intraperitoneal administration. Finally, 8m showed antitumor efficacy with no significant toxicity in a HEL xenograft model. Col&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01597&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01597" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01597&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01597" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01597&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01597" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01597&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01597&amp;href=/doi/10.1021/acs.jmedchem.8b01597" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01597" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01597" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (15 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01597%26sid%3Dliteratum%253Aachs%26pmid%3D30901208%26genre%3Darticle%26aulast%3DLiang%26date%3D2019%26atitle%3DDiscovery%2Bof%2BNovel%2BJanus%2BKinase%2B%2528JAK%2529%2Band%2BHistone%2BDeacetylase%2B%2528HDAC%2529%2BDual%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BHematological%2BMalignancies%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D8%26spage%3D3898%26epage%3D3923%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292580" title="Binding modes">Binding modes</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/jmcmar.2019.62.issue-8/20190425/jmcmar.2019.62.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors. Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivatives as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which <b>8m</b> possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concentration at the nanomolar level. <b>8m</b> exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematological cell lines. Remarkably, <b>8m</b> exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2<sup>V617F</sup> mutation. Pharmacokinetic studies in mice showed that <b>8m</b> possessed good bioavailability after intraperitoneal administration. Finally, <b>8m</b> showed antitumor efficacy with no significant toxicity in a HEL xenograft model. Collectively, the results confirm the therapeutic potential of JAK and HDAC dual inhibitors in hematological malignancies and provide valuable leads for further structural optimization and antitumor mechanism study.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85716" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85716" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Histone deacetylase (HDAC) inhibitors are widely applied in the treatment of various cancers.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1â3)</a> However, recent research showed that HDAC inhibitors promoted BRD4-mediated activation of leukemia inhibitory factor receptor, which in turn activated Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling and restrained the efficacy of HDAC inhibitors in some solid tumors. Concurrent inhibition of JAK or BRD4 sensitized some solid tumors to HDAC inhibitors.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In addition, a recent study also found that the resistance to HDAC inhibitors in lymphoma cell lines and cutaneous T-cell lymphoma (CTCL) patients was associated with the persistent activation of STATs, a key module in the JAK-STAT signaling pathway.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Therefore, the development of JAK and HDAC dual inhibitors is of great value and significance in the treatment of cancers.</div><div class="NLM_p">Janus kinases (JAKs), a family of intracellular nonreceptor tyrosine kinases consisting of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), are critical in transducing cytokine-mediated signals via the JAK-signal transducer and activator of transcription (STAT) pathway and are implicated in the pathogenesis of various hematological malignancies and autoimmune diseases.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> The discovery of the activating V617F mutation in JAK2 in the majority of patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs),<a onclick="showRef(event, 'ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11">(8â11)</a> including myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia, provided a strong impetus for the development of JAK2 inhibitors, culminating in the U.S. Food and Drug Administration (FDA) approval of the JAK1/2 inhibitor ruxolitinib (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) for patients with MF or PV.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Despite the success of ruxolitinib in ameliorating MPN-related symptoms, the ability of JAK inhibitors to reduce neoplastic allele burden in MPN patients seems limited, and resistance/persistence upon chronic drug exposure has been seen.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref17 ref18 ref19">(13â19)</a> It has been revealed that JAK2 inhibitor persistence is associated with overexpression of JAK2 and heterodimerization between JAK2 and JAK1 or TYK2.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Encouragingly, many preclinical research studies indicated that histone deacetylase (HDAC) inhibitors could strongly inhibit the growth of tumor cells bearing the JAK2<sup>V617F</sup> mutation through downregulation of the JAK2<sup>V617F</sup> protein level and depletion of its downstream signaling.<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20â22)</a> Therefore, it is reasonable to believe that the combination of JAK and HDAC inhibitors holds the promise of improving therapeutic efficacy and circumventing drug resistance/persistence in MPN patients.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13â15)</a> Preliminary results from a phase Ib trial of JAK inhibitor ruxolitinib and HDAC inhibitor panobinostat (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) in patients with MF have been published in the abstract form, which showed that the combination therapy was well tolerated and resulted in reductions in JAK2<sup>V617F</sup> allele burden and improvements in bone marrow fibrosis in some patients.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In addition, there are three active clinical trials of ruxolitinib in combination with HDAC inhibitors for MPN patients (NCT01433445, NCT01693601, NCT02267278).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the approved JAK inhibitor and HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">HDACs are a family of important epigenetic targets for the treatment of cancer, inflammation, neurological disorders, and infections.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> To date, four HDAC inhibitors, vorinostat (<b>3</b>, SAHA), romidepsin (<b>4</b>, FK228), belinostat (<b>5</b>, PXD101), and panobinostat (<b>2</b>, LBH589), have been approved by the U.S. Food and Drug Administration, and one HDAC inhibitor chidamide (<b>6</b>, CS005) was approved by the China Food and Drug Administration for the therapy of hematologic malignancies (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> To be specific, SAHA is for the treatment of CTCL, FK228 for the treatment of CTCL and peripheral T-cell lymphoma (PTCL), PXD101 and CS005 for the treatment of PTCL, and LBH589 for the treatment of multiple myeloma. It has been revealed that constitutive activation of STAT is involved in resistance to SAHA across a variety of lymphoma cell lines, including CTCL.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Combination of SAHA with a pan-inhibitor of JAK, the upstream activator of STAT, resulted in synergistic growth inhibition in SAHA-resistant CTCL cell lines. These results seem to be of clinical relevance because high levels of phosphorylated STAT3 (p-STAT3) and nuclear localization of STAT1 in skin biopsies obtained from CTCL patients correlate with a lack of clinical response to SAHA.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p last">Based on this information, rational combination therapy with JAK and HDAC inhibitors is a potential therapeutic strategy for not only MPN but also CTCL and even other intractable hematological malignancies. However, the employment of drug combination is often concomitant with poor patient compliance, unpredictable pharmacokinetic (PK) profile, and drugâdrug interactions.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28â30)</a> An alternative strategy to circumvent these drawbacks is the development of JAK and HDAC dual inhibitors. Herein, we report the design, synthesis, activity, and pharmacokinetic evaluation of pyrimidin-2-amino-pyrazol hydroxamate derivatives as JAK and HDAC dual inhibitors, which were derived from our previously reported 4-amino-(1<i>H</i>)-pyrazole-based JAK inhibitor.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In comparison to the approved HDAC inhibitor SAHA and JAK inhibitor ruxolitinib, most of the compounds exhibited superior antiproliferative activities in several hematological cell lines due to their potent and balanced activities against both JAKs and HDACs. In the JAK2<sup>V617F</sup>-mutated erythroleukemia cell line HEL and the JAK2 wild-type chronic myeloid leukemia cell line K562, combination of SAHA and ruxolitinib exhibited synergistic and additive effects, respectively. Strikingly, our dual inhibitors were significantly more potent than the drug combination.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Rational Design of Novel JAK and HDAC Dual Inhibitors</h3><div class="NLM_p">Most HDAC inhibitors fit a common pharmacophore, which is mainly composed of a zinc binding group (ZBG) that chelates the catalytic zinc ion located at the bottom of the HDAC active site, a surface recognition cap (SRC) that interacts with the amino acid residues around the entrance of the active site, and a linker that connects the ZBG with SRC (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Generally, potent HDAC inhibitors can be obtained through tethering a ZBG, such as hydroxamic acid, to various aromatic SRCs via a linker of five to seven carbons, like the approved HDAC inhibitor SAHA (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). The JAK adenosine 5â²-triphosphate (ATP) active pocket contains a hinge region and a p-loop. Most JAK inhibitors possess specific functional groups, which could form strong hydrogen bonds with the JAK hinge region, like the approved JAK inhibitor ruxolitinib (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). In our previous research, a potent 4-amino-(1<i>H</i>)-pyrazole-based JAK inhibitor <b>7</b> with notable antiproliferative potency was identified.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Structural analysis indicated that the alkyl hydroxamate of SAHA could be readily tethered to compound <b>7</b> via the alkylation of the N1 atom of pyrazole, leading to a potential JAK and HDAC dual inhibitor <b>8a</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). It is worth noting that during the preparation of our work, a series of ruxolitinib-based JAK and HDAC dual inhibitors designed by a similar strategy was reported, among which compound <b>9</b> exhibited potent in vitro antiproliferative activities against a range of hematological cell lines.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Before synthesis, the proposed binding modes of compound <b>8a</b> in the active sites of HDAC2 and JAK2 were analyzed using a molecular docking study. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C shows the binding mode of <b>8a</b> in the active site of HDAC2, which displayed the classical binding mode of hydroxamate-based HDAC inhibitors: the hydroxamic acid groups chelate the Zn<sup>2+</sup> in a bidentate manner and form multiple hydrogen bonds, the aliphatic chains occupy the hydrophobic channel, and the terminal cap groups interact with the amino acid residues at the entrance of the active site. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D shows the binding mode of <b>8a</b> in the ATP pocket of JAK2. Compound <b>8a</b> formed dual hydrogen bonds between its aminopyrimidine moiety and the Leu932 residue. The phenyl group of <b>8a</b> occupied the same hydrophobic pocket of JAK2 with the pyrrole ring of compound <b>1</b>. It is worth noting that the alkyl hydroxamate part of <b>8a</b> was projected toward the solvent region, minimally interfering the binding between <b>8a</b> and JAK2. The above docking results strongly supported the chemical synthesis and biological evaluation of <b>8a</b> and its analogues as JAK and HDAC dual inhibitors.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of JAK and HDAC dual inhibitors based on the HDAC inhibitor pharmacophore. The three parts of the HDAC inhibitor pharmacophore are indicated in three colors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Binding mode of SAHA (<b>3</b>) in the active site of HDAC2 (Protein Data Bank (PDB) code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IWG">5IWG</a>). The hydroxamic acid group of SAHA chelates the Zn<sup>2+</sup> in a bidentate manner and forms multiple hydrogen bonds with the Tyr308 residue and the His145 residue. The aliphatic chain occupies the hydrophobic channel, and the phenylamino group interacts with the Asp104 residue at the entrance of the active site. (B) Binding mode of ruxolitinib (<b>1</b>) in the active site of JAK2 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). The pyrrolopyrimidine ring of compound <b>1</b> forms dual hydrogen bonds with the backbone residues (Leu932 and Glu930) of the hinge region of JAK2. (C) Binding mode of <b>8a</b> in the active site of HDAC2. (D) Binding mode of <b>8a</b> in the ATP pocket of JAK2. Yellow dashed lines represent the hydrogen bonds. Oxygen, nitrogen, chlorine, and polar hydrogen atoms are shown in pink, blue, violet, and white, respectively. The figures were generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">The syntheses of key intermediates <b>15a</b>â<b>h</b> and <b>17a</b>â<b>o</b> are described in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, respectively. In <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, reduction of the starting material <b>10</b>, followed by Boc protection, led to compound <b>12</b>, which reacted with commercially available bromoalkanes <b>13a</b>â<b>h</b> under basic condition of cesium carbonate or 1,8-diazabicyclo[5.4.0]undec-7-ene to produce intermediates <b>14a</b>â<b>h</b>. Deprotection of <b>14a</b>â<b>h</b> yielded intermediates <b>15a</b>â<b>h</b>, respectively. In <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, intermediates <b>17a</b>â<b>o</b> were obtained by the reaction of 5-substituted-2,4-dichloropyrimidine <b>16a</b>â<b>d</b> with various aromatic or aliphatic amines under different conditions.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediates <b>15a</b>â<b>h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd/C, H<sub>2</sub>, EtOH, room temperature (rt), 1â2 days, 90%; (b) (Boc)<sub>2</sub>O, NaHCO<sub>3</sub>/H<sub>2</sub>O, tetrahydrofuran (THF), rt, 1â2 days, 75%; (c) cesium carbonate, CH<sub>3</sub>CN, 40â50 Â°C, 10 h, 51â82%; (d) HCl/EtOAc, rt, 6â10 h, 63â93%.</p></p></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0021.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Intermediates <b>17a</b>â<b>o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (e) for <b>17a</b> and <b>17l</b>, corresponding amines, Na<sub>2</sub>CO<sub>3</sub>, EtOH, rt, overnight, 40â44%; for <b>17b</b>, <b>17d</b>â<b>f</b>, corresponding amines, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), dimethylformamide (DMF), rt, overnight, 57â82%; for <b>17c</b>, corresponding amine, DIPEA, <i>N</i>-methylpyrrolidone (NMP), 100 Â°C, overnight, 40%; for <b>17g</b>â<b>k</b>, corresponding amines, EtOH, 0 Â°C, 0.5â3 h, 63â83%; for <b>17m</b>, corresponding amine, H<sub>2</sub>O/CH<sub>3</sub>OH = 3:1, 50 Â°C, 5 h, 68%; for <b>17n</b> and <b>17o</b>, corresponding amines, EtOH, â50 Â°C, 1 h, 25â30%.</p></p></figure><div class="NLM_p">The target compounds <b>8a</b>â<b>z</b> were synthesized according to the procedures in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Intermediates <b>17a</b>â<b>o</b> reacted with intermediates <b>15a</b>â<b>h</b> using trifluoroacetyl (TFA) as a catalyst at high temperature to give <b>18a</b>â<b>z</b>, which were converted to hydroxamic acid compounds <b>8a</b>â<b>z</b> by NH<sub>2</sub>OK in dry methanol, respectively.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Target Compounds <b>8a</b>â<b>z</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (f) TFA, <i>n</i>-BuOH, 130 Â°C, 3 h, 20â70%; (g) NH<sub>2</sub>OK, CH<sub>3</sub>OH (dry), rt, 0.5â1 h, 34â80%.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vitro JAK and HDAC Inhibition Assay</h3><div class="NLM_p">The JAK and HDAC inhibitory activities of <b>8a</b> were evaluated by determining its half-maximal inhibitory concentration (IC<sub>50</sub>) values against JAK2 and HeLa nuclear extracts, respectively. The JAK inhibitor <b>7</b> and the HDAC inhibitor <b>3</b> were used as the positive controls. The results in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> showed that <b>8a</b> exhibited comparable JAK2 inhibitory activity to <b>7</b> (IC<sub>50</sub> value: 0.010 vs 0.002 Î¼M) and more potent HDAC inhibitory activity than <b>3</b> (IC<sub>50</sub> value: 0.020 vs 0.168 Î¼M), validating our JAK and HDAC dual inhibitor design strategy shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. Compounds <b>8b</b>â<b>k</b> with the same aliphatic linker length as <b>8a</b> (<i>n</i> = 6) were synthesized to investigate the effects of the terminal phenyl group on JAK2 and HDAC inhibition. All these analogues exhibited potent JAK2 inhibition with IC<sub>50</sub> values lower than 50 nM. Among these analogues, compounds <b>8i</b>, <b>8l</b>, <b>8m</b>, and <b>8w</b> exhibited the most potent JAK2 inhibition with IC<sub>50</sub> values lower than 10 nM. Note that the aliphatic linker length of five or six methylenes had no dramatic influence on JAK2 inhibition (<b>8l</b> vs <b>8a</b>, <b>8m</b> vs <b>8b</b>, <b>8n</b> vs <b>8c</b>, <b>8o</b> vs <b>8k</b>, <b>8w</b> vs <b>8f</b>). With reference to their HDAC inhibitory activities, structureâactivity relationships (SARs) were revealed. (1) Analogues with aromatic terminal groups (<b>8a</b>â<b>f</b>) were generally more potent than analogues with aliphatic terminal groups (<b>8g</b>â<b>k</b>). (2) Para-substitution on the terminal phenyl group was beneficial. The HDAC IC<sub>50</sub> values of the para-substituted compounds <b>8b</b>, <b>8e</b>, and <b>8f</b> reached the single-digit nanomolar range, over 50-fold more potent than the positive control <b>3</b>. The above two SARs were also observed in compounds with shorter aliphatic chains (<b>8l</b>â<b>o</b> and <b>8w</b>, <i>n</i> = 5), among which <b>8l</b>â<b>n</b> and <b>8w</b> with the aromatic terminal group of substituted phenyls exhibited more potent HDAC inhibition than <b>8o</b> with the terminal methyl group, and the <i>para</i>-chlorine compound <b>8m</b> was more potent than its <i>meta</i>- and <i>ortho</i>-chlorine analogues (<b>8l</b> and <b>8n</b>). Taken together, the results in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> indicate that the structural modification of the terminal phenyl group of <b>8a</b> was generally tolerated for JAK2 and HDAC inhibition, leading to compound <b>8m</b> with the most potent activities toward both JAK2 and total HDAC.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Comparison of Structures and in Vitro Enzyme Inhibitory Activities of the Target Compounds <b>8a</b>â<b>o</b> and <b>8w</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0019.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Assays were performed in replicate (<i>n</i> > 2); IC<sub>50</sub> values are shown as mean Â± standard deviation (SD).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Not active at 10 Î¼M.</p></div></div><div></div></div><div class="NLM_p">To investigate the effects of substituents of the pyrimidine group on JAK2 and HDAC inhibition, compounds <b>8p</b>, <b>8q</b>, and <b>8r</b> were synthesized and compared with <b>8f</b>. The results in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> show that replacement of the chlorine on the pyrimidine of <b>8f</b> with H, F, and CF<sub>3</sub> led to decreased JAK2 inhibition (<b>8p</b>, <b>8q</b>, and <b>8r</b>). With reference to their HDAC inhibitory activities, compounds <b>8q</b> (IC<sub>50</sub> = 0.003 Î¼M) and <b>8f</b> (IC<sub>50</sub> = 0.003 Î¼M) with halogen substituents exhibited the most potent activities, which were over 50-fold more potent than the positive control <b>3</b> (IC<sub>50</sub> = 0.168 Î¼M). Similar trends were observed in the comparison of <b>8k</b> and <b>8s</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Comparison of Structures and in Vitro Enzyme Inhibitory Activities of the Target Compounds <b>8p</b>â<b>s</b>, <b>8f</b>, and <b>8k</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0006.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Assays were performed in replicate (<i>n</i> > 2); IC<sub>50</sub> values are shown as mean Â± SD.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Not active at 10 Î¼M.</p></div></div><div></div></div><div class="NLM_p">To investigate the effects of the linker on JAK2 and HDAC inhibition, compounds <b>8t</b>â<b>z</b> were synthesized and evaluated (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). For compounds with aliphatic linkers (<b>8t</b>â<b>x</b> and <b>8f</b>), HDAC inhibitory activities first increased and then decreased with the linker length, culminating in compound <b>8f</b> (IC<sub>50</sub> = 0.003 Î¼M); however, no obvious trend on JAK2 inhibition was observed from the aliphatic linker length. For compounds with aromatic linkers (<b>8y</b> and <b>8z</b>), the <i>N</i>-hydroxybenzamide <b>8y</b> possessed more potent HDAC and JAK2 inhibitory activities than the <i>N</i>-hydroxycinnamide <b>8z</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Comparison of Structures and in Vitro Enzyme Inhibitory Activities of the Target Compounds <b>8t</b>â<b>z</b> and <b>8f</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0004.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Assays were performed in replicate (<i>n</i> > 2); IC<sub>50</sub> values are shown as mean Â± SD.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Not active at 10 Î¼M.</p></div></div><div></div></div><div class="NLM_p">After the completion of evaluation for JAK and HDAC enzymatic activity of all compounds, SARs were developed and are summarized in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. To sum up, (1) the hydroxamate group of the target compounds acts as the zinc binding group that chelates the catalytic zinc ion in HDAC and therefore achieves a potent HDAC inhibitory activity; (2) the aminopyrimidine moiety of the target compounds acts as the pharmacophore of JAKs and therefore achieves a potent JAK inhibitory activity; (3) proper linker length is very important for HDAC inhibitory activity; the target compounds with linker length five or six methylene groups possess the most potent inhibitory activities against HDACs; however, no obvious trend on JAK2 inhibition is observed from the aliphatic linker length and the linker types; (4) the R<sup>1</sup> group shows a decisive effect on JAK2 inhibitory activity; the target compounds with the chlorine atom on the R<sup>1</sup> group possess the most potent inhibitory activity against JAK2; and (5) different substituents of the R<sup>2</sup> group are well tolerated in both JAK2 and HDACs.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0010.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SAR summary of JAK and HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> JAK Isoform Selectivity Profile</h3><div class="NLM_p">The JAK2 IC<sub>50</sub> values of five representative compounds <b>8a</b>, <b>8b</b>, <b>8h</b>, <b>8i</b>, and <b>8m</b> were determined. The results in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> confirm the significant JAK2 inhibitory activity of these five compounds, among which compounds <b>8a</b>, <b>8i</b>, and <b>8m</b> possessed IC<sub>50</sub> values in the single-digit nanomolar range. To profile their JAK isoform selectivity, these five compounds were further evaluated against the other three JAK isoforms (JAK1, JAK3, and TYK2). It was revealed that compounds with aromatic terminal groups (<b>8a</b>, <b>8b</b>, <b>8m</b>) were moderately selective to JAK1/2/3 over TYK2, whereas compounds with aliphatic terminal groups, especially compound <b>8h</b>, showed JAK3 preference to some extent.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. JAK Isoform Selectivity Profiles of Representative Compounds<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Assays were performed in replicate (<i>n</i> > 2); the SD values are <20% of the means.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Not determined.</p></div></div><div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> HDAC Isoform Selectivity Profile</h3><div class="NLM_p">Class I HDAC isoforms and class IIb HDAC isoforms are involved in tumorigenesis and its development. To profile the HDAC isoform selectivity of these JAK and HDAC dual inhibitors, seven representative compounds <b>8a</b>, <b>8k</b>, <b>8m</b>, <b>8v</b>, <b>8x</b>, <b>8y</b>, and <b>8z</b> were tested against two class I isoforms (HDAC2/8) and one class IIb isoform (HDAC6) with compound <b>3</b> as the positive control. Based on the results in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, we see that, except for compound <b>8y</b> being HDAC6/8 selective over HDAC2, all tested compounds showed HDAC2/6 preference over HDAC8, which was similar to the selectivity profile of <b>3</b>. It is worth noting that compounds <b>8a</b>, <b>8k</b>, and <b>8m</b> exhibited more potent inhibitory activity against all the three HDAC isoforms tested than <b>3</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. HDAC Isoform Selectivity Profiles of Representative Compounds<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0013.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Assays were performed in replicate (<i>n</i> > 2); the SD values are <20% of the means.</p></div></div><div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Western Blot Analysis</h3><div class="NLM_p">Western blot analysis was performed to evaluate the cellular potency of the target compounds. The results in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> show that, similar to <b>3</b> (SAHA), our compounds <b>8a</b> and <b>8k</b> simultaneously increased the intracellular levels of the HDAC1/2/3 substrate acetyl-histone H4 (Ac-HH4) and the HDAC6 substrate acetyl-Î±-tubulin (Ac-Tub). Note that the HDAC6 selective inhibitor tubastatin A (Tub A, HDAC6 IC<sub>50</sub>: 15 nM, 1093-fold selective vs HDAC1)<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> only increased the intracellular levels of acetyl-Î±-tubulin. It was worth noting that at the same concentrations of 80 and 400 nM, the effects of <b>8a</b> and <b>8k</b> on acetyl-histone H4 were comparable to that of <b>3</b>, whereas at the same concentration of 80 nM, the effects of <b>8a</b> and <b>8k</b> on acetyl-Î±-tubulin were much superior to those of tubastatin A and <b>3</b>.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) A549 cells were treated with dimethyl sulfoxide (DMSO) or compounds for 6 h. The levels of acetyl-Î±-tubulin (Ac-Tub) and acetyl-histone H4 (Ac-HH4) were determined by immunoblotting. Î²-Actin was used as a loading control. The result is the representative of three independent experiments. (B) ImageJ was used to quantify the Western blot data. At 80 nM, the effects of <b>8a</b> and <b>8k</b> on acetyl-Î±-tubulin were much superior to those of tubastatin A and <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It was recently revealed that HDAC inhibitor SAHA activates the JAK-STAT pathway and attenuates the efficacy of HDAC inhibitors in some solid tumors, and concurrent inhibition of JAK and HDAC improves the efficacy of the HDAC inhibitors in the treatment of breast cancers.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> To validate the intracellular dual actions of <b>8m</b>, another set of Western blot analysis was performed. The results in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> validate that <b>3</b> (SAHA) upregulates the p-STAT3-Tyr705 level via activating the JAK-STAT pathway, and cotreatment with <b>1</b> (ruxolitinib) successfully suppresses the JAK-STAT pathway. To our delight, our dual inhibitor <b>8m</b> led to decreased levels of p-STAT3-Tyr705 relative to <b>3</b> and increased levels of Ac-Tub and Ac-HH3 relative to the control group, indicating the concurrent inhibition of intracellular JAK and HDAC (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0015.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. MDA-MB-231 cells were treated with DMSO or compounds for 12 h. The levels of phosphorylated STAT3 (p-STAT3-Tyr705), total STAT3, acetyl-Î±-tubulin (Ac-Tub), and acetyl-histone H3 (Ac-HH3) were determined by immunoblotting. GAPDH was used as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vitro Antiproliferation Assay</h3><div class="NLM_p">Given the promising cellular potencies validated by Western blot analysis, most of our target compounds were progressed to an in vitro antiproliferation assay. In addition to the human erythroleukemia cell line HEL bearing the JAK2<sup>V617F</sup> mutation, three other human hematological cancer cell lines including the chronic myelogenous leukemia cell line K562, the acute lymphoblastic leukemia cell line MOLT4, and the acute T-cell leukemia cell line Jurkat were tested as both JAK inhibitors and HDAC inhibitors are of great potential for the therapy of hematological malignancies.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> From the results listed in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, it was found that compared with the positive controls <b>1</b> and <b>3</b>, almost all our tested compounds showed greater antiproliferative activity against the four hematological cancer cell lines. Note that the K562 cell line was less sensitive to our compounds than HEL, MOLT4, and Jurkat cell lines. Moreover, the combinatorial cytotoxic effects of the JAK inhibitor <b>1</b> and the HDAC inhibitor <b>3</b> were determined, revealing the strong synergistic effect (combination index (CI) = 0.48) in the JAK2<sup>V617F</sup>-mutated HEL cell line and the additive effect (CI = 0.97) in the JAK2 wild-type K562 cell line. Strikingly, most of our dual inhibitors were more potent than the combination of <b>1</b> and <b>3</b>. Of particular note were compounds <b>8l</b> and <b>8m</b>, whose IC<sub>50</sub> values against HEL, MOLT4, and Jurkat cell lines were all below 0.1 Î¼M, reflecting their potent and balanced inhibition activity against both JAK and HDAC as shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vitro Antiproliferative Activities of Representative Compounds<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center">IC<sub>50</sub> (Î¼M)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">HEL</th><th class="colsep0 rowsep0" align="center">K562</th><th class="colsep0 rowsep0" align="center">MOLT4</th><th class="colsep0 rowsep0" align="center">Jurkat</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="left">0.14Â Â±Â 0.03</td><td class="colsep0 rowsep0" align="left">0.38Â Â±Â 0.03</td><td class="colsep0 rowsep0" align="left">0.13Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="left">0.10Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="left">0.12Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="left">0.32Â Â±Â 0.03</td><td class="colsep0 rowsep0" align="left">0.12Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">0.10Â Â±Â 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="left">0.34Â Â±Â 0.07</td><td class="colsep0 rowsep0" align="left">0.86Â Â±Â 0.05</td><td class="colsep0 rowsep0" align="left">0.51Â Â±Â 0.06</td><td class="colsep0 rowsep0" align="left">0.25Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8d</b></td><td class="colsep0 rowsep0" align="left">0.18Â Â±Â 0.04</td><td class="colsep0 rowsep0" align="left">0.42Â Â±Â 0.16</td><td class="colsep0 rowsep0" align="left">0.16Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="left">0.09Â Â±Â 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8e</b></td><td class="colsep0 rowsep0" align="left">0.21Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="left">0.62Â Â±Â 0.04</td><td class="colsep0 rowsep0" align="left">0.17Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="left">0.13Â Â±Â 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8f</b></td><td class="colsep0 rowsep0" align="left">0.21Â Â±Â 0.03</td><td class="colsep0 rowsep0" align="left">0.50Â Â±Â 0.13</td><td class="colsep0 rowsep0" align="left">0.22Â Â±Â 0.05</td><td class="colsep0 rowsep0" align="left">0.12Â Â±Â 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8g</b></td><td class="colsep0 rowsep0" align="left">0.47Â Â±Â 0.10</td><td class="colsep0 rowsep0" align="left">0.91Â Â±Â 0.15</td><td class="colsep0 rowsep0" align="left">0.32Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="left">0.17Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8i</b></td><td class="colsep0 rowsep0" align="left">0.08Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">0.38Â Â±Â 0.08</td><td class="colsep0 rowsep0" align="left">0.15Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">0.05Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8k</b></td><td class="colsep0 rowsep0" align="left">0.10Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="left">0.59Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">0.11Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="left">0.07Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8l</b></td><td class="colsep0 rowsep0" align="left">0.08Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">0.58Â Â±Â 0.06</td><td class="colsep0 rowsep0" align="left">0.08Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="left">0.05Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8m</b></td><td class="colsep0 rowsep0" align="left">0.09Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">0.49Â Â±Â 0.08</td><td class="colsep0 rowsep0" align="left">0.08Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="left">0.06Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8n</b></td><td class="colsep0 rowsep0" align="left">0.43Â Â±Â 0.07</td><td class="colsep0 rowsep0" align="left">1.81Â Â±Â 0.18</td><td class="colsep0 rowsep0" align="left">0.63Â Â±Â 0.14</td><td class="colsep0 rowsep0" align="left">0.31Â Â±Â 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8r</b></td><td class="colsep0 rowsep0" align="left">0.42Â Â±Â 0.08</td><td class="colsep0 rowsep0" align="left">0.48Â Â±Â 0.11</td><td class="colsep0 rowsep0" align="left">0.24Â Â±Â 0.07</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8w</b></td><td class="colsep0 rowsep0" align="left">0.15Â Â±Â 0.03</td><td class="colsep0 rowsep0" align="left">0.42Â Â±Â 0.14</td><td class="colsep0 rowsep0" align="left">0.12Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="left">0.06Â Â±Â 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8z</b></td><td class="colsep0 rowsep0" align="left">0.60Â Â±Â 0.15</td><td class="colsep0 rowsep0" align="left">1.03Â Â±Â 0.07</td><td class="colsep0 rowsep0" align="left">0.33Â Â±Â 0.06</td><td class="colsep0 rowsep0" align="left">0.15Â Â±Â 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">18.6Â Â±Â 6.2</td><td class="colsep0 rowsep0" align="left">23.2Â Â±Â 2.0</td><td class="colsep0 rowsep0" align="left">15.8Â Â±Â 1.4</td><td class="colsep0 rowsep0" align="left">>5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">0.65Â Â±Â 0.07</td><td class="colsep0 rowsep0" align="left">1.11Â Â±Â 0.05</td><td class="colsep0 rowsep0" align="left">0.4Â Â±Â 0.07</td><td class="colsep0 rowsep0" align="left">0.27Â Â±Â 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b>Â +Â <b>3</b><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.30Â Â±Â 0.02Â (CIÂ =Â 0.48)<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">1.03Â Â±Â 0.03Â (CIÂ =Â 0.97)<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Assays were performed in replicate (<i>n</i> > 2); IC<sub>50</sub> values are shown as mean Â± SD.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Not determined.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Combined at a mole ratio of 1:1.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Combination index (CI) was calculated based on the ChouâTalalay method.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> CI > 1 indicates antagonism, CI = 1 indicates an additive effect, and CI < 1 indicates synergism.</p></div></div></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Apoptosis Assay</h3><div class="NLM_p">The apoptosis-inducing abilities of compounds <b>8a</b> and <b>8m</b> were evaluated by flow cytometry analysis. In this figure, there are four regions. The lower-left corner and the upper-left corner of the diagram show the number of living cancer cells and dead cancer cells, respectively. The upper right, combined with the lower-right region of the diagram, represents the number of apoptotic cancer cells. It was demonstrated that 1.0 Î¼M of <b>8m</b> could induce almost complete HEL cell apoptosis (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) and over 70% K562 cell apoptosis (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), which was in line with its antiproliferative results that HEL was more sensitive to <b>8m</b> than K562 (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Notably, at the same concentration of 1.0 Î¼M, the apoptosis-inducing abilities of <b>8a</b> and <b>8m</b> in both HEL (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) and K562 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) cells were much stronger than those of <b>1</b> (ruxolitinib) and <b>3</b> (SAHA), confirming the notable cellular potencies of our JAK and HDAC dual inhibitors.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Induction of apoptosis in HEL cells after 24 h of treatment. (B) Ability of compounds <b>3</b>, <b>1</b>, <b>8a</b>, and <b>8m</b> to induce apoptosis in HEL cells after 24 h of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0016.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Induction of apoptosis in K562 cells after 24 h of treatment. (B) Ability of compounds <b>3</b>, <b>1</b>, <b>8a</b>, and <b>8m</b> to induce apoptosis in K562 cells after 24 h of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> In Vivo Pharmacokinetic (PK) Profile</h3><div class="NLM_p">Due to its closely matched JAK/HDAC inhibitory activity and potent antiproliferative and proapoptotic capacities, compound <b>8m</b> was progressed into an in vivo pharmacokinetic study. Compound <b>8m</b> was administered intravenously (IV) at 2 mg/kg or orally (PO) at 10 mg/kg in male Sprague-Dawley rats. The PK parameters and concentrationâtime curves of <b>8m</b> indicated the poor PK properties of <b>8m</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01597/suppl_file/jm8b01597_si_001.pdf" class="ext-link">Table S1 and Figure S1</a>, Supporting Information). To be specific, after intravenous administration, <b>8m</b> was rapidly cleared with the clearance (CL) of 160.9 mL/(min kg) and the half-life (<i>t</i><sub>1/2</sub>) of 0.32 h. The oral bioavailability of <b>8m</b> was lower than 1%. To further investigate the in vivo pharmacokinetic properties in mice, <b>8m</b> was intraperitoneally and intravenously administrated in male ICR (CD-1) mice. The results in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> showed that <b>8m</b> possessed a good bioavailability after intraperitoneal administration; however, the clearance of <b>8m</b> in mice was also very rapid.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. PK Parameters of <b>8m</b> in ICR (CD-1) Mice (<i>N</i> = 9, Male)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">administration</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0â<i>t</i></sub> (ngÂ h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">MRT<sub>0â<i>t</i></sub> (h)</th><th class="colsep0 rowsep0" align="center">Vz (L/kg)</th><th class="colsep0 rowsep0" align="center">CL (mL/(minÂ kg))</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">IP</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">118</td><td class="colsep0 rowsep0" align="char" char=".">33.0</td><td class="colsep0 rowsep0" align="char" char=".">0.36</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">116</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">28.4</td><td class="colsep0 rowsep0" align="char" char=".">0.27</td><td class="colsep0 rowsep0" align="left">18.4</td><td class="colsep0 rowsep0" align="left">643</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr></tbody></table></div></div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> In Vitro Liver Microsomal Stability Assay</h3><div class="NLM_p last">We further determined the metabolic stability of compound <b>8m</b> in the liver microsome. The reduced nicotinamide adenine dinucleotide phosphate (NADPH) and uridine diphosphate glucuronic acid (UDPGA) were used as cofactors for phase I and phase II metabolic stability evaluation, respectively. The results showed that compound <b>8m</b> was rapidly degraded by phase I metabolism, with <i>t</i><sub>1/2</sub> of 14.6 and 25.8 min in rat and human microsomes, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01597/suppl_file/jm8b01597_si_001.pdf" class="ext-link">Figure S2</a>, Supporting Information). The phase II metabolic stability indicated that <b>8m</b> was also readily transformed by UDP-glucuronosyltransferase in rat microsome (<i>t</i><sub>1/2</sub> = 41.6 min). Interestingly, the phase II metabolic stability of <b>8m</b> in human microsome was very good (<i>t</i><sub>1/2</sub> = 361.1 min), demonstrating the species differences in drug metabolism (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01597/suppl_file/jm8b01597_si_001.pdf" class="ext-link">Figure S3</a>, Supporting Information). Taken together, compound <b>8m</b> showed poor phase I and phase II metabolic stabilities in rat microsome, which could partially contribute to its rapid in vivo clearance.</div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> In Vivo Antitumor Activity Evaluation and Determination of Drug Exposure</h3><div class="NLM_p">Considering its good intraperitoneal bioavailability, <b>8m</b> was intraperitoneally administrated in a HEL xenograft model to preliminarily evaluate its in vivo antitumor potency. Another objective of this set of experiments was to investigate the in vivo effects of the combination of <b>1</b> and <b>3</b>. Compounds <b>3</b> (100 mg/kg), <b>1</b> (100 mg/kg), <b>8m</b> (100 mg/kg), and <b>3</b> + <b>1</b> (60 + 70 mg/kg, similar mole number as <b>8m</b>) were dosed intraperitoneally for 16 consecutive days. Tumor growth inhibition (TGI) was calculated at the end of treatment. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>, a combination of <b>1</b> and <b>3</b> exhibited improved in vivo antitumor potency compared with each drug alone and possessed the best antitumor potency with TGI of 57%. <b>8m</b> showed a moderate in vivo antitumor potency with TGI of 36%. The tumor growth curve and the final tumor tissue size are presented in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A,B, respectively, which explicitly demonstrates the superior in vivo potency of the combination group. Though <b>8m</b> possessed much better in vitro activity than <b>3</b>, the in vivo potency of <b>8m</b> was a little inferior, which could be attributed to its short half-life and rapid clearance shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. To further determine the compound exposure, the tumor and plasma concentrations of compounds <b>1</b>, <b>3</b>, and <b>8m</b> in mice were measured after the last of five daily doses (100 mg/(kg day), IP). The results in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A reveal the lower tumor exposure of <b>8m</b> compared with compounds <b>3</b> and <b>1</b>, which may provide a basis for the modest antitumor activity of <b>8m</b> in comparison to compounds <b>3</b> and <b>1</b>. The low concentration of <b>8m</b> in plasma (about 100 nM in vivo, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B) suggests a desirable in vivo toxic profile of <b>8m</b>. Furthermore, both the mice treated with <b>8m</b> alone and the mice cotreated with <b>1</b> and <b>3</b> showed good tolerance, indicated by no significant body weight loss and no observable toxic signs.</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0002.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Growth curve of the implanted HEL xenograft in nude mice. (B) Picture of dissected HEL tumor tissues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0017.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Drug concentrations in tumor. (B) Drug concentrations in plasma. The tumor and plasma concentrations of compounds <b>1</b>, <b>3</b>, and <b>8m</b> in mice were measured after the last of five daily doses (100 mg/(kg day), IP). Mice were sacrificed at 0.5, 1.0, and 4.0 h, respectively, after administration; then, blood and tumor samples were collected.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. In Vivo Antitumor Efficacy in the HEL Xenograft Model</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">administration</th><th class="colsep0 rowsep0" align="center" char=".">TGI (%)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">100Â mg/(kgÂ day),Â IP</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">100Â mg/(kgÂ day),Â IP</td><td class="colsep0 rowsep0" align="char" char=".">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b>Â +Â <b>1</b></td><td class="colsep0 rowsep0" align="left">60Â +Â 70Â mg/(kgÂ day),Â IP</td><td class="colsep0 rowsep0" align="char" char=".">57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8m</b></td><td class="colsep0 rowsep0" align="left">100Â mg/(kgÂ day),Â IP</td><td class="colsep0 rowsep0" align="char" char=".">36</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Compared with the control group, all treated groups showed statistically significant (<i>P</i> < 0.05) TGI by Studentâs two-tailed <i>t</i> test. The TGI values are based on the tumor weights.</p></div></div></div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Protein Kinase Selectivity Profile</h3><div class="NLM_p">Based on the low drug concentrations in plasma in vivo (about 100 nM, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B), compound <b>8m</b> was further tested against 85 kinds of kinases to characterize its protein kinase selective profiles at 20 and 200 nM, separately. The results in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a> show that at the concentration of 20 nM, <b>8m</b> led to over 90% inhibition of RET kinase, which was encoded by RET proto-oncogene. The mutations of RET kinase are associated with the development of various types of human cancers.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In addition, 20 nM of compound <b>8m</b> also exhibited over 50% inhibition against FMS-like receptor tyrosine kinase 3 (FLT3) and vascular endothelial growth factor receptor 2 (VEGFR2). In fact, FLT3 also plays important roles in the progress of hematological malignancies, which is simultaneously targeted by the JAK inhibitor pacritinib in phase III clinical trials,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> whereas VEGFR2 is a validated antiangiogenesis target.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Meanwhile, at the large concentration of 200 nM, <b>8m</b> could lead to over 90% inhibition of RET kinase, FLT3 kinase, and VEGFR2, which is consistent with the conclusion above. Overall, our kinase profiling, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, indicated the relatively low but acceptable kinase selectivity of compound <b>8m</b>.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Kinome Selectivity Profiles for Compound <b>8m</b><a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0022.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0020.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">% inhibition of phosphorylation of substrates at the indicated test compound concentration using a LANCE or HTRF detection method supplied by Eurofins Cerep Corporation. In these heat maps, inhibition <50% is assigned as green, inhibition >90% inhibition is assigned as red, and 50%< inhibition <90% is assigned as yellow. In the kinome selectivity profiles, ATP concentration is close to the <i>K</i><sub>m</sub> of each tested kinase.</p></div></div><div></div></div></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Binding Mode Analysis</h3><div class="NLM_p">Through the enzymatic assays of compound <b>8m</b>, we found that the inhibitory activities of compound <b>8m</b> against HDAC6, JAK2, FLT3, VEGFR2, and RET kinase were at the nanomolar levels. To gain deeper insights into the molecular basis of the inhibitory activity, we further analyzed the binding modes of compound <b>8m</b> with HDAC6, JAK2, FLT3, VEGFR2, and RET kinase. The results are shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>. <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A shows the binding mode of <b>8m</b> in the active pocket of HDAC6. The hydroxamic acid group of compound <b>8m</b> chelates the Zn<sup>2+</sup> in a bidentate manner and forms a hydrogen bond with His573, the aliphatic chains occupy the hydrophobic channel, and the aminopyrimidine group interacts with the Asp460 residue at the entrance of the active site. The binding mode of <b>8m</b> in the active pocket of HDAC6 matches the classical binding mode of hydroxamate-based HDAC inhibitors. <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B shows the binding mode of <b>8m</b> in the ATP pocket of JAK2. Compound <b>8m</b> forms dual hydrogen bonds between its aminopyrimidine moiety and the Leu932 residue. The alkyl hydroxamate part of <b>8m</b> is projected toward the solvent region and forms hydrogen bonds with Asp949 and Lys943. The binding modes of compound <b>8m</b> with FLT3 and VEGFR2 are similar to the binding modes of FF-10101 (a novel FLT3 inhibitor) with FLT3 and pazopanib (a VEGFR2 inhibitor) with VEGFR2 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>C,D).<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> In brief, the aminopyrimidine moiety of compound <b>8m</b> forms a strong hydrogen bond interaction with the amino acid residues at the ATP active sites of FLT3 and VEGFR2. The alkyl hydroxamate part of <b>8m</b> fits well into the active pocket. The binding mode of compound <b>8m</b> with RET kinase is similar to the binding mode of the inhibitor ZD6474 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>E). The aminopyrimidine and pyrazol moieties of compound <b>8m</b> form dual strong hydrogen bond interactions with the ALA807 residue at the ATP active site of RET kinase. The alkyl hydroxamate part of <b>8m</b> forms strong hydrogen bond interactions with Glu775 residues and water. The perfect binding modes between <b>8m</b> and kinases reasonably explain the significant inhibitory activities of compound <b>8m</b> against HDAC6, JAK2, FLT3, VEGFR2, and RET.</div><figure id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0018.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Binding mode of <b>8m</b> in the active site of HDAC6 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>). (B) Binding mode of <b>8m</b> in the active site of JAK2 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). (C) Binding mode of <b>8m</b> in the active site of FLT3 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X02">5X02</a>). (D) Binding mode of <b>8m</b> in the active site of VEGFR2 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3CJG">3CJG</a>). (E) Binding mode of <b>8m</b> in the active site of RET kinase (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVU">2IVU</a>). Yellow dashed lines represent the hydrogen bonds. Oxygen, nitrogen, chlorine, and polar hydrogen atoms are shown in pink, blue, violet, and white, respectively. The figures were generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66808" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66808" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In the present work, based on the polypharmacological strategy and the favorable interaction between JAK and HDAC inhibitors, a series of pyrimidin-2-amino-pyrazol hydroxamate derivatives as JAK and HDAC dual inhibitors were designed, synthesized, and evaluated. Most of these compounds simultaneously inhibit JAK2 and total HDACs at nanomolar levels, leading to their more potent antiproliferative capacities against hematological tumor cell lines than the currently approved HDAC inhibitor SAHA, the approved JAK inhibitor ruxolitinib, and even the SAHA plus ruxolitinib combination treatment. The representative compound <b>8m</b> possesses potent proapoptotic activity and acceptable kinase selectivity. In vivo, compound <b>8m</b> showed a moderate antitumor potency and no significant toxicity. In summary, the merit of our research is the development of a series of JAK and HDAC dual inhibitors with excellent in vitro antitumor activity, which not only validated the biology-oriented multitarget drug design strategy but also could be further structurally optimized to develop novel compounds with favorable PK properties and uncompromised in vivo activity in the future.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51446" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51446" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Chemistry</h3><div class="NLM_p last">Unless otherwise noted, all solvents and reagents were commercially available (Bide, Adamas-Î², etc.) and used without further purification. All reactions were monitored by thin-layer chromatography (TLC) on 0.25 mm silica gel plates (60 GF-254) and visualized with UV light or iodine vapor. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were obtained using a Bruker DRX spectrometer at 400 and 100 MHz, respectively. Chemical shifts were reported in parts per million (ppm). Multiplicity of <sup>1</sup>H NMR signals was reported as single (s), double (d), triplet (t), quarter (q), and multiplet (m). Electrospray ionization mass spectrometry (ESI-MS) was determined on an API 4000 spectrometer. High-resolution mass spectra (HRMS) were conducted by Shandong Analysis and Test Center in Jiânan. Melting points were determined on an electrothermal melting point apparatus and were uncorrected. HPLC analysis was carried out on Agilent 1200 with an extended C18 column (4.6 mm Ã 250 mm, 5 Î¼m). The flow rate is 1 mL/min. All final compounds achieved a minimum of 95% purity.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedure for the Preparation of <b>8a</b>â<b>z</b></h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 7-(4-((5-Chloro-4-((3-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8a</b>)</h4><div class="NLM_p last">A mixture of ethyl 7-(4-((5-chloro-4-((3-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18a</b>, 0.15 g, 0.33 mmol) in NH<sub>2</sub>OK/CH<sub>3</sub>OH (20 mL) was stirred at room temperature for 0.5â1 h. When TLC showed the reaction was completed, evaporation of the solvent under reduced pressure gave a residue, which was dissolved in water (15 mL). The mixture was neutralized by adding 1 M HCl. The white precipitate was filtered and dried to give compound <b>8a</b> (0.08 g, yield 53%) as a white solid. mp 172â174 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.34 (s, 1H), 9.27 (s, 1H), 8.97 (s, 1H), 8.65 (s, 1H), 8.11 (s, 1H), 7.84â7.15 (m, 6H), 3.91 (s, 2H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.62 (s, 2H), 1.51â1.35 (m, 2H), 1.19 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.52, 157.70, 140.87, 133.22, 130.49, 130.11, 123.29, 119.92, 51.84, 32.67, 30.33, 28.60, 26.21, 25.48. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 464.1363, found 464.1364. Retention time: 6.6 min, eluted with 30% acetonitrile/70% water (containing 0.4% formic acid).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 7-(4-((5-Chloro-4-((4-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8b</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((5-chloro-4-((4-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18b</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8b</b> as a white solid, 34% yield. mp 184â186 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.32 (s, 1H), 9.22 (s, 1H), 8.94 (s, 1H), 8.64 (s, 1H), 8.09 (s, 1H), 7.92â7.13 (m, 6H), 3.87 (s, 2H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.63 (s, 2H), 1.44 (dd, <i>J</i> = 14.5, 7.2 Hz, 2H), 1.22 (d, <i>J</i> = 9.9 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.53, 157.69, 138.32, 128.79, 123.35, 119.83, 51.79, 32.67, 30.38, 28.61, 26.23, 25.51. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 464.1363, found 464.1368. Retention time: 5.8 min, eluted with 30% acetonitrile/70% water (containing 0.4% formic acid).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 7-(4-((5-Chloro-4-((2-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8c</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((5-chloro-4-((2-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18c</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8c</b> as a white solid, 47% yield. mp 182â184 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.35 (s, 1H), 9.61â8.52 (m, 3H), 8.06 (s, 1H), 7.57â7.47 (m, 5H), 6.90 (s, 1H), 3.71 (s, 2H), 1.93 (t, <i>J</i> = 7.3 Hz, 2H), 1.47 (dt, <i>J</i> = 14.6, 10.3 Hz, 4H), 1.19 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.43, 157.59, 155.21, 136.76, 130.13, 129.23, 128.23, 123.55, 118.90, 51.71, 32.65, 30.46, 28.60, 26.17, 25.52. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 464.1363, found 464.1361. Retention time: 7.2 min, eluted with 30% acetonitrile/70% water (containing 0.4% formic acid).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 7-(4-((5-Chloro-4-(phenylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8d</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((5-chloro-4-(phenylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18d</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8d</b> as a white solid, 67% yield. mp 180â182 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.34 (s, 1H), 9.56 (s, 1H), 9.18 (s, 1H), 8.83 (s, 1H), 8.65 (s, 1H), 8.06 (s, 1H), 7.52â7.20 (m, 6H), 3.84 (s, 2H), 1.93 (t, <i>J</i> = 7.3 Hz, 2H), 1.60 (s, 2H), 1.46 (dd, <i>J</i> = 14.1, 7.2 Hz, 2H), 1.19 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.53, 157.71, 128.95, 123.44, 51.74, 32.67, 30.33, 28.58, 26.19, 25.49. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>24</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 430.1753, found 430.1754. Retention time: 10.5 min eluted with 20% acetonitrile/80% water (containing 0.4% formic acid).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 7-(4-((5-Chloro-4-((4-methoxyphenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8e</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((5-chloro-4-((4-methoxyphenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18e</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8e</b> as a white solid, 53% yield. mp 156â158 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.34 (s, 1H), 9.14 (s, 1H), 8.70â8.60 (m, 2H), 8.00 (s, 1H), 7.35â7.15 (m, 4H), 6.99 (d, <i>J</i> = 7.2 Hz, 2H), 3.78 (s, 5H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.57 (s, 2H), 1.50â1.40 (m, 2H), 1.26â1.10 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.53, 157.64, 154.77, 123.57, 114.18, 55.70, 51.71, 32.67, 30.37, 28.60, 26.18, 25.52. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>26</sub>ClN<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup> 460.1858, found 460.1857. Retention time: 11.7 min, eluted with 20% acetonitrile/80% water (containing 0.4% formic acid).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 7-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8f</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((5-chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18f</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8f</b> as a white solid, 52% yield. mp 180â182 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.34 (s, 1H), 9.18 (s, 1H), 8.88 (s, 1H), 8.65 (s, 1H), 8.06 (s, 1H), 7.52 (s, 2H), 7.23 (t, <i>J</i> = 8.4 Hz, 4H), 3.86 (s, 2H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.60 (s, 2H), 1.51â1.40 (m, 2H), 1.20 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.54, 157.68, 155.21, 135.53, 129.71, 123.47, 119.60, 115.69, 115.47, 51.79, 32.68, 30.34, 28.58, 26.19, 25.49. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>23</sub>ClFN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 448.1659, found 448.1658. Retention time: 5.2 min, eluted with 25% acetonitrile/75% water (containing 0.4% formic acid).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 7-(4-((5-Chloro-4-morpholinopyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8g</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((5-chloro-4-morpholinopyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18g</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8g</b> as a white solid, 79% yield. mp 118â120 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.31 (s, 1H), 9.29 (s, 1H), 8.64 (s, 1H), 8.06 (s, 1H), 7.76 (s, 1H), 7.45 (s, 1H), 4.02 (t, <i>J</i> = 6.9 Hz, 2H), 3.82â3.65 (m, 4H), 3.64â3.50 (m, 4H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.72 (dd, <i>J</i> = 13.7, 6.8 Hz, 2H), 1.45 (dd, <i>J</i> = 14.4, 7.1 Hz, 2H), 1.22 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 188.59, 169.49, 157.75, 130.23, 123.28, 66.36, 51.73, 48.00, 32.66, 30.29, 28.58, 26.19, 25.47. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>26</sub>ClN<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup> 424.1858, found 424.1857. Retention time: 7.2 min, eluted with 20% acetonitrile/80% water (containing 0.4% formic acid).</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 7-(4-((5-Chloro-4-(piperidin-1-yl)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8h</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((5-chloro-4-(piperidin-1-yl)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18h</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8h</b> as a white solid, 83% yield. mp 150â152 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.32 (s, 1H), 9.20 (s, 1H), 8.64 (s, 1H), 7.99 (s, 1H), 7.77 (s, 1H), 7.45 (s, 1H), 4.01 (t, <i>J</i> = 6.9 Hz, 2H), 3.55 (s, 4H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.72 (dd, <i>J</i> = 13.9, 7.0 Hz, 2H), 1.63 (s, 6H), 1.45 (dd, <i>J</i> = 14.5, 7.2 Hz, 2H), 1.22 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.52, 161.07, 157.79, 130.18, 123.53, 119.69, 51.78, 48.52, 32.67, 30.26, 28.59, 26.21, 25.88, 25.47, 24.42. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>28</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 422.2066, found 422.2069. Retention time: 23.7 min, eluted with 20% acetonitrile/80% water (containing 0.4% formic acid).</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 7-(4-((5-Chloro-4-(cyclopropylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8i</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((5-chloro-4-(cyclopropylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18i</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8i</b> as a brown solid, 79% yield. mp 180â182 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.31 (s, 1H), 9.12 (s, 1H), 8.64 (s, 1H), 7.95 (s, 1H), 7.85 (s, 1H), 7.50 (s, 1H), 7.15 (s, 1H), 4.00 (t, <i>J</i> = 6.9 Hz, 2H), 2.83 (dt, <i>J</i> = 10.3, 3.3 Hz, 1H), 1.91 (t, <i>J</i> = 7.3 Hz, 2H), 1.79â1.63 (m, 2H), 1.44 (dd, <i>J</i> = 14.3, 7.0 Hz, 2H), 1.21 (s, 4H), 0.77 (d, <i>J</i> = 5.1 Hz, 2H), 0.70â0.56 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.52, 159.39, 158.11, 153.66, 129.84, 124.04, 119.44, 51.77, 32.67, 30.33, 28.60, 26.24, 25.46, 24.55, 6.95. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>24</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 394.1753, found 394.1755. Retention time: 15.1 min, eluted with 15% acetonitrile/85% water (containing 0.4% formic acid).</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 7-(4-((5-Chloro-4-(propylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8j</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((5-chloro-4-(propylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18j</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8j</b> as a pink solid, 79% yield. mp 182â184 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.35 (s, 1H), 9.01 (s, 1H), 8.67 (s, 1H), 7.84 (s, 1H), 7.77 (s, 1H), 7.45 (s, 1H), 7.11 (s, 1H), 4.00 (t, <i>J</i> = 6.9 Hz, 2H), 3.40â3.34 (m, 2H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.72 (dd, <i>J</i> = 13.7, 6.8 Hz, 2H), 1.66â1.55 (m, 2H), 1.51â1.40 (m, 2H), 1.22 (d, <i>J</i> = 3.2 Hz, 4H), 0.91 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.51, 158.15, 153.44, 129.91, 123.95, 119.25, 51.79, 42.70, 32.65, 30.37, 28.60, 26.24, 25.49, 22.51, 11.86. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>26</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 396.1909, found 396.1912. Retention time: 8.2 min, eluted with 18% acetonitrile/82% water (containing 0.4% formic acid).</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 7-(4-((5-Chloro-4-(methylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8k</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18k</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8k</b> as a white solid, 87% yield. mp 184â186 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.33 (s, 1H), 9.03 (s, 1H), 8.65 (s, 1H), 7.83 (d, <i>J</i> = 13.1 Hz, 2H), 7.47 (s, 1H), 7.08 (s, 1H), 4.01 (t, <i>J</i> = 6.8 Hz, 2H), 2.91 (d, <i>J</i> = 3.7 Hz, 3H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.79â1.64 (m, 2H), 1.45 (dd, <i>J</i> = 14.1, 7.0 Hz, 2H), 1.23 (d, <i>J</i> = 2.9 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.50, 158.61, 158.25, 153.15, 130.01, 123.88, 119.54, 51.70, 32.66, 30.30, 28.58, 28.25, 26.21, 25.48. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>22</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 368.1596, found 368.1599. Retention time: 14.1 min, eluted with 12% acetonitrile/88% water (containing 0.4% formic acid).</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 6-(4-((5-Chloro-4-((3-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>8l</b>)</h4><div class="NLM_p last">Ethyl 6-(4-((5-chloro-4-((3-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>18l</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8l</b> as a white solid, 57% yield. mp 160â162 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.35 (s, 1H), 9.62 (s, 1H), 9.28 (s, 1H), 8.99 (s, 1H), 8.12 (s, 1H), 7.67â7.23 (m, 6H), 3.91 (s, 2H), 1.91 (t, <i>J</i> = 7.3 Hz, 2H), 1.63 (s, 2H), 1.53â1.40 (m, 2H), 1.19 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.41, 157.68, 140.92, 133.22, 130.52, 123.30, 51.77, 32.59, 30.20, 26.10, 25.15. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 450.1207, found 450.1284. Retention time: 9.4 min, eluted with 25% acetonitrile/75% water (containing 0.4% formic acid).</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 6-(4-((5-Chloro-4-((4-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>8m</b>)</h4><div class="NLM_p last">Ethyl 6-(4-((5-chloro-4-((4-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>18m</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8m</b> as a white solid, yield 86%. mp 192â194 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.35 (s, 1H), 9.97 (s, 1H), 9.24 (s, 1H), 8.98 (s, 1H), 8.09 (s, 1H), 7.81â7.21 (m, 6H), 3.87 (s, 2H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.64 (s, 2H), 1.55â1.39 (m, 2H), 1.19 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.39, 157.65, 138.35, 129.96, 128.82, 123.36, 119.83, 51.73, 32.61, 30.24, 26.13, 25.16. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 450.1207, found 450.1235. Retention time: 8.1 min, eluted with 25% acetonitrile/75% water (containing 0.4% formic acid).</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 6-(4-((5-Chloro-4-((2-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>8n</b>)</h4><div class="NLM_p last">Ethyl 6-(4-((5-chloro-4-((2-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>18n</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8n</b> as a white solid, yield 57%. mp 142â144 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.39 (s, 1H), 10.22 (s, 1H), 9.24 (s, 1H), 8.94 (s, 1H), 8.70 (s, 1H), 8.05 (s, 1H), 7.72â7.37 (m, 4H), 6.99 (m, 1H), 3.70 (s, 2H), 1.93 (t, <i>J</i> = 7.3 Hz, 2H), 1.61â1.37 (m, 4H), 1.12 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.44, 157.58, 130.16, 128.29, 123.56, 51.64, 32.58, 30.32, 26.03, 25.15. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 450.1207, found 450.1351. Retention time: 10.9 min, eluted with 25% acetonitrile/75% water (containing 0.4% formic acid).</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 6-(4-((5-Chloro-4-(methylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>8o</b>)</h4><div class="NLM_p last">Ethyl 6-(4-((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>18o</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8o</b> as a white solid, 63% yield. mp 164â166 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.33 (s, 1H), 9.02 (d, <i>J</i> = 13.8 Hz, 1H), 8.66 (s, 1H), 7.83 (d, <i>J</i> = 12.9 Hz, 2H), 7.46 (s, 1H), 7.09 (d, <i>J</i> = 3.5 Hz, 1H), 4.01 (t, <i>J</i> = 6.9 Hz, 2H), 2.90 (d, <i>J</i> = 3.8 Hz, 3H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.79â1.63 (m, 2H), 1.56â1.41 (m, 2H), 1.19 (dt, <i>J</i> = 15.2, 7.7 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.42, 165.59, 158.23, 129.99, 123.89, 119.53, 51.65, 32.60, 30.18, 28.26, 26.11, 25.15. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>20</sub>ClN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 354.1744, found 354.1712. Retention time: 11.9 min, eluted with 10% acetonitrile/90% water (containing 0.4% formic acid).</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 7-(4-((4-((4-Fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8p</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18p</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8p</b> as a white solid, 52% yield. mp 186â188 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.32 (s, 1H), 9.28 (s, 1H), 8.96 (s, 1H), 8.64 (s, 1H), 7.95 (d, <i>J</i> = 5.7 Hz, 1H), 7.72 (s, 3H), 7.40 (s, 1H), 7.15 (t, <i>J</i> = 8.8 Hz, 2H), 6.08 (d, <i>J</i> = 5.7 Hz, 1H), 3.97 (t, <i>J</i> = 6.5 Hz, 2H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.77â1.61 (m, 2H), 1.45 (dd, <i>J</i> = 14.5, 7.1 Hz, 2H), 1.22 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.54, 159.53, 156.60, 130.14, 123.78, 119.91, 115.72, 115.50, 51.75, 32.66, 30.37, 28.60, 26.23, 25.50. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>24</sub>FN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 414.2043, found 414.2047. Retention time: 13.4 min, eluted with 18% acetonitrile/82% water (containing 0.4% formic acid).</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 7-(4-((5-Fluoro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8q</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((5-fluoro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18q</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8q</b> as a white solid, 52% yield. mp 198â200 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.35 (s, 1H), 9.32 (s, 1H), 9.02 (s, 1H), 8.65 (s, 1H), 8.04 (d, <i>J</i> = 3.8 Hz, 1H), 7.71 (s, 3H), 7.34 (s, 1H), 7.19 (t, <i>J</i> = 8.8 Hz, 2H), 3.94 (s, 2H), 1.92 (t, <i>J</i> = 7.4 Hz, 2H), 1.66 (s, 2H), 1.51â1.37 (m, 2H), 1.20 (dd, <i>J</i> = 13.1, 8.5 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.53, 155.73, 135.46, 129.88, 123.95, 119.49, 115.65, 115.43, 51.76, 32.67, 30.35, 28.59, 26.22, 25.50. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>23</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 432.1954, found 432.1954. Retention time: 8.5 min, eluted with 20% acetonitrile/80% water (containing 0.4% formic acid).</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 7-(4-((4-((4-Fluorophenyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyheptanamide (<b>8r</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((4-((4-fluorophenyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18r</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8r</b> as a white solid, 52% yield. mp 176â178 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.34 (s, 1H), 9.68 (s, 1H), 8.81 (s, 1H), 8.65 (s, 1H), 8.26 (s, 1H), 7.44â7.35 (m, 2H), 7.30 (t, <i>J</i> = 8.6 Hz, 2H), 7.17 (s, 1H), 7.06 (s, 1H), 3.76 (t, <i>J</i> = 6.9 Hz, 2H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.60â1.49 (m, 2H), 1.49â1.36 (m, 2H), 1.30â1.03 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.53, 161.73, 160.06, 159.33, 159.06, 155.93, 135.32, 130.05, 129.97, 129.65, 122.72, 119.74, 116.01, 115.79, 51.81, 32.67, 30.41, 28.57, 26.15, 25.50. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>23</sub>F<sub>4</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 482.1922, found 482.1926. Retention time: 8.4 min, eluted with 30% acetonitrile/70% water (containing 0.4% formic acid).</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-Hydroxy-7-(4-((4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanamide (<b>8s</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18s</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8s</b> as a white solid, 38% yield. mp 192â194 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.32 (s, 1H), 9.54 (s, 1H), 8.64 (s, 1H), 8.08 (s, 1H), 7.85 (s, 1H), 7.54 (s, 1H), 7.07 (s, 1H), 4.03 (t, <i>J</i> = 6.3 Hz, 2H), 2.95 (s, 3H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.79â1.63 (m, 2H), 1.45 (dd, <i>J</i> = 14.4, 7.1 Hz, 2H), 1.22 (d, <i>J</i> = 3.3 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.52, 160.71, 159.38, 154.79, 130.31, 123.03, 120.14, 51.75, 32.65, 30.27, 28.79, 28.57, 26.20, 25.47. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>22</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 402.1860, found 402.1859. Retention time: 5.3 min, eluted with 18% acetonitrile/82% water (containing 0.4% formic acid).</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 3-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxypropanamide (<b>8t</b>)</h4><div class="NLM_p last">Methyl 3-(4-((5-chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)propanoate (<b>18t</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8t</b> as a white solid, 30% yield. mp 216â218 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.46 (s, 1H), 9.18 (s. 1H), 8.85 (s, 2H), 8.07 (s, 1H), 7.53â7.28 (m, 6H), 4.12 (s, 2H), 2.46 (d, <i>J</i> = 6.2 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 166.79, 157.68, 135.47, 130.47, 123.36, 120.17, 115.68, 115.47, 47.81, 33.43. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>15</sub>ClFN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 392.1033, found 392.1034. Retention time: 6.7 min, eluted with 18% acetonitrile/82% water (containing 0.4% formic acid).</div></div><div id="sec4_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxybutanamide (<b>8u</b>)</h4><div class="NLM_p last">Ethyl 4-(4-((5-chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)butanoate (<b>18u</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8u</b> as a white solid, 52% yield. mp 218â220 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.40 (s, 1H), 9.24 (s, 1H), 8.92 (s, 1H), 8.73 (s, 1H), 8.07 (s, 1H), 7.77â6.86 (m, 6H), 3.88 (s, 2H), 1.88 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 168.79, 157.68, 155.18, 135.54, 130.10, 123.57, 119.70, 115.67, 115.50, 51.28, 29.62, 26.54. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>17</sub>ClFN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 406.1189, found 406.1192. Retention time: 7.6 min, eluted with 18% acetonitrile/82% water (containing 0.4% formic acid).</div></div><div id="sec4_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 5-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxypentanamide (<b>8v</b>)</h4><div class="NLM_p last">Ethyl 5-(4-((5-chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)pentanoate (<b>18v</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8v</b> as a white solid, 52% yield. mp > 250 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.40 (s, 1H), 9.44 (s, 1H), 9.10 (s, 1H), 8.75 (s, 1H), 8.08 (d, <i>J</i> = 3.4 Hz, 1H), 7.78 (s, 3H), 7.39 (d, <i>J</i> = 8.0 Hz, 3H), 3.98 (s, 2H), 1.96 (t, <i>J</i> = 7.2 Hz, 2H), 1.79â1.53 (m, 2H), 1.44 (dd, <i>J</i> = 14.7, 7.5 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.25, 155.61, 150.24, 130.07, 128.80, 123.87, 119.67, 51.51, 32.21, 30.08, 22.80. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>19</sub>ClFN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 420.1346, found 420.1346. Retention time: 12.9 min, eluted with 18% acetonitrile/82% water (containing 0.4% formic acid).</div></div><div id="sec4_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 6-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyhexanamide (<b>8w</b>)</h4><div class="NLM_p last">Ethyl 6-(4-((5-chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>18w</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8w</b> as a yellow solid, 42% yield. mp 190â192 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.37 (s, 1H), 9.23 (s, 1H), 8.94 (s, 1H), 8.70 (s, 1H), 8.06 (s, 1H), 7.94â7.07 (m, 6H), 3.83 (s, 2H), 1.91 (t, <i>J</i> = 7.3 Hz, 2H), 1.60 (s, 2H), 1.55â1.35 (m, 2H), 1.13 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.39, 157.62, 135.52, 123.44, 51.71, 32.59, 30.20, 26.09, 25.11. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>21</sub>ClFN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 434.1502, found 434.1503. Retention time: 15.3 min, eluted with 18% acetonitrile/82% water (containing 0.4% formic acid).</div></div><div id="sec4_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 8-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-hydroxyoctanamide (<b>8x</b>)</h4><div class="NLM_p last">Ethyl 8-(4-((5-chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)octanoate (<b>18x</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8x</b> as a brown solid, 50% yield. mp 178â180 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.39 (s, 1H), 9.24 (s, 1H), 8.95 (s, 1H), 8.06 (s, 1H), 7.76 (s, 1H), 7.48 (s, 2H), 7.25 (s, 4H), 3.83 (s, 2H), 1.93 (t, <i>J</i> = 7.3 Hz, 2H), 1.58 (s, 2H), 1.47 (dd, <i>J</i> = 14.0, 7.0 Hz, 2H), 1.21 (s, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 169.56, 157.67, 135.27, 123.44, 119.62, 119.25, 115.70, 115.49, 51.81, 32.71, 30.46, 28.96, 28.70, 26.37, 25.51. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>25</sub>ClFN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 462.1815, found 462.1812. Retention time: 9.0 min, eluted with 25% acetonitrile/75% water (containing 0.4% formic acid).</div></div><div id="sec4_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 4-((4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)methyl)-<i>N</i>-hydroxybenzamide (<b>8y</b>)</h4><div class="NLM_p last">Methyl 4-((4-((5-chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)methyl)benzoate (<b>18y</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8y</b> as a light-yellow solid, 30% yield. mp 202â204 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.19 (s, 1H), 9.27 (s, 1H), 9.03 (s, 1H), 8.89 (s, 1H), 8.07 (s, 1H), 7.69 (d, <i>J</i> = 8.2 Hz, 2H), 7.48 (s, 4H), 7.15 (t, <i>J</i> = 8.6 Hz, 4H), 5.17 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 164.34, 157.62, 132.46, 130.79, 129.99, 127.56, 127.46, 124.15, 120.13, 115.64, 115.42, 55.02. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>17</sub>ClFN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 454.1189, found 454.1192. Retention time: 18.5 min, eluted with 18% acetonitrile/82% water (containing 0.4% formic acid).</div></div><div id="sec4_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>E</i>)-3-(4-((4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)methyl)phenyl)-<i>N</i>-hydroxyacrylamide (<b>8z</b>)</h4><div class="NLM_p last">Methyl (<i>E</i>)-3-(4-((4-((5-chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)methyl)phenyl)acrylate (<b>18z</b>) was reacted using a procedure similar to the synthesis of compound <b>8a</b>, affording <b>8z</b> as a light-yellow solid, 30% yield. mp 192â194 Â°C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.26 (s, 1H), 8.88 (s, 1H), 8.06 (s, 1H), 7.86â6.90 (m, 11H), 6.46 (d, <i>J</i> = 15.9 Hz, 1H), 5.13 (s, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 157.64, 134.61, 128.06, 124.13, 120.06, 119.65, 115.63, 115.41, 55.11. HRMS (AP-ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>19</sub>ClFN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 480.1346, found 480.1349. Retention time: 9.3 min, eluted with 25% acetonitrile/75% water (containing 0.4% formic acid).</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 1<i>H</i>-Pyrazol-4-amine (<b>11</b>)</h3><div class="NLM_p last">To a solution of 4-nitro-1<i>H</i>-pyrazole (<b>10</b>, 5.0 g, 44.2 mmol) in ethanol (160 mL) was added Pd/C (0.8 g, 10 wt %). The reaction was stirred under a hydrogen atmosphere for 1â2 days. Upon completion of the reaction, the mixture was filtered through celite and concentrated under reduced pressure to give compound <b>11</b> (3.6 g, yield 90%) as red oil, which became a red solid in a cold place. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.87 (brs, 1H), 6.97 (s, 2H), 3.76 (brs, 2H). ESI-MS <i>m</i>/<i>z</i>: 84.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>tert</i>-Butyl (1<i>H</i>-Pyrazol-4-yl)carbamate (<b>12</b>)</h3><div class="NLM_p last">To a solution of 1<i>H</i>-pyrazol-4-amine (<b>11</b>, 3.0 g, 36.1 mmol) in THF (7.5 g/160 mL) was slowly added a solution of di-<i>tert</i>-butyl dicarbonate (8.6 g, 39.7 mmol) in THF (50 mL) and a solution of NaHCO<sub>3</sub> (aq, 7.5 g/50 mL water). The reaction was stirred at room temperature for 1â2 days. Upon completion of the reaction, to the resulting mixture was added 100 mL of water and extracted with ethyl acetate (3 Ã 100 mL). The organic layer was combined, dried over sodium sulfate, and concentrated. The residue was stirred in hexane (160 mL) to give compound <b>12</b> (5.0 g, yield 75%) as a light-brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 12.44 (s, 1H), 9.07 (s,1H), 7.58 (s, 1H), 7.34 (s, 1H), 1.44 (s, 9H). ESI-MS <i>m</i>/<i>z</i>: 184.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> General Procedure for the Preparation of <b>14a</b>â<b>h</b></h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Methyl 3-(4-((<i>tert</i>-Butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)propanoate (<b>14a</b>)</h4><div class="NLM_p last">Cesium carbonate (3.5 g, 10.8 mmol) was added to a solution of methyl 3-bromopropanoate (<b>13a</b>, 1.07 g, 6.5 mmol) and <i>tert</i>-butyl (1<i>H</i>-pyrazol-4-yl)carbamate (<b>12</b>, 1.0 g, 5.43 mmol) in acetonitrile (150 mL). The resulting mixture was heated at 40â50 Â°C for 10 h. Upon completion of the reaction, evaporation of the solvent under reduced pressure gave a residue, which was dissolved in ethyl acetate (300 mL). The organic layer was washed with citric acid (100 mL), water (100 mL), and brine (100 mL), dried over sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel chromatography (petroleum ether/ethyl acetate, 5:1) to give compound <b>14a</b> (1.2 g, yield 82%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.14 (s, 1H), 7.63 (s, 1H), 7.27 (s, 1H), 4.25 (t, <i>J</i> = 6.6 Hz, 2H), 3.59 (s, 3H), 2.82 (t, <i>J</i> = 6.6 Hz, 2H), 1.44 (s, 9H). ESI-MS <i>m</i>/<i>z</i>: 270.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Ethyl 4-(4-((<i>tert</i>-Butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)butanoate (<b>14b</b>)</h4><div class="NLM_p last">Commercially available ethyl 4-bromobutanoate (<b>13b</b>) and <i>tert</i>-butyl (1<i>H</i>-pyrazol-4-yl)carbamate (<b>12)</b> were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14b</b> as a colorless oil, yield 75%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.66 (s, 1H), 7.32 (s, 1H), 6.41 (s, 1H), 4.13 (q, <i>J</i> = 7.1 Hz, 4H), 2.29 (t, <i>J</i> = 7.2 Hz, 2H), 2.15 (p, <i>J</i> = 6.9 Hz, 2H), 1.50 (s, 9H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 298.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Ethyl 5-(4-((<i>tert</i>-Butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)pentanoate (<b>14c</b>)</h4><div class="NLM_p last">Commercially available ethyl 5-bromopentanoate (<b>13c</b>) and <i>tert</i>-butyl (1<i>H</i>-pyrazol-4-yl)carbamate (<b>12</b>) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14c</b> as a colorless oil, yield 71%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.13 (s, 1H), 7.67 (s, 1H), 7.31 (s, 1H), 4.07â4.02 (m, 2H), 4.00 (d, <i>J</i> = 6.6 Hz, 2H), 2.38â2.22 (m, 2H), 1.77â1.63 (m, 2H), 1.44 (s, 9H), 1.40 (d, <i>J</i> = 7.5 Hz, 2H), 1.16 (t, <i>J</i> = 7.1 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 312.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Ethyl 6-(4-((<i>tert</i>-Butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>14d</b>)</h4><div class="NLM_p last">Commercially available ethyl 6-bromohexanoate (<b>13d</b>) and <i>tert</i>-butyl (1<i>H</i>-pyrazol-4-yl)carbamate (<b>12</b>) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14d</b> as a colorless oil, 76% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.13 (s, 1H), 7.62 (s, 1H), 7.25 (s, 1H), 4.06â4.01 (m, 2H), 4.01â3.95 (m, 2H), 2.25 (t, <i>J</i> = 7.4 Hz, 2H), 1.76â1.64 (m, 2H), 1.54â1.48 (m, 2H), 1.44 (s, 9H), 1.22â1.13 (m, 5H). ESI-MS <i>m</i>/<i>z</i>: 326.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Ethyl 7-(4-((<i>tert</i>-Butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14e</b>)</h4><div class="NLM_p last">Commercially available ethyl 7-bromoheptanoate (<b>13e</b>) and <i>tert</i>-butyl (1<i>H</i>-pyrazol-4-yl)carbamate (<b>12</b>) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14e</b> as a colorless oil, 78% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.09 (s, 1H), 7.60 (s, 1H), 7.23 (s, 1H), 4.05â4.00 (m, 2H), 3.99â3.94 (m, 2H), 2.23 (t, <i>J</i> = 7.4 Hz, 2H), 1.67 (p, <i>J</i> = 7.1 Hz, 2H), 1.49â1.44 (m, 2H), 1.42 (s, 9H), 1.27â1.21 (m, 2H), 1.15 (td, <i>J</i> = 7.2, 3.6 Hz, 5H). ESI-MS <i>m</i>/<i>z</i>: 340.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Ethyl 8-(4-((<i>tert</i>-Butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)octanoate (<b>14f</b>)</h4><div class="NLM_p last">Commercially available ethyl 8-bromooctanoate (<b>13f</b>) and <i>tert</i>-butyl (1<i>H</i>-pyrazol-4-yl)carbamate (<b>12</b>) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14f</b> as a colorless oil, 84% yield. ESI-MS <i>m</i>/<i>z</i>: 354.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Methyl 4-((4-((<i>tert</i>-Butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)methyl)benzoate (<b>14g</b>)</h4><div class="NLM_p last">Commercially available methyl 4-(bromomethyl)benzoate (<b>13g</b>) and <i>tert</i>-butyl (1<i>H</i>-pyrazol-4-yl)carbamate (<b>12</b>) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14g</b> as a white solid, 55% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.19 (s, 1H), 7.92 (d, <i>J</i> = 8.3 Hz, 2H), 7.78 (s, 1H), 7.36â7.25 (m, 3H), 5.34 (s, 2H), 3.84 (s, 3H), 1.43 (s, 9H). ESI-MS <i>m</i>/<i>z</i>: 332.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Methyl (<i>E</i>)-3-(4-((4-((<i>tert</i>-Butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)methyl) phenyl)acrylate (<b>14h</b>)</h4><div class="NLM_p last">Commercially available (<i>E</i>)-3-(4-(bromomethyl)phenyl)acrylate (<b>13h</b>) and <i>tert</i>-butyl (1<i>H</i>-pyrazol-4-yl)carbamate (<b>12</b>) were reacted using a procedure similar to the synthesis of <b>14a</b>, affording compound <b>14h</b> as a white solid, 51% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.16 (s, 1H), 7.74 (s, 1H), 7.68 (d, <i>J</i> = 8.2 Hz, 2H), 7.63 (d, <i>J</i> = 16.1 Hz, 1H), 7.31 (s, 1H), 7.22 (d, <i>J</i> = 8.1 Hz, 2H), 6.62 (d, <i>J</i> = 16.0 Hz, 1H), 5.26 (s, 2H), 3.72 (s, 3H), 1.43 (s, 9H). ESI-MS <i>m</i>/<i>z</i>: 358.2 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> General Procedure for the Preparation of <b>15a</b>â<b>h</b></h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Methyl 3-(4-Amino-1<i>H</i>-pyrazol-1-yl)propanoate Hydrochloride (<b>15a</b>)</h4><div class="NLM_p last">A mixture of methyl 3-(4-((<i>tert</i>-butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)propanoate (<b>14a</b>, 0.6 g, 2.23 mmol) in HCl/ethyl acetate (25 mL) was stirred at room temperature for 6â10 h. The white precipitate was filtered to give the pure compound <b>15a</b> (0.4 g, yield 87%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.26 (s, 3H), 7.96 (s, 1H), 7.53 (s, 1H), 4.36 (t, <i>J</i> = 6.6 Hz, 2H), 3.59 (s, 3H), 2.88 (t, <i>J</i> = 6.6 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 170.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Ethyl 4-(4-Amino-1<i>H</i>-pyrazol-1-yl)butanoate Hydrochloride (<b>15b</b>)</h4><div class="NLM_p last">Ethyl 4-(4-((<i>tert</i>-butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)butanoate (<b>14b</b>) was reacted using a procedure similar to the synthesis of <b>15a</b>, affording compound <b>15b</b> as a white solid, 85% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.39 (s, 3H), 7.97 (s, 1H), 7.54 (s, 1H), 4.15 (t, <i>J</i> = 6.9 Hz, 2H), 4.05 (q, <i>J</i> = 7.1 Hz, 2H), 2.25 (t, <i>J</i> = 7.4 Hz, 2H), 1.99 (p, <i>J</i> = 7.1 Hz, 2H), 1.17 (t, <i>J</i> = 7.1 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 198.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Ethyl 5-(4-Amino-1<i>H</i>-pyrazol-1-yl)pentanoate Hydrochloride (<b>15c</b>)</h4><div class="NLM_p last">Ethyl 5-(4-((<i>tert</i>-butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)pentanoate (<b>14c</b>) was reacted using a procedure similar to the synthesis of <b>15a</b>, affording compound <b>15c</b> as a white solid, 80% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.30 (s, 3H), 7.97 (s, 1H), 7.53 (s, 1H), 4.12 (t, <i>J</i> = 6.9 Hz, 2H), 4.04 (q, <i>J</i> = 7.1 Hz, 2H), 2.31 (t, <i>J</i> = 7.5 Hz, 2H), 1.87â1.68 (m, 2H), 1.44 (dt, <i>J</i> = 15.1, 7.6 Hz, 2H), 1.17 (t, <i>J</i> = 7.1 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 212.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Ethyl 6-(4-Amino-1<i>H</i>-pyrazol-1-yl)hexanoate Hydrochloride (<b>15d</b>)</h4><div class="NLM_p last">Ethyl 6-(4-((<i>tert</i>-butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl) hexanoate (<b>14d</b>) was reacted using a procedure similar to the synthesis of <b>15a</b>, affording compound <b>15d</b> as a white solid, 75% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.35 (s, 3H), 7.97 (s, 1H), 7.52 (s, 1H), 4.10 (t, <i>J</i> = 7.0 Hz, 2H), 4.04 (q, <i>J</i> = 7.1 Hz, 2H), 2.26 (t, <i>J</i> = 7.4 Hz, 2H), 1.82â1.65 (m, 2H), 1.61â1.44 (m, 2H), 1.19 (dt, <i>J</i> =14.2, 7.6 Hz, 5H). ESI-MS <i>m</i>/<i>z</i>: 226.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Ethyl 7-(4-Amino-1<i>H</i>-pyrazol-1-yl)heptanoate Hydrochloride (<b>15e</b>)</h4><div class="NLM_p last">Ethyl 7-(4-((<i>tert</i>-butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>14e</b>) was reacted using a procedure similar to the synthesis of <b>15a</b>, affording compound <b>15e</b> as a white solid, 63% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.22 (s, 3H), 7.95 (s, 1H), 7.52 (s, 1H), 4.10 (t, <i>J</i> = 7.0 Hz, 2H), 4.04 (q, <i>J</i> = 7.1 Hz, 2H), 2.22 (s, 2H), 1.82â1.65 (m, 2H), 1.57â1.40 (m, 2H), 1.28 (dd, <i>J</i> = 15.2, 7.3 Hz, 2H), 1.24â1.19 (m, 2H), 1.17 (t, <i>J</i> = 7.1 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 240.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Ethyl 8-(4-Amino-1<i>H</i>-pyrazol-1-yl)octanoate Hydrochloride (<b>15f</b>)</h4><div class="NLM_p last">Ethyl 8-(4-((<i>tert</i>-butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)octanoate (<b>14f</b>) was reacted using a procedure similar to the synthesis of <b>15a</b>, affording compound <b>15f</b> as a white solid, 93% yield. ESI-MS <i>m</i>/<i>z</i>: 254.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Methyl 4-((4-Amino-1<i>H</i>-pyrazol-1-yl)methyl)benzoate Hydrochloride (<b>15g</b>)</h4><div class="NLM_p last">Methyl 4-((4-((<i>tert</i>-butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)methyl)benzoate (<b>14g</b>) was reacted using a procedure similar to the synthesis of <b>15a</b>, affording compound <b>15g</b> as a white solid, 75% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.18 (s, 3H), 8.13 (s, 1H), 7.94 (d, <i>J</i> = 8.3 Hz, 2H), 7.60 (s, 1H), 7.35 (d, <i>J</i> = 8.3 Hz, 2H), 5.46 (s, 2H), 3.84 (s, 3H). ESI-MS <i>m</i>/<i>z</i>: 232.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Methyl (<i>E</i>)-3-(4-((4-Amino-1<i>H</i>-pyrazol-1-yl)methyl)phenyl)acrylate Hydrochloride (<b>15h</b>)</h4><div class="NLM_p last">Methyl (<i>E</i>)-3-(4-((4-((<i>tert</i>-butoxycarbonyl)amino)-1<i>H</i>-pyrazol-1-yl)methyl) phenyl)acrylate (<b>14h</b>) was reacted using a procedure similar to the synthesis of <b>15a</b>, affording compound <b>15h</b> as a white solid, 63% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.12 (d, <i>J</i> = 39.7 Hz, 3H), 8.09 (s, 1H), 7.70 (d, <i>J</i> = 8.2 Hz, 2H), 7.64 (d, <i>J</i> = 16.1 Hz, 1H), 7.58 (s, 1H), 7.27 (d, <i>J</i> = 8.2 Hz, 2H), 6.63 (d, <i>J</i> = 16.1 Hz, 1H), 5.38 (s, 2H). ESI-MS <i>m</i>/<i>z</i>: 258.3 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 2,5-Dichloro-<i>N</i>-(3-chlorophenyl)pyrimidin-4-amine (<b>17a</b>)</h3><div class="NLM_p last">To a solution of 2,4,5-trichloropyrimidine (<b>16a</b>, 0.6 g, 3.3 mmol) and 3-chloroaniline (0.48 g, 3.8 mmol) in ethanol (30 mL) was added Na<sub>2</sub>CO<sub>3</sub> (1.4 g, 13.2 mmol). The mixture was stirred at room temperature overnight. When the reaction was complete as determined by TLC, the resulting mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (120 mL) and washed with water (50 mL), 1 M citric acid (50 mL), and brine (100 mL) and then dried over sodium sulfate. Filtration and solvent evaporation gave the crude product, which was purified by silica gel chromatography (petroleum ether/ethyl acetate, 5:1) to afford <b>17a</b> (0.4 g, yield 44%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.62 (s, 1H), 8.43 (s, 1H), 7.76 (s, 1H), 7.61 (d, <i>J</i> = 8.1 Hz, 1H), 7.42 (t, <i>J</i> = 8.1 Hz, 1H), 7.25 (d, <i>J</i> = 8.0 Hz, 1H). ESI-MS <i>m</i>/<i>z</i>: 274.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 2,5-Dichloro-<i>N</i>-(4-chlorophenyl)pyrimidin-4-amine (<b>17b</b>)</h3><div class="NLM_p last"><i>N</i>-Ethyl-<i>N</i>-isopropylpropan-2-amine (1.3 g, 10.0 mmol) was added to a solution of 2,4,5-trichloropyrimidine (<b>16a</b>, 1.0 g, 5.5 mmol) and 4-chloroaniline (1.27 g, 10 mmol) in DMF (30 mL). The mixture was stirred at room temperature overnight. When the reaction was completed as detected by TLC, the solution was poured into ethyl acetate (150 mL) and washed with water (50 mL Ã 3), 1 M citric acid (50 mL), and brine (100 mL) and then dried over sodium sulfate. Filtration and solvent evaporation gave the crude product, which was purified by silica gel chromatography (petroleum ether/ethyl acetate, 5:1) to afford <b>17b</b> (0.9 g, yield 60%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.59 (s, 1H), 8.41 (s, 1H), 7.72â7.56 (m, 2H), 7.51â7.39 (m, 2H). ESI-MS <i>m</i>/<i>z</i>: 274.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 2,5-Dichloro-<i>N</i>-(2-chlorophenyl)pyrimidin-4-amine (<b>17c</b>)</h3><div class="NLM_p last"><i>N</i>-Ethyl-<i>N</i>-isopropylpropan-2-amine (1.0 g, 7.7 mmol) was added to a solution of 2,4,5-trichloropyrimidine (<b>16a</b>, 1.0 g, 5.5 mmol) and 2-chloroaniline (0.74 g, 5.5 mmol) in NMP (20 mL). The mixture was stirred at 100 Â°C overnight. When the reaction was complete as determined by TLC, the solution was poured into ethyl acetate (150 mL) and washed with water (50 mL Ã 3), 1 M citric acid (50 mL), and brine (100 mL) and then dried over sodium sulfate. Filtration and solvent evaporation gave the crude product, which was purified by silica gel chromatography (petroleum ether/ethyl acetate, 50:1) to afford <b>17c</b> (0.6 g, yield 40%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.63 (s, 1H), 8.40 (s, 1H), 7.60 (dd, <i>J</i> = 7.8, 1.1 Hz, 1H), 7.52 (dd, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.40 (m, 2H). ESI-MS <i>m</i>/<i>z</i>: 274.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> 2,5-Dichloro-<i>N</i>-phenylpyrimidin-4-amine (<b>17d</b>)</h3><div class="NLM_p last">2,4,5-Trichloropyrimidine (<b>16a</b>) and aniline were reacted using a procedure similar to the synthesis of compound <b>17b</b>, affording <b>17d</b> as a white solid, 77% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.70 (s, 1H), 8.86â8.36 (s, 1H), 8.09â7.15 (m, 5H). ESI-MS <i>m</i>/<i>z</i>: 240.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 2,5-Dichloro-<i>N</i>-(4-methoxyphenyl)pyrimidin-4-amine (<b>17e</b>)</h3><div class="NLM_p last">2,4,5-Trichloropyrimidine (<b>16a</b>) and 4-methoxyaniline were reacted using a procedure similar to the synthesis of compound <b>17b</b>, affording <b>17e</b> as a gold yellow solid, 82% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.44 (s, 1H), 8.32 (s, 1H), 7.43 (d, <i>J</i> = 8.9 Hz, 2H), 6.96 (d, <i>J</i> = 9.0 Hz, 2H), 3.77 (s, 3H). ESI-MS <i>m</i>/<i>z</i>: 270.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 2,5-Dichloro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine (<b>17f</b>)</h3><div class="NLM_p last">2,4,5-Trichloropyrimidine (<b>16a</b>) and 4-fluoroaniline were reacted using a procedure similar to the synthesis of compound <b>17b</b>, affording <b>17f</b> as an off-white solid, 57% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.57 (s, 1H), 8.37 (d, <i>J</i> = 3.7 Hz, 1H), 7.66â7.53 (m, 2H), 7.31â7.18 (m, 2H). ESI-MS <i>m</i>/<i>z</i>: 258.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 4-(2,5-Dichloropyrimidin-4-yl)morpholine (<b>17g</b>)</h3><div class="NLM_p last">To a solution of 2,4,5-trichloropyrimidine (<b>16a</b>, 1.0 g, 5.5 mmol) in ethanol (30 mL) was slowly added morpholine (0.87 g, 10 mmol) in an ice bath. The mixture was stirred for about 3 h; when the reaction was complete as determined by TLC, the resulting mixture was concentrated under reduced pressure. The residue was washed with 20 mL of petroleum ether to obtain <b>17g</b> (0.9 g, yield 70%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.53 (s, 1H), 3.84â3.75 (m, 2H), 3.10â3.02 (m, 2H). ESI-MS <i>m</i>/<i>z</i>: 234.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 2,5-Dichloro-4-(piperidin-1-yl)pyrimidine (<b>17h</b>)</h3><div class="NLM_p last">2,4,5-Trichloropyrimidine (<b>16a</b>) and piperidine were reacted using a procedure similar to the synthesis of <b>17g</b>, affording compound <b>17h</b> as a white solid, 78% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.27 (s, 1H), 3.69 (d, <i>J</i> = 5.7 Hz, 4H), 1.61 (d, <i>J</i> = 7.9 Hz, 6H). ESI-MS <i>m</i>/<i>z</i>: 232.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 2,5-Dichloro-<i>N</i>-cyclopropylpyrimidin-4-amine (<b>17i</b>)</h3><div class="NLM_p last">2,4,5-Trichloropyrimidine (<b>16a</b>) and cyclopropanamine were reacted using a procedure similar to the synthesis of <b>17g</b>, affording compound <b>17i</b> as a white solid, 63% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.39 (s, 3H), 2.53 (dd, <i>J</i> = 7.6, 4.2 Hz, 1H), 0.78â0.72 (m, 2H), 0.71â0.63 (m, 2H). ESI-MS <i>m</i>/<i>z</i>: 204.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 2,5-Dichloro-<i>N</i>-propylpyrimidin-4-amine (<b>17j</b>)</h3><div class="NLM_p last">2,4,5-Trichloropyrimidine (<b>16a</b>) and propan-1-amine were reacted using a procedure similar to the synthesis of <b>17g</b>, affording compound <b>17j</b> as a white solid, 73% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.19 (s, 3H), 2.82â2.60 (m, 2H), 1.74â1.47 (m, 2H), 0.90 (t, <i>J</i> = 7.5 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 206.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 2,5-Dichloro-<i>N</i>-methylpyrimidin-4-amine (<b>17k</b>)</h3><div class="NLM_p last">2,4,5-Trichloropyrimidine (<b>16a</b>) and CH<sub>3</sub>NH<sub>2</sub>/ethanol were reacted using a procedure similar to the synthesis of <b>17g</b>, affording compound <b>17k</b> as a white sold, 83% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.13 (s, 1H), 7.92 (br, 1H), 2.86 (d, <i>J</i> = 4.8 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 177.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> 2-Chloro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine (<b>17l</b>)</h3><div class="NLM_p last">2,4-Dichloropyrimidine (<b>16b</b>) and 4-fluoroaniline were reacted using a procedure similar to the synthesis of compound <b>17a</b>, affording <b>17l</b> as a white solid, 40% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.03 (s, 1H), 8.15 (d, <i>J</i> = 5.9 Hz, 1H), 7.59 (dd, <i>J</i> = 8.8, 5.0 Hz, 2H), 7.29â7.16 (m, 2H), 6.71 (d, <i>J</i> = 5.9 Hz, 1H). ESI-MS <i>m</i>/<i>z</i>: 224.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> 2-Chloro-5-fluoro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine (<b>17m</b>)</h3><div class="NLM_p last">The solution of 2,4-dichloro-5-fluoropyrimidine (<b>16c</b>, 1.0 g, 6.1 mmol) and 4-fluoroaniline (0.75 g, 6.7 mmol) in the mixed reagents (30 mL water/10 mL methanol) was stirred at 50 Â°C for 5 h until a substantial amount of white precipitate appeared. The white precipitate was filtered and washed with 20 mL of petroleum ether. The precipitate was collected and dried in air to afford <b>17m</b> (1.0 g, yield 68%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.02 (s, 1H), 8.32 (d, <i>J</i> = 3.5 Hz, 1H), 7.82â7.60 (m, 2H), 7.32â7.18 (m, 2H). ESI-MS <i>m</i>/<i>z</i>: 242.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> 2-Chloro-<i>N</i>-(4-fluorophenyl)-5-(trifluoromethyl)pyrimidin-4-amine (<b>17n</b>)</h3><div class="NLM_p last">The solution of 2,4-dichloro-5-(trifluoromethyl)pyrimidine (<b>16d</b>, 1.2 g, 5.5 mmol) and 4-fluoroaniline (0.74 g, 6.6 mmol) in 50 mL of ethanol was stirred at â50 Â°C for 1 h. When the reaction was complete as determined by TLC, the resulting mixture was concentrated under reduced pressure. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate, 10:1) to afford <b>17n</b> (0.4 g, 25%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.54 (s, 1H), 8.58 (s, 1H), 7.45 (dd, <i>J</i> = 8.7, 5.0 Hz, 2H), 7.25 (t, <i>J</i> = 8.7 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 292.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> 2-Chloro-<i>N</i>-methyl-5-(trifluoromethyl)pyrimidin-4-amine (<b>17o</b>)</h3><div class="NLM_p last">2,4-Dichloro-5-(trifluoromethyl)pyrimidine (<b>16d</b>) and methylamine in ethanol were reacted using a procedure similar to the synthesis of compound <b>17n</b>, affording <b>17o</b> as a white solid, 30% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.48 (s, 1H), 8.04 (s, 1H), 3.00 (d, <i>J</i> = 4.5 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 212.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> General Procedure for the Preparation of <b>18a</b>â<b>z</b></h3><div id="sec4_22_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> Ethyl 7-(4-((5-Chloro-4-((3-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18a</b>)</h4><div class="NLM_p last">To a solution of 2,5-dichloro-<i>N</i>-(3-chlorophenyl)pyrimidin-4-amine (<b>17a</b>, 0.25 g, 0.91 mmol) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>, 0.16 g, 0.59 mmol) in butanol (12 mL) was added trifluoroacetic acid (0.5 mL). The mixture was irradiated in a microwave (150 W) at 130 Â°C for 3 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane/methanol/tetraethylammonium, 100:1:0.25) to afford <b>18a</b> (0.15 g, yield 53%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.25 (s, 1H), 8.96 (s, 1H), 8.10 (s, 1H), 7.50â7.29 (m, 6H), 4.02 (q, <i>J</i> = 7.1 Hz, 2H), 3.89 (d, <i>J</i> = 6.8 Hz, 2H), 2.20 (dt, <i>J</i> = 21.5, 7.4 Hz, 2H), 1.60 (s, 2H), 1.45 (ddd, <i>J</i> = 12.3, 7.1, 3.4 Hz, 2H), 1.22 (t, <i>J</i> = 7.7 Hz, 2H), 1.15 (dd, <i>J</i> = 6.7, 5.3 Hz, 5H). ESI-MS <i>m</i>/<i>z</i>: 477.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> Ethyl 7-(4-((5-Chloro-4-((4-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18b</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(4-chlorophenyl)pyrimidin-4-amine (<b>17b</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18b</b> as a white solid, 60% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.22 (s, 1H), 8.94 (s, 1H), 8.09 (s, 1H), 7.99â7.14 (m, 6H), 3.99 (t, <i>J</i> = 6.6 Hz, 2H), 3.89 (s, 2H), 2.24 (t, <i>J</i> = 7.3 Hz, 2H), 1.60â1.41 (m, 4H), 1.38â1.21 (m, 4H), 0.87 (t, <i>J</i> = 7.3 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 477.6 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Ethyl 7-(4-((5-Chloro-4-((2-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18c</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(2-chlorophenyl)pyrimidin-4-amine (<b>17c</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18c</b> as a white solid, 38% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.21 (s, 1H), 8.91 (s, 1H), 8.04 (s, 1H), 7.95â7.23 (m, 4H), 7.09 (s, 1H), 6.87 (s, 1H), 4.02 (q, <i>J</i> = 7.1 Hz, 2H), 3.69 (s, 2H), 2.22 (dt, <i>J</i> = 14.2, 7.3 Hz, 2H), 1.74â1.34 (m, 4H), 1.22 (t, <i>J</i> = 7.8 Hz, 2H), 1.15 (dt, <i>J</i> = 7.1, 4.0 Hz, 5H). ESI-MS <i>m</i>/<i>z</i>: 477.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Ethyl 7-(4-((5-Chloro-4-(phenylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18d</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-phenylpyrimidin-4-amine (<b>17d</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18d</b> as a white solid, 60% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.18 (s, 1H), 8.84 (s, 1H), 8.06 (s, 1H), 7.50 (d, <i>J</i> = 19.1 Hz, 2H), 7.40 (t, <i>J</i> = 7.4 Hz, 3H), 7.23â7.13 (m, 2H), 4.06â3.95 (m, 2H), 3.85 (s, 2H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.56â1.47 (m, 4H), 1.28â1.14 (m, 4H), 0.87 (t, <i>J</i> = 7.3 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 443.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> Ethyl 7-(4-((5-Chloro-4-((4-methoxyphenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18e</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(4-methoxyphenyl)pyrimidin-4-amine (<b>17e</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride <b>(15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18e</b> as a white solid, 53% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.16 (s, 1H), 8.76 (s, 1H), 8.01 (s, 1H), 7.28â7.18 (m, 4H), 6.99 (d, <i>J</i> = 7.2 Hz, 2H), 4.00 (t, <i>J</i> = 6.6 Hz, 2H), 3.79 (s, 5H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.56â1.47 (m, 4H), 1.31 (dq, <i>J</i> = 14.6, 7.4 Hz, 4H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 473.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> Ethyl 7-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18f</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine <b>(17f</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18f</b> as a white solid, 63% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.46 (s, 1H), 10.16 (s, 1H), 8.30 (s, 1H), 7.67â7.21 (m, 6H), 4.07â3.94 (m, 2H), 3.81 (s, 2H), 2.35â2.14 (m, 2H), 1.58â1.44 (m, 4H), 1.37â1.19 (m, 4H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 461.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Ethyl 7-(4-((5-Chloro-4-morpholinopyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl) heptanoate (<b>18g</b>)</h4><div class="NLM_p last">4-(2,5-Dichloropyrimidin-4-yl)morpholine (<b>17g</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18g</b> as a white solid, 23% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.30 (s, 1H), 8.05 (s, 1H), 7.76 (s, 1H), 7.45 (s, 1H), 4.01 (dt, <i>J</i> = 13.3, 6.7 Hz, 4H), 3.79â3.67 (m, 4H), 3.63â3.50 (m, 4H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.77â1.66 (m, 2H), 1.53â1.49 (m, 2H), 1.36â1.23 (m, 4H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 437.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Ethyl 7-(4-((5-Chloro-4-(piperidin-1-yl)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18h</b>)</h4><div class="NLM_p last">2,5-Dichloro-4-(piperidin-1-yl)pyrimidine (<b>17h</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18h</b> as a white solid, 60% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.21 (s, 1H), 7.99 (s, 1H), 7.77 (s, 1H), 7.45 (s, 1H), 4.10â3.93 (m, 4H), 3.55 (s, 4H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.77â1.66 (m, 2H), 1.63 (s, 6H), 1.53â1.48 (m, 2H), 1.29 (ddd, <i>J</i> = 16.3, 12.1, 6.9 Hz, 4H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 435.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Ethyl 7-(4-((5-Chloro-4-(cyclopropylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18i</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-cyclopropylpyrimidin-4-amine (<b>17i</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18i</b> as a white solid, 36% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.12 (s, 1H), 7.96 (s, 1H), 7.85 (s, 1H), 7.49 (s, 1H), 7.15 (s, 1H), 3.99 (t, <i>J</i> = 6.6 Hz, 4H), 2.90â2.78 (m, 1H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.81â1.64 (m, 2H), 1.53â1.48 (m, 2H), 1.29 (ddd, <i>J</i> = 24.5, 16.1, 8.7 Hz, 4H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H), 0.76 (d, <i>J</i> = 5.2 Hz, 2H), 0.71â0.58 (m, 2H). ESI-MS <i>m</i>/<i>z</i>: 407.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> Ethyl 7-(4-((5-Chloro-4-(propylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18j</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-propylpyrimidin-4-amine (<b>17j</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18j</b> as a white solid, 48% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.00 (s, 1H), 7.84 (s, 1H), 7.77 (s, 1H), 7.43 (s, 1H), 7.10 (s, 1H), 3.99 (dd, <i>J</i> = 13.1, 6.6 Hz, 4H), 3.36 (dd, <i>J</i> = 9.0, 4.8 Hz, 2H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.79â1.66 (m, 2H), 1.60 (td, <i>J</i> = 14.8, 7.5 Hz, 2H), 1.53â1.48 (m, 2H), 1.36â1.24 (m, 4H), 0.89 (dt, <i>J</i> = 14.6, 7.4 Hz, 6H). ESI-MS <i>m</i>/<i>z</i>: 409.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> Ethyl 7-(4-((5-Chloro-4-(methylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18k</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-methylpyrimidin-4-amine (<b>17k</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18k</b> as a white solid, 64% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.03 (s, 1H), 7.84 (s, 1H), 7.81 (s, 1H), 7.46 (s, 1H), 7.08 (s, 1H), 4.18â3.89 (m, 4H), 2.91 (s, 3H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.81â1.64 (m, 2H), 1.50 (td, <i>J</i> = 14.5, 7.2 Hz, 2H), 1.38â1.20 (m, 4H), 1.16 (t, <i>J</i> = 7.1 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 381.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> Ethyl 6-(4-((5-Chloro-4-((3-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>18l</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(3-chlorophenyl)pyrimidin-4-amine (<b>17a</b>) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate hydrochloride (<b>15d</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18l</b> as a white solid, 43% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.26 (s, 1H), 8.95 (s, 1H), 8.11 (s, 1H), 7.95â7.01 (m, 6H), 3.98 (t, <i>J</i> = 6.6 Hz, 2H), 3.92 (s, 2H), 2.24 (t, <i>J</i> = 7.3 Hz, 2H), 1.64 (s, 2H), 1.30 (dq, <i>J</i> = 14.5, 7.3 Hz, 2H), 1.18 (d, <i>J</i> = 6.6 Hz, 2H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 463.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> Ethyl 6-(4-((5-Chloro-4-((4-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>18m</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(4-chlorophenyl)pyrimidin-4-amine (<b>17b</b>) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate hydrochloride (<b>15d</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18m</b> as a white solid, 37% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.22 (s, 1H), 8.93 (s, 1H), 8.09 (s, 1H), 7.94â7.18 (m, 6H), 4.08â3.96 (m, 2H), 3.84 (s, 2H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.65 (s, 2H), 1.38â1.23 (m, 2H), 1.20 (dd, <i>J</i> = 13.6, 6.6 Hz, 2H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 463.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> Ethyl 6-(4-((5-Chloro-4-((2-chlorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>18n</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(2-chlorophenyl)pyrimidin-4-amine (<b>17c</b>) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate hydrochloride (<b>15d</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18n</b> as a white solid, 50% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.22 (s, 1H), 8.93 (s, 1H), 8.09 (s, 1H), 7.94â7.18 (m, 6H), 4.08â3.96 (m, 2H), 3.84 (s, 2H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.65 (s, 2H), 1.38â1.23 (m, 2H), 1.20 (dd, <i>J</i> = 13.6, 6.6 Hz, 2H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 463.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> Ethyl 6-(4-((5-Chloro-4-(methylamino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>18o</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-methylpyrimidin-4-amine (<b>17k</b>) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate hydrochloride (<b>15d</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18o</b> as a white solid, 57% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.02 (s, 1H), 7.83 (d, <i>J</i> = 10.7 Hz, 2H), 7.46 (s, 1H), 7.03 (s, 1H), 4.00 (dt, <i>J</i> = 13.2, 6.8 Hz, 4H), 2.91 (d, <i>J</i> = 4.2 Hz, 3H), 2.26 (t, <i>J</i> = 7.3 Hz, 2H), 1.80â1.65 (m, 2H), 1.52 (dd, <i>J</i> = 6.9, 2.2 Hz, 2H), 1.27â1.17 (m, 2H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 367.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> Ethyl 7-(4-((4-((4-Fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18p</b>)</h4><div class="NLM_p last">2-Chloro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine (<b>17l</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18p</b> as a white solid, 53% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.27 (s, 1H), 8.98 (s, 1H), 7.96 (d, <i>J</i> = 5.7 Hz, 1H), 7.71â7.69 (m, 3H), 7.41 (s, 1H), 7.15 (t, <i>J</i> = 8.6 Hz, 2H), 6.08 (d, <i>J</i> = 5.7 Hz, 1H), 4.86 (q, <i>J</i> = 6.3 Hz, 2H), 3.97 (t, <i>J</i> = 7.2 Hz, 2H), 2.20 (t, <i>J</i> = 7.3 Hz, 2H), 1.69 (t, <i>J</i> = 7.3 Hz, 2H), 1.48 (t, <i>J</i> = 7.4 Hz, 2H), 1.37â1.18 (m, 4H), 1.15 (d, <i>J</i> = 6.3 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 427.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Ethyl 7-(4-((5-Fluoro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18q</b>)</h4><div class="NLM_p last">2-Chloro-5-fluoro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine <b>(17m</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18q</b> as a white solid, 32% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.30 (s, 1H), 9.00 (s, 1H), 8.03 (d, <i>J</i> = 3.8 Hz, 1H), 7.70 (s, 3H), 7.33 (s, 1H), 7.19 (t, <i>J</i> = 8.8 Hz, 2H), 4.05â3.91 (m, 4H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.73â1.60 (m, 2H), 1.53â1.48 (m, 2H), 1.29 (ddd, <i>J</i> = 24.6, 16.1, 8.4 Hz, 4H), 0.88 (dd, <i>J</i> = 7.3, 4.2 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 445.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Ethyl 7-(4-((4-((4-Fluorophenyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18r</b>)</h4><div class="NLM_p last">2-Chloro-<i>N</i>-(4-fluorophenyl)-5-(trifluoromethyl)pyrimidin-4-amine (<b>17n</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18r</b> as a white solid, 20% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.68 (s, 1H), 8.81 (s, 1H), 8.26 (s, 1H), 7.44â7.35 (m, 2H), 7.29 (t, <i>J</i> = 8.7 Hz, 2H), 7.18 (s, 1H), 7.07 (s, 1H), 4.00 (t, <i>J</i> = 6.5 Hz, 2H), 3.76 (t, <i>J</i> = 6.9 Hz, 2H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.52 (dt, <i>J</i> = 6.5, 5.3 Hz, 4H), 1.29â1.19 (m, 4H), 0.93â0.82 (m, 3H). ESI-MS <i>m</i>/<i>z</i>: 495.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> Ethyl 7-(4-((4-(Methylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)heptanoate (<b>18s</b>)</h4><div class="NLM_p last">2-Chloro-<i>N</i>-methyl-5-(trifluoromethyl)pyrimidin-4-amine (<b>17o</b>) and ethyl 7-(4-amino-1<i>H</i>-pyrazol-1-yl)heptanoate hydrochloride (<b>15e</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18s</b> as a white solid, 54% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.55 (s, 1H), 8.08 (s, 1H), 7.85 (s, 1H), 7.53 (s, 1H), 7.07 (s, 1H), 4.01 (dt, <i>J</i> = 13.2, 6.4 Hz, 4H), 2.95 (s, 3H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.83â1.57 (m, 2H), 1.53â1.48 (m, 2H), 1.37â1.23 (m, 4H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 415.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> Methyl 3-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)propanoate (<b>18t</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine (<b>17f</b>) and methyl 3-(4-amino-1<i>H</i>-pyrazol-1-yl)propanoate hydrochloride (<b>15a</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18t</b> as a white solid, 22% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.22 (s, 1H), 8.91 (s, 1H), 8.07 (s, 1H), 7.90â7.10 (m, 6H), 4.13 (s, 3H), 3.99 (t, <i>J</i> = 6.5 Hz, 2H), 2.76 (s, 2H). ESI-MS <i>m</i>/<i>z</i>: 391.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> Ethyl 4-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)butanoate (<b>18u</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine (<b>17f</b>) and ethyl 4-(4-amino-1<i>H</i>-pyrazol-1-yl)butanoate hydrochloride (<b>15b</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18u</b> as a white solid, 58% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.23 (s, 1H), 8.93 (s, 1H), 8.06 (s, 1H) 7.90â7.10 (m, 6H), 4.86 (p, <i>J</i> = 6.3 Hz, 2H), 3.83 (s, 2H), 2.21 (t, <i>J</i> = 7.3 Hz, 2H), 1.80 (s, 2H), 1.17 (d, <i>J</i> = 6.4 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 419.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> Ethyl 5-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)pentanoate (<b>18v</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine (<b>17f</b>) and ethyl 5-(4-amino-1<i>H</i>-pyrazol-1-yl)pentanoate hydrochloride (<b>15c</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18v</b> as a white solid, 49% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.57 (s, 1H), 9.46 (s, 1H), 9.12 (s, 1H), 8.08 (d, <i>J</i> = 3.6 Hz, 1H), 7.77 (s, 2H), 7.39 (d, <i>J</i> = 8.3 Hz, 3H), 4.01 (t, <i>J</i> =6.8 Hz, 4H), 2.29 (t, <i>J</i> = 7.3 Hz, 2H), 1.87â1.61 (m, 2H), 1.49 (dd, <i>J</i> = 15.9, 7.9 Hz, 2H), 1.18â1.10 (m, 3H). ESI-MS <i>m</i>/<i>z</i>: 433.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> Ethyl 6-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)hexanoate (<b>18w</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine (<b>17f</b>) and ethyl 6-(4-amino-1<i>H</i>-pyrazol-1-yl)hexanoate hydrochloride (<b>15d</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18w</b> as a white solid, yield 38%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.23 (s, 1H), 8.93 (s, 1H), 8.06 (s, 1H), 7.77 (s, 1H), 7.48 (s, 2H), 7.25 (s, 3H), 4.86 (p, <i>J</i> = 6.2 Hz, 2H), 3.83 (s, 2H), 2.21 (t, <i>J</i> = 7.3 Hz, 2H), 1.60 (s, 2H), 1.50 (t, <i>J</i> = 7.7 Hz, 2H), 1.15 (d, <i>J</i> = 6.2 Hz, 5H). ESI-MS <i>m</i>/<i>z</i>: 447.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> Ethyl 8-(4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)octanoate (<b>18x</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine (<b>17f</b>) and ethyl 8-(4-amino-1<i>H</i>-pyrazol-1-yl)octanoate hydrochloride (<b>15f</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18x</b> as a white solid, 38% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.23 (s, 1H), 8.93 (s, 1H), 8.06 (s, 1H), 7.61â7.50 (m, 2H), 7.24 (s, 4H), 3.99 (t, <i>J</i> = 6.6 Hz, 2H), 3.83 (s, 2H), 2.26 (t, <i>J</i> = 7.3 Hz, 2H), 1.55â1.46 (m, 4H), 1.31 (dt, <i>J</i> = 14.8, 7.4 Hz, 2H), 1.24 (d, <i>J</i> = 14.0 Hz, 4H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 478.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> Methyl 4-((4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)methyl)benzoate (<b>18y</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine (<b>17f</b>) and methyl 4-((4-amino-1<i>H</i>-pyrazol-1-yl)methyl)benzoate hydrochloride (<b>15g</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18y</b> as a white solid, 77% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.26 (s, 1H), 8.87 (s, 1H), 8.07 (s, 1H), 7.92 (d, <i>J</i> = 8.3 Hz, 2H), 7.46 (s, 4H), 7.20 (s, 2H), 7.11 (s, 2H), 5.23 (s, 2H), 3.84 (s, 3H). ESI-MS <i>m</i>/<i>z</i>: 453.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_22_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> Methyl (<i>E</i>)-3-(4-((4-((5-Chloro-4-((4-fluorophenyl)amino)pyrimidin-2-yl)amino)-1<i>H</i>-pyrazol-1-yl)methyl)phenyl)acrylate (<b>18z</b>)</h4><div class="NLM_p last">2,5-Dichloro-<i>N</i>-(4-fluorophenyl)pyrimidin-4-amine (<b>17f</b>) and methyl (<i>E</i>)-3-(4-((4-amino-1<i>H</i>-pyrazol-1-yl)methyl)phenyl)acrylate hydrochloride (<b>15h</b>) were reacted using a procedure similar to the synthesis of compound <b>18a</b>, affording <b>18z</b> as a white solid, 74% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.23 (s, 1H), 8.85 (s, 1H), 8.06 (s, 1H), 7.74â7.57 (m, 4H), 7.43 (m, 3H), 7.17 (dt, <i>J</i> = 16.7, 8.1 Hz, 4H), 6.61 (dd, <i>J</i> = 16.0, 3.4 Hz, 1H), 5.17 (s, 2H), 3.32 (s, 3H). ESI-MS <i>m</i>/<i>z</i>: 479.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> Molecular Docking Study</h3><div class="NLM_p last">The crystal structures of JAK2 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) and HDAC2 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IWG">5IWG</a>) were obtained from Protein Data Bank. Before the docking process, the structure of the protein was treated by adding hydrogen atoms, deleting water molecules, assigning AMBER7 FF99 charges, and a 100-step minimization process using Sybyl X_2.1. The molecular structure was generated with the Sybyl/Sketch module and optimized using Powellâs method with the Tripos force field with the convergence criterion set at 0.005 kcal/(Ã mol) and assigned charges with the GasteigerâHÃ¼ckel method. Other docking parameters were kept to the default values. Molecular docking was carried out via the Sybyl/Surflex-Dock module.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> Kinase Inhibition Assay</h3><div class="NLM_p last">The kinase inhibition assays were performed by Eurofins Cerep Corporation in France. In brief, evaluation of the effects of compounds on the activity of the human JAKs was quantified by measuring the phosphorylation of the substrate Ulight-CAGAGAIETDKEYYTVKD using human recombinant enzymes and the LANCE detection method. Other kinase inhibition assays were performed as the above method. Origin data analysis software was used to calculate the IC<sub>50</sub> data by the nonlinear curve fitting method (allowed to float and fitted as a parameter).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> In Vitro HDAC Inhibition Fluorescence Assay</h3><div class="NLM_p last">In vitro HDAC inhibition assays were performed as previously described.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> In brief, 10 Î¼L of enzyme solution (HeLa cell nuclear extract, HDAC2, HDAC6, or HDAC8) was mixed with different concentrations of the tested compound (50 Î¼L). The mixture was incubated at 37 Â°C for 5 min, followed by adding 40 Î¼L of the fluorogenic substrate (Boc-Lys(acetyl)-AMC for HeLa cell nuclear extracts, HDAC2 and HDAC6, Boc-Lys(triflouroacetyl)-AMC for HDAC8). After incubation at 37 Â°C for 30 min, the mixture was quenched by addition of 100 Î¼L of the developer containing trypsin and trichostatin A. Over another incubation at 37 Â°C for 20 min, fluorescence intensity was measured using a microplate reader at excitation and emission wavelengths of 390 and 460 nm, respectively. The inhibition ratios were calculated from the fluorescence intensity readout of tested wells relative to those of control wells, and the IC<sub>50</sub> values were calculated using the Prism nonlinear curve fitting method (allowed to float and fitted as a parameter).</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> Western Blot Analysis</h3><div class="NLM_p last">The A549 cells were treated with compounds or DMSO for a specified period of time. Then, the cells were washed twice with cold phosphate-buffered saline (PBS) and lysed in ice-cold radioimmunoprecipitation assay buffer. Lysates were cleared by centrifugation. Protein concentrations were determined using the bicinchoninic acid assay. Equal amounts of cell extracts were then resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, and probed with Ac-histone H4 antibody, Ac-Tub antibody, and Î²-actin antibody, separately. Blots were detected using an enhanced chemiluminescence system. The MDA-MB-231 cells were treated with compounds or DMSO for a specified period of time. The cells were collected and lysed in SDS buffer. Lysates were cleared by centrifugation. The supernate was then resolved by SDS-PAGE, transferred to nitrocellulose membranes, and probed with p-STAT3 antibody, STAT3 antibody, Ac-Tub antibody, Ac-histone H3 antibody, and GAPDH antibody, separately. Blots were detected using an enhanced chemiluminescence system.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> In Vitro Antiproliferative Assay</h3><div class="NLM_p last">Cell proliferation assay was determined by the 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2<i>H</i>-tetrazolium bromide (MTT) method. Briefly, all cell lines were maintained in Roswell Park Memorial Institute 1640 medium containing 10% fetal bovine serum at 37 Â°C in a 5% CO<sub>2</sub> humidified incubator. Cells were passaged into a 96-well cell plate, allowed to grow for 12 h, and then treated with different concentrations of compounds for 48 h. Then, 0.5% MTT solution was added to each well. After incubation for another 4 h, formazan formed from MTT was extracted by adding 200 Î¼L of DMSO. Absorbance was then determined using an enzyme-linked immunosorbent assay reader at 570 nm.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> Apoptosis Assay</h3><div class="NLM_p last">HEL and K562 cells (2 Ã 10<sup>5</sup>) were treated with different concentrations of test compounds for 24 h. Cells were collected after incubation, washed twice in cold PBS, centrifuged, and resuspended in 1Ã annexin-binding buffer. Cells were diluted in 1Ã annexin-binding buffer to about 1 Ã 10<sup>6</sup> cells/mL, preparing a sufficient volume to have 100 Î¼L/assay. To the cell suspension was added 5 Î¼L of annexin V and 10 Î¼L of propidium iodide. After being gently mixed, the flow tube should be incubated at room temperature for 15 min. After the incubation period, the stained cells were analyzed by flow cytometry.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> Pharmacokinetics</h3><div class="NLM_p last">All experiments involving laboratory animals were performed with the approval of the Shandong University Laboratory Animal Center ethics committee. Compound <b>8m</b> was subjected to PK studies in Sprague-Dawley rats and ICR (CD-1) mice. In SD rats, compound <b>8m</b> was dissolved in the solution of 10% DMSO, 40% poly(ethylene glycol)-400, and 50% pure water and then administrated via the oral route at 10 mg/kg (six rats) or administrated via the intravenous route at 2 mg/kg (six rats). Blood samples were collected from each animalâs via jugular vein and stored in ice (0â4 Â°C) at the specific time points. Plasma was separated from the blood by centrifugation and stored in a freezer at â80 Â°C. All samples for the tested compounds were analyzed by liquid chromatography-tandem mass spectrometry (LCâMS/MS). The procedure in ICR (CD-1) mice is similar to above. The difference between the PK studies in ICR (CD-1) mice and in Sprague-Dawley rats is that the former one used IP, not PO dosing (as was employed in Sprague-Dawley rats).</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i128" class="anchor-spacer"></div><h3 class="article-section__title" id="_i128"> In Vitro Stability Evaluation in Sprague-Dawley Rats and Human Liver Microsomes</h3><div class="NLM_p last">For phase I and phase II metabolic stability evaluation, liver microsomes containing compound <b>8m</b> were incubated with NADPH and UDPGA at 37 Â°C. At the specific time points, samples were added to acetonitrile to terminate the reaction, then subjected to vortex mixing for 5 min, and stored in a freezer at â80 Â°C. Before analysis, the samples were centrifuged at 4000 rpm for 15 min. The remaining of <b>8m</b> in the supernatants were analyzed by LCâMS/MS. The <i>t</i><sub>1/2</sub> values were calculated using the equation <i>t</i><sub>1/2</sub> = â0.693/<i>k</i>, where <i>k</i> is the slope found in the linear fit of the natural logarithm of the fraction remaining of <b>8m</b> versus incubation time.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> In Vivo Antitumor Activity Assay in the HEL Xenograft Model</h3><div class="NLM_p">In vivo human tumor xenograft models were established as previously described.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> First, 1 Ã 10<sup>7</sup> HEL cells were inoculated subcutaneously in the right flank of male BALB/c-nu mice (5â6 weeks old, Beijing HFK Bioscience Co., Ltd.). Ten days after injection, tumors were palpable and mice were randomized into treatment and control groups (six mice per group). The treatment groups received specified concentrations of compounds by intraperitoneal administration, and the blank control group received intraperitoneal administration of an equal volume of PBS (5% DMSO). During treatment, subcutaneous tumors were measured with a Vernier caliper every 3 days, and body weight was monitored regularly. Tumor volume (<i>V</i>) was estimated using the equation (<i>V</i> = <i>ab</i><sup>2</sup>/2, where <i>a</i> and <i>b</i> stand for the longest and shortest diameters, respectively).</div><div class="NLM_p">After treatment, mice were sacrificed and dissected to weigh the tumor tissues and to examine the internal organ injury by macroscopic analysis. TGI was calculated according to the following formula:</div><div class="NLM_p">TGI = (mean tumor weight of control group â mean tumor weight of treated group)/mean tumor weight of control group.</div><div class="NLM_p last">All the obtained data were used to evaluate the antitumor potency and toxicity of compounds. Data were analyzed by Studentâs two-tailed <i>t</i> test. A <i>P</i> level <0.05 was considered statistically significant.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> Determination of Drug Concentrations in Plasma and Tumor</h3><div class="NLM_p last">When tumors were palpable, the male BALB/c-nu mice were randomized into treatment and control groups. The treatment groups received specified concentrations of compounds by intraperitoneal administration, and the blank control group received intraperitoneal administration of an equal volume of PBS (5% DMSO). After 5 days treatment with <b>3</b>, <b>1</b>, and <b>8m</b>, mice were sacrificed at 0.5, 1.0, and 4.0 h, respectively, after administration and dissected to collect the blood and weigh the tumor tissues at the specific time points. Plasma was separated from the blood by centrifugation and stored in a freezer at â80 Â°C. The tumor tissues were homogenized with normal saline (5:1 v/w) before ultrasound treatment. The plasma samples and tumor samples were deproteinized with methanol containing an internal standard. After centrifugation, the supernatant was diluted with methanol and acetonitrile and then centrifugated again. The compound concentrations in the supernatant were analyzed by LCâMS/MS.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i131"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01597" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40242" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40242" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01597" class="ext-link">10.1021/acs.jmedchem.8b01597</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H NMR, <sup>13</sup>C NMR, and HPLC spectra of all target compounds and supporting figures and tables (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01597/suppl_file/jm8b01597_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula stings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01597/suppl_file/jm8b01597_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01597/suppl_file/jm8b01597_si_001.pdf">jm8b01597_si_001.pdf (3.84 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01597/suppl_file/jm8b01597_si_002.csv">jm8b01597_si_002.csv (3.15 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01597" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08158" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08158" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0863-7853" title="Orcid link">http://orcid.org/0000-0002-0863-7853</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d9b1b5b0ac99b4b8b0b5f7aab1bab7baf7b8baf7bab7"><span class="__cf_email__" data-cfemail="244c484d516449454d480a574c474a470a45470a474a">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingjie Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Shandong University, Jiânan, Shandong 250012, P. R. China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6118-6695" title="Orcid link">http://orcid.org/0000-0001-6118-6695</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#92e8faf3fcf5ebfbfcf5f8fbf7d2e1f6e7bcf7f6e7bcf1fc"><span class="__cf_email__" data-cfemail="90eaf8f1fef7e9f9fef7faf9f5d0e3f4e5bef5f4e5bef3fe">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuewu Liang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Shandong University, Jiânan, Shandong 250012, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie Zang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Shandong University, Jiânan, Shandong 250012, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyang Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina 29425, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3684-2106" title="Orcid link">http://orcid.org/0000-0003-3684-2106</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuai Tang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Huang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meiyu Geng</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">C. James Chou</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina 29425, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6808-9089" title="Orcid link">http://orcid.org/0000-0001-6808-9089</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunpu Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yichun Cao</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Fudan University, 826 Zhanghen Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenfang Xu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Shandong University, Jiânan, Shandong 250012, P. R. China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e7989-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i132">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58546" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58546" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by National High-Tech R&D Program of China (863 Program) (2014AA020523), Natural Science Foundation of Shandong Province (Grant No. ZR2018QH007), Major Project of Science and Technology of Shandong Province (2017CXGC1401), and Young Scholars Program of Shandong University (YSPSDU, 2016WLJH33).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">CTCL</td><td class="NLM_def"><p class="first last">cutaneous T-cell lymphoma</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-like receptor tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">MF</td><td class="NLM_def"><p class="first last">myelofibrosis</p></td></tr><tr><td class="NLM_term">MPNs</td><td class="NLM_def"><p class="first last">Philadelphia chromosome-negative myeloproliferative neoplasms</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">PTCL</td><td class="NLM_def"><p class="first last">peripheral T-cell lymphoma</p></td></tr><tr><td class="NLM_term">PV</td><td class="NLM_def"><p class="first last">polycythemia vera</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">UDPGA</td><td class="NLM_def"><p class="first last">uridine diphosphate glucuronic acid</p></td></tr><tr><td class="NLM_term">VEGFR2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 2</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i134">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26566" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26566" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 43 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabner, B. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors in Cancer Therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5459</span>â <span class="NLM_lpage">5468</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2009.22.1291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1200%2FJCO.2009.22.1291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=19826124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKkt7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=5459-5468&author=A.+A.+Laneauthor=B.+A.+Chabner&title=Histone+Deacetylase+Inhibitors+in+Cancer+Therapy&doi=10.1200%2FJCO.2009.22.1291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors in cancer therapy</span></div><div class="casAuthors">Lane, Andrew A.; Chabner, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5459-5468</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose: Epigenetic processes are implicated in cancer causation and progression.  The acetylation status of histones regulates access of transcription factors to DNA and influences levels of gene expression.  Histone deacetylase (HDAC) activity diminishes acetylation of histones, causing compaction of the DNA/histone complex.  This compaction blocks gene transcription and inhibits differentiation, providing a rationale for developing HDAC inhibitors.  Methods: In this review, we explore the biol. of the HDAC enzymes, summarize the pharmacol. properties of HDAC inhibitors, and examine results of selected clin. trials.  We consider the potential of these inhibitors in combination therapy with targeted drugs and with cytotoxic chemotherapy.  Results: HDAC inhibitors promote growth arrest, differentiation, and apoptosis of tumor cells, with minimal effects on normal tissue.  In addn. to decompaction of the histone/DNA complex, HDAC inhibition also affects acetylation status and function of nonhistone proteins.  HDAC inhibitors have demonstrated antitumor activity in clin. trials, and one drug of this class, vorinostat, is US Food and Drug Administration approved for the treatment of cutaneous T-cell lymphoma.  Other inhibitors in advanced stages of clin. development, including depsipeptide and MGCD0103, differ from vorinostat in structure and isoenzyme specificity, and have shown activity against lymphoma, leukemia, and solid tumors.  Promising preclin. activity in combination with cytotoxics, inhibitors of heat shock protein 90, and inhibitors of proteasome function have led to combination therapy trials.  Conclusion: HDAC inhibitors are an important emerging therapy with single-agent activity against multiple cancers, and have significant potential in combination use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVyuJFNi_TFrVg90H21EOLACvtfcHk0lhWXzpSQ-Otrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKkt7vE&md5=2752b7df219427b6758b69828f95efb4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.1291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.1291%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DA.%2BA.%26aulast%3DChabner%26aufirst%3DB.%2BA.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520in%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D5459%26epage%3D5468%26doi%3D10.1200%2FJCO.2009.22.1291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Libby, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burwick, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensinger, W. I.</span></span> <span> </span><span class="NLM_article-title">Panobinostat: A Review of Trial Results and Future Prospects in Multiple Myeloma</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">18</span>, <span class="refDoi">Â DOI: 10.1586/17474086.2015.983065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1586%2F17474086.2015.983065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=25410127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvFemsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=9-18&author=E.+N.+Libbyauthor=P.+S.+Beckerauthor=N.+Burwickauthor=D.+J.+Greenauthor=L.+Holmbergauthor=W.+I.+Bensinger&title=Panobinostat%3A+A+Review+of+Trial+Results+and+Future+Prospects+in+Multiple+Myeloma&doi=10.1586%2F17474086.2015.983065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat: a review of trial results and future prospects in multiple myeloma</span></div><div class="casAuthors">Libby, Edward N.; Becker, Pamela S.; Burwick, Nicholas; Green, Damian J.; Holmberg, Leona; Bensinger, William Ira</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Multiple myeloma is an incurable often devastating disease that is responsible for 1-2% of all cancers.  Multiple myeloma is the second most common hematol. malignancy.  Over the past two decades, advances in therapy have doubled life expectancy.  Unfortunately, all patients ultimately relapse.  Novel agents (immunomodulatory drugs and proteasome inhibitors) have changed the outlook for patients, but further breakthroughs are needed.  Epigenetic treatments offer potential for advancing therapy by modifying oncogene responses.  The acetylation status of various proteins can affect the availability of chromatin for transcription.  This response may be modulated epigenetically to advantage using histone deacetylase inhibitors like panobinostat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYo-p3uvsAR7Vg90H21EOLACvtfcHk0lj7ZgnHuKjXhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvFemsA%253D%253D&md5=dd585819692a3a7af7b6786041ec6010</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1586%2F17474086.2015.983065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17474086.2015.983065%26sid%3Dliteratum%253Aachs%26aulast%3DLibby%26aufirst%3DE.%2BN.%26aulast%3DBecker%26aufirst%3DP.%2BS.%26aulast%3DBurwick%26aufirst%3DN.%26aulast%3DGreen%26aufirst%3DD.%2BJ.%26aulast%3DHolmberg%26aufirst%3DL.%26aulast%3DBensinger%26aufirst%3DW.%2BI.%26atitle%3DPanobinostat%253A%2520A%2520Review%2520of%2520Trial%2520Results%2520and%2520Future%2520Prospects%2520in%2520Multiple%2520Myeloma%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2015%26volume%3D8%26spage%3D9%26epage%3D18%26doi%3D10.1586%2F17474086.2015.983065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Anticancer Activities of Histone Deacetylase Inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">769</span>â <span class="NLM_lpage">784</span>, <span class="refDoi">Â DOI: 10.1038/nrd2133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+W.+Johnstone&title=Anticancer+Activities+of+Histone+Deacetylase+Inhibitors&doi=10.1038%2Fnrd2133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0lj7ZgnHuKjXhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DAnticancer%2520Activities%2520of%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784%26doi%3D10.1038%2Fnrd2133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span> <span> </span><span class="NLM_article-title">Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">459</span>â <span class="NLM_lpage">473</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2Fj.ccell.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=27622335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=459-473&author=H.+Zengauthor=J.+Quauthor=N.+Jinauthor=J.+Xuauthor=C.+Linauthor=Y.+Chenauthor=X.+Yangauthor=X.+Heauthor=S.+Tangauthor=X.+Lanauthor=X.+Yangauthor=Z.+Chenauthor=M.+Huangauthor=J.+Dingauthor=M.+Geng&title=Feedback+Activation+of+Leukemia+Inhibitory+Factor+Receptor+Limits+Response+to+Histone+Deacetylase+Inhibitors+in+Breast+Cancer&doi=10.1016%2Fj.ccell.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer</span></div><div class="casAuthors">Zeng, Hanlin; Qu, Jia; Jin, Nan; Xu, Jun; Lin, Chenchu; Chen, Yi; Yang, Xinying; He, Xiang; Tang, Shuai; Lan, Xiaojing; Yang, Xiaotong; Chen, Ziqi; Huang, Min; Ding, Jian; Geng, Meiyu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-473</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have demonstrated clin. benefits in subtypes of hematol. malignancies.  However, the efficacy of HDAC inhibitors in solid tumors remains uncertain.  This study takes breast cancer as a model to understand mechanisms accounting for limited response of HDAC inhibitors in solid tumors and to seek combination solns.  We discover that feedback activation of leukemia inhibitory factor receptor (LIFR) signaling in breast cancer limits the response to HDAC inhibition.  Mechanistically, HDAC inhibition increases histone acetylation at the LIFR gene promoter, which recruits bromodomain protein BRD4, upregulates LIFR expression, and activates JAK1-STAT3 signaling.  Importantly, JAK1 or BRD4 inhibition sensitizes breast cancer to HDAC inhibitors, implicating combination inhibition of HDAC with JAK1 or BRD4 as potential therapies for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL24sYbhFYeLVg90H21EOLACvtfcHk0lj7ZgnHuKjXhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI&md5=9ce620c7a19519a95edd714f8012518c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DLan%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26atitle%3DFeedback%2520Activation%2520of%2520Leukemia%2520Inhibitory%2520Factor%2520Receptor%2520Limits%2520Response%2520to%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520Breast%2520Cancer%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D459%26epage%3D473%26doi%3D10.1016%2Fj.ccell.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loboda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooden, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span> <span> </span><span class="NLM_article-title">Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-cell Lymphoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">3785</span>â <span class="NLM_lpage">3794</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-07-6091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1158%2F0008-5472.CAN-07-6091" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3785-3794&author=V.+R.+Fantinauthor=A.+Lobodaauthor=C.+P.+Paweletzauthor=R.+C.+Hendricksonauthor=J.+W.+Pierceauthor=J.+A.+Rothauthor=L.+Liauthor=F.+Goodenauthor=S.+Korenchukauthor=X.+S.+Houauthor=E.+A.+Harringtonauthor=S.+Randolphauthor=J.+F.+Reillyauthor=C.+M.+Wareauthor=M.+E.+Kadinauthor=S.+R.+Frankelauthor=V.+M.+Richon&title=Constitutive+Activation+of+Signal+Transducers+and+Activators+of+Transcription+Predicts+Vorinostat+Resistance+in+Cutaneous+T-cell+Lymphoma&doi=10.1158%2F0008-5472.CAN-07-6091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6091%26sid%3Dliteratum%253Aachs%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DLoboda%26aufirst%3DA.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DHendrickson%26aufirst%3DR.%2BC.%26aulast%3DPierce%26aufirst%3DJ.%2BW.%26aulast%3DRoth%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGooden%26aufirst%3DF.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DHou%26aufirst%3DX.%2BS.%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DRandolph%26aufirst%3DS.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DWare%26aufirst%3DC.%2BM.%26aulast%3DKadin%26aufirst%3DM.%2BE.%26aulast%3DFrankel%26aufirst%3DS.%2BR.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26atitle%3DConstitutive%2520Activation%2520of%2520Signal%2520Transducers%2520and%2520Activators%2520of%2520Transcription%2520Predicts%2520Vorinostat%2520Resistance%2520in%2520Cutaneous%2520T-cell%2520Lymphoma%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3785%26epage%3D3794%26doi%3D10.1158%2F0008-5472.CAN-07-6091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">QuintÃ¡s-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Janus Kinase Inhibitors for the Treatment of Myeloproliferative Neoplasias and Beyond</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">140</span>, <span class="refDoi">Â DOI: 10.1038/nrd3264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnrd3264" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=127-140&author=A.+Quint%C3%A1s-Cardamaauthor=H.+Kantarjianauthor=J.+Cortesauthor=S.+Verstovsek&title=Janus+Kinase+Inhibitors+for+the+Treatment+of+Myeloproliferative+Neoplasias+and+Beyond&doi=10.1038%2Fnrd3264"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd3264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3264%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DJanus%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Myeloproliferative%2520Neoplasias%2520and%2520Beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D127%26epage%3D140%26doi%3D10.1038%2Fnrd3264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borie, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">A New Modality for Immunosuppression: Targeting the JAK/STAT Pathway</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">555</span>â <span class="NLM_lpage">564</span>, <span class="refDoi">Â DOI: 10.1038/nrd1441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnrd1441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=15232577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Oru7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=555-564&author=J.+J.+O%E2%80%99Sheaauthor=M.+Pesuauthor=D.+C.+Borieauthor=P.+S.+Changelian&title=A+New+Modality+for+Immunosuppression%3A+Targeting+the+JAK%2FSTAT+Pathway&doi=10.1038%2Fnrd1441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A new modality for immunosuppression: targeting the JAK/STAT pathway</span></div><div class="casAuthors">O'Shea, John J.; Pesu, Marko; Borie, Dominic C.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">555-564</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Thousands of organs are transplanted each year and millions of people suffer from autoimmune diseases, which creates a need for an armamentarium of immunosuppressive drugs.  Unfortunately, immunosuppressants have unwanted side effects owing, in part, to the fact that they have ubiquitous mol. targets.  Cytokines have emerged as important controllers of the immune response, and work during the past decade has identified Janus kinases (JAKs) and signal transducers, and activators of transcription (STATs), as crucial intracellular elements in cytokine signalling.  Here, we discuss the potential of the JAK/STAT pathway as a target for new immunosuppressants.  In particular, the inhibition of JAK3 seems to be an excellent strategy, because of the selective expression and precise functions of this kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhrBmh4tsEibVg90H21EOLACvtfcHk0lgl615xW-nATg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Oru7o%253D&md5=7f09261dbb7c43b4eedb750a35f8e7d5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd1441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1441%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DA%2520New%2520Modality%2520for%2520Immunosuppression%253A%2520Targeting%2520the%2520JAK%252FSTAT%2520Pathway%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D555%26epage%3D564%26doi%3D10.1038%2Fnrd1441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourouclas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassiliou, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bench, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erber, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. R.</span></span> <span> </span><span class="NLM_article-title">Cancer Genome, Project. Acquired Mutation of the Tyrosine Kinase JAK2 in Human Myeloproliferative Disorders</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">1054</span>â <span class="NLM_lpage">1061</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(05)74230-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2FS0140-6736%2805%2974230-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=15781101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFGrs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=1054-1061&author=E.+J.+Baxterauthor=L.+M.+Scottauthor=P.+J.+Campbellauthor=C.+Eastauthor=N.+Fourouclasauthor=S.+Swantonauthor=G.+S.+Vassiliouauthor=A.+J.+Benchauthor=E.+M.+Boydauthor=N.+Curtinauthor=M.+A.+Scottauthor=W.+N.+Erberauthor=A.+R.+Green&title=Cancer+Genome%2C+Project.+Acquired+Mutation+of+the+Tyrosine+Kinase+JAK2+in+Human+Myeloproliferative+Disorders&doi=10.1016%2FS0140-6736%2805%2974230-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</span></div><div class="casAuthors">Baxter, E. Joanna; Scott, Linda M.; Campbell, Peter J.; East, Clare; Fourouclas, Nasios; Swanton, Soheila; Vassiliou, George S.; Bench, Anthony J.; Boyd, Elaine M.; Curtin, Natasha; Scott, Mike A.; Erber, Wendy N.; Green, Anthony R.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">9464</span>),
    <span class="NLM_cas:pages">1054-1061</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Human myeloproliferative disorders form a range of clonal haematol. malignant diseases, the main members of which are polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.  The mol. pathogenesis of these disorders is unknown, but tyrosine kinases have been implicated in several related disorders.  We investigated the role of the cytoplasmic tyrosine kinase JAK2 in patients with a myeloproliferative disorder.  Methods: We obtained DNA samples from patients with polycythemia vera, essential thrombocythemia, or idiopathic myelofibrosis.  The coding exons of JAK2 were bidirectionally sequenced from peripheral-blood granulocytes, T cells, or both.  Allele-specific PCR, mol. cytogenetic studies, microsatellite PCR, Affymetrix single nucleotide polymorphism array analyses, and colony assays were undertaken on subgroups of patients.  Findings: A single point mutation (Val617Phe) was identified in JAK2 in 71 (97%) of 73 patients with polycythemia vera, 29 (57%) of 51 with essential thrombocythemia, and eight (50%) of 16 with idiopathic myelofibrosis.  The mutation is acquired, is present in a variable proportion of granulocytes, alters a highly conserved valine present in the neg. regulatory JH2 domain, and is predicted to dysregulate kinase activity.  It was heterozygous in most patients, homozygous in a subset as a result of mitotic recombination, and arose in a multipotent progenitor capable of giving rise to erythroid and myeloid cells.  The mutation was present in all erythropoietin-independent erythroid colonies.  Interpretation: A single acquired mutation of JAK2 was noted in more than half of patients with a myeloproliferative disorder.  Its presence in all erythropoietin-independent erythroid colonies demonstrates a link with growth factor hypersensitivity, a key biol. feature of these disorders.  Relevance to practice: Identification of the Val617Phe JAK2 mutation lays the foundation for new approaches to the diagnosis, classification, and treatment of myeloproliferative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8cc-kg2leZrVg90H21EOLACvtfcHk0lgl615xW-nATg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFGrs7g%253D&md5=3c9dc565a1986a47d12e4bccd8c8cc1a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974230-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974230-6%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26aulast%3DEast%26aufirst%3DC.%26aulast%3DFourouclas%26aufirst%3DN.%26aulast%3DSwanton%26aufirst%3DS.%26aulast%3DVassiliou%26aufirst%3DG.%2BS.%26aulast%3DBench%26aufirst%3DA.%2BJ.%26aulast%3DBoyd%26aufirst%3DE.%2BM.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BA.%26aulast%3DErber%26aufirst%3DW.%2BN.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26atitle%3DCancer%2520Genome%252C%2520Project.%2520Acquired%2520Mutation%2520of%2520the%2520Tyrosine%2520Kinase%2520JAK2%2520in%2520Human%2520Myeloproliferative%2520Disorders%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D1054%26epage%3D1061%26doi%3D10.1016%2FS0140-6736%2805%2974230-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">James, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Couedic, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staerk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delhommeau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacout, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raslova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennaceur-Griscelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeval, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadevall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span> <span> </span><span class="NLM_article-title">A Unique Clonal JAK2 Mutation Leading to Constitutive Signalling Causes Polycythaemia Vera</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span>,  <span class="NLM_fpage">1144</span>â <span class="NLM_lpage">1148</span>, <span class="refDoi">Â DOI: 10.1038/nature03546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnature03546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=15793561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=1144-1148&author=C.+Jamesauthor=V.+Ugoauthor=J.+P.+Le+Couedicauthor=J.+Staerkauthor=F.+Delhommeauauthor=C.+Lacoutauthor=L.+Garconauthor=H.+Raslovaauthor=R.+Bergerauthor=A.+Bennaceur-Griscelliauthor=J.+L.+Villevalauthor=S.+N.+Constantinescuauthor=N.+Casadevallauthor=W.+Vainchenker&title=A+Unique+Clonal+JAK2+Mutation+Leading+to+Constitutive+Signalling+Causes+Polycythaemia+Vera&doi=10.1038%2Fnature03546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span></div><div class="casAuthors">James, Chloe; Ugo, Valerie; Le Couedic, Jean-Pierre; Staerk, Judith; Delhommeau, Francois; Lacout, Catherine; Garcon, Loic; Raslova, Hana; Berger, Roland; Bennaceur-Griscelli, Annelise; Villeval, Jean Luc; Constantinescu, Stefan N.; Casadevall, Nicole; Vainchenker, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7037</span>),
    <span class="NLM_cas:pages">1144-1148</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative disorders are clonal hematopoietic stem cell malignancies characterized by independency or hypersensitivity of hematopoietic progenitors to numerous cytokines.  The mol. basis of most myeloproliferative disorders is unknown.  On the basis of the model of chronic myeloid leukemia, it is expected that a constitutive tyrosine kinase activity could be at the origin of these diseases.  Polycythemia vera is an acquired myeloproliferative disorder, characterized by the presence of polycythemia diversely assocd. with thrombocytosis, leukocytosis and splenomegaly.  Polycythemia vera progenitors are hypersensitive to erythropoietin and other cytokines.  Here, the authors describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (>80%) polycythemia vera patients.  The mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model.  As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new mol. classification of these disorders and novel therapeutical approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-6NigTwc97Vg90H21EOLACvtfcHk0ljQ1PZzZRBj7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D&md5=9e9c223dd4e2da2ebf52d14edda85963</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature03546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03546%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DC.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DLe%2BCouedic%26aufirst%3DJ.%2BP.%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DLacout%26aufirst%3DC.%26aulast%3DGarcon%26aufirst%3DL.%26aulast%3DRaslova%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBennaceur-Griscelli%26aufirst%3DA.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26atitle%3DA%2520Unique%2520Clonal%2520JAK2%2520Mutation%2520Leading%2520to%2520Constitutive%2520Signalling%2520Causes%2520Polycythaemia%2520Vera%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D1144%26epage%3D1148%26doi%3D10.1038%2Fnature03546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kralovics, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buser, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiedt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passweg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoda, R. C.</span></span> <span> </span><span class="NLM_article-title">A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1779</span>â <span class="NLM_lpage">1790</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa051113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1056%2FNEJMoa051113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=15858187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1779-1790&author=R.+Kralovicsauthor=F.+Passamontiauthor=A.+S.+Buserauthor=S.+S.+Teoauthor=R.+Tiedtauthor=J.+R.+Passwegauthor=A.+Tichelliauthor=M.+Cazzolaauthor=R.+C.+Skoda&title=A+Gain-of-Function+Mutation+of+JAK2+in+Myeloproliferative+Disorders&doi=10.1056%2FNEJMoa051113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A gain-of-function mutation of JAK2 in myeloproliferative disorders</span></div><div class="casAuthors">Kralovics, Robert; Passamonti, Francesco; Buser, Andreas S.; Teo, Soon-Siong; Tiedt, Ralph; Passweg, Jakob R.; Tichelli, Andre; Cazzola, Mario; Skoda, Radek C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1779-1790</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are clonal myeloproliferative disorders arising from a multi-potent progenitor.  The loss of heterozygosity (LOH) on the short arm of chromosome 9 (9pLOH) in myeloproliferative disorders suggests that 9p harbors a mutation that contributes to the cause of clonal expansion of hematopoietic cells in these diseases.  METHODS We performed microsatellite mapping of the 9pLOH region and DNA sequencing in 244 patients with myeloproliferative disorders (128 with polycythemia vera, 93 with essential thrombocythemia, and 23 with idiopathic myelofibrosis).  RESULTS Microsatellite mapping identified a 9pLOH region that included the Janus kinase 2 (JAK2) gene.  In patients with 9pLOH, JAK2 had a homozygous GâT transversion, causing phenylalanine to be substituted for valine at position 617 of JAK2 (V617F).  All 51 patients with 9pLOH had the V617F mutation.  Of 193 patients without 9pLOH, 66 were heterozygous for V617F and 127 did not have the mutation.  The frequency of V617F was 65 % among patients with polycythemia vera (83 of 128), 57 % among patients with idiopathic myelofibrosis (13 of 23), and 23 % among patients with essential thrombocythemia (21 of 93).  V617F is a somatic mutation present in hematopoietic cells.  Mitotic recombination probably causes both 9pLOH and the transition from heterozygosity to homozygosity for V617F.  Genetic evidence and in vitro functional studies indicate that V617F gives hematopoietic precursors proliferative and survival advantages.  Patients with the V617F mutation had a significantly longer duration of disease and a higher rate of complications (fibrosis, hemorrhage, and thrombosis) and treatment with cytoreductive therapy than patients with wild-type JAK2.  CONCLUSIONS A high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqTe7EsB_527Vg90H21EOLACvtfcHk0ljQ1PZzZRBj7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsLw%253D&md5=5dd4bc090ded1c812b61923cad36e77e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa051113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa051113%26sid%3Dliteratum%253Aachs%26aulast%3DKralovics%26aufirst%3DR.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DBuser%26aufirst%3DA.%2BS.%26aulast%3DTeo%26aufirst%3DS.%2BS.%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DPassweg%26aufirst%3DJ.%2BR.%26aulast%3DTichelli%26aufirst%3DA.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26atitle%3DA%2520Gain-of-Function%2520Mutation%2520of%2520JAK2%2520in%2520Myeloproliferative%2520Disorders%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1779%26epage%3D1790%26doi%3D10.1056%2FNEJMoa051113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadleigh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntly, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelsperger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Activating Mutation in the Tyrosine Kinase JAK2 in Polycythemia Vera, Essential Thrombocythemia, and Myeloid Metaplasia with Myelofibrosis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">387</span>â <span class="NLM_lpage">397</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2005.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2Fj.ccr.2005.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=15837627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=387-397&author=R.+L.+Levineauthor=M.+Wadleighauthor=J.+Coolsauthor=B.+L.+Ebertauthor=G.+Wernigauthor=B.+J.+Huntlyauthor=T.+J.+Boggonauthor=I.+Wlodarskaauthor=J.+J.+Clarkauthor=S.+Mooreauthor=J.+Adelspergerauthor=S.+Kooauthor=J.+C.+Leeauthor=S.+Gabrielauthor=T.+Mercherauthor=A.+D%E2%80%99Andreaauthor=S.+Frohlingauthor=K.+Dohnerauthor=P.+Marynenauthor=P.+Vandenbergheauthor=R.+A.+Mesaauthor=A.+Tefferiauthor=J.+D.+Griffinauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=T.+R.+Golubauthor=S.+J.+Leeauthor=D.+G.+Gilliland&title=Activating+Mutation+in+the+Tyrosine+Kinase+JAK2+in+Polycythemia+Vera%2C+Essential+Thrombocythemia%2C+and+Myeloid+Metaplasia+with+Myelofibrosis&doi=10.1016%2Fj.ccr.2005.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</span></div><div class="casAuthors">Levine, Ross L.; Wadleigh, Martha; Cools, Jan; Ebert, Benjamin L.; Wernig, Gerlinde; Huntly, Brian J. P.; Boggon, Titus J.; Wlodarska, Iwona; Clark, Jennifer J.; Moore, Sandra; Adelsperger, Jennifer; Koo, Sumin; Lee, Jeffrey C.; Gabriel, Stacey; Mercher, Thomas; D'Andrea, Alan; Froehling, Stefan; Doehner, Konstanze; Marynen, Peter; Vandenberghe, Peter; Mesa, Ruben A.; Tefferi, Ayalew; Griffin, James D.; Eck, Michael J.; Sellers, William R.; Meyerson, Matthew; Golub, Todd R.; Lee, Stephanie J.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">387-397</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors.  An internet-based protocol was used to collect clin. information and biol. specimens from patients with these diseases.  High-throughput DNA re-sequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations.  Mol. and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele.  JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not obsd. in 269 normal individuals.  In vitro anal. demonstrated that JAK2V617F is a constitutively active tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJNzUFm3Q3bVg90H21EOLACvtfcHk0lilagrY4d4Ysg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D&md5=2a3e893867b114e8749cd6f5e55990b7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DHuntly%26aufirst%3DB.%2BJ.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DAdelsperger%26aufirst%3DJ.%26aulast%3DKoo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DMercher%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DActivating%2520Mutation%2520in%2520the%2520Tyrosine%2520Kinase%2520JAK2%2520in%2520Polycythemia%2520Vera%252C%2520Essential%2520Thrombocythemia%252C%2520and%2520Myeloid%2520Metaplasia%2520with%2520Myelofibrosis%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D387%26epage%3D397%26doi%3D10.1016%2Fj.ccr.2005.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Overcoming Treatment Challenges in Myelofibrosis and Polycythemia Vera: the Role of Ruxolitinib</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1125</span>â <span class="NLM_lpage">1142</span>, <span class="refDoi">Â DOI: 10.1007/s00280-016-3012-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1007%2Fs00280-016-3012-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=27017614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28XltF2rtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2016&pages=1125-1142&author=J.+C.+Bryanauthor=S.+Verstovsek&title=Overcoming+Treatment+Challenges+in+Myelofibrosis+and+Polycythemia+Vera%3A+the+Role+of+Ruxolitinib&doi=10.1007%2Fs00280-016-3012-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib</span></div><div class="casAuthors">Bryan, Jeffrey C.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1125-1142</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Myelofibrosis (MF) and polycythemia vera (PV) are BCR-ABL1-neg. myeloproliferative neoplasms assocd. with somatic hematopoietic stem cell mutations leading to over activation of JAK-STAT signaling.  MF and PV are pathogenically related and share specific clin. features such as splenomegaly and constitutional symptoms.  The MF phenotype is dominated by the effects of progressive bone marrow fibrosis resulting in shortened survival.  In contrast, elevated thrombosis risk due to erythrocytosis is the primary clin. concern in PV.  Ruxolitinib, an oral JAK1/JAK2 inhibitor, is approved in the USA for the treatment of patients with intermediate- or high-risk MF and patients with PV who have had an inadequate response to or are intolerant of hydroxyurea.  For MF, results of two phase III studies demonstrated that ruxolitinib therapy reduced spleen vol. and MF-related symptom burden, improved quality-of-life measures, and was assocd. with prolonged overall survival.  Treatment benefits were generally sustained with continued therapy.  Dose-dependent cytopenias were common but generally manageable with transfusions (for anemia), dose redn., or treatment interruption.  Optimal dosing management is crit. to maintain long-term treatment benefit, because cessation of therapy resulted in rapid return of symptoms to baseline levels.  Results of the phase III PV trial showed that ruxolitinib was significantly more effective than std. therapy in controlling hematocrit levels and improving splenomegaly and PV-related symptoms.  Only 1 of 110 patients in the ruxolitinib arm compared with 6 of 112 patients in the control arm experienced a thromboembolic event through week 32.  Grade â¥3 cytopenias were uncommon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJdrGniqBGrVg90H21EOLACvtfcHk0lilagrY4d4Ysg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltF2rtrY%253D&md5=8e24890058631f83b5fd157d7d6f2b0f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3012-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3012-z%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DJ.%2BC.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DOvercoming%2520Treatment%2520Challenges%2520in%2520Myelofibrosis%2520and%2520Polycythemia%2520Vera%253A%2520the%2520Role%2520of%2520Ruxolitinib%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D77%26spage%3D1125%26epage%3D1142%26doi%3D10.1007%2Fs00280-016-3012-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bose, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">JAK2 Inhibitors for Myeloproliferative Neoplasms: What Is Next?</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">115</span>â <span class="NLM_lpage">125</span>, <span class="refDoi">Â DOI: 10.1182/blood-2017-04-742288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1182%2Fblood-2017-04-742288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=28500170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WnurbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=115-125&author=P.+Boseauthor=S.+Verstovsek&title=JAK2+Inhibitors+for+Myeloproliferative+Neoplasms%3A+What+Is+Next%3F&doi=10.1182%2Fblood-2017-04-742288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2 inhibitors for myeloproliferative neoplasms: what is next?</span></div><div class="casAuthors">Bose, Prithviraj; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-126</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing.  Several other JAK2 inhibitors have entered clin. testing, but none have been approved and many have been discontinued.  Importantly, the activity of these agents is not restricted to patients with JAK2 V617F or exon 12 mutations.  Although JAK2 inhibitors provide substantial clin. benefit, their disease-modifying activity is limited, and rational combinations with other targeted agents are needed, particularly in MF, in which survival is short.  Many such combinations are being explored, as are other novel agents, some of which could successfully be combined with JAK2 inhibitors in the future.  In addn., new JAK2 inhibitors with the potential for less myelosuppression continue to be investigated.  Given the proven safety and efficacy of ruxolitinib, it is likely that ruxolitinib-based combinations will be a major way forward in drug development for MF.  If approved, less myelosuppressive JAK2 inhibitors such as pacritinib or NS-018 could prove to be very useful addns. to the therapeutic armamentarium in MF.  In PV, inhibitors of histone deacetylases and human double minute 2 have activity, but their role, if any, in the future treatment algorithm is uncertain, given the availability of ruxolitinib and renewed interest in interferons.  Ruxolitinib is in late-phase clin. trials in essential thrombocythemia, in which it could fill an important void for patients with troublesome symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr05BKuhh_JNLVg90H21EOLACvtfcHk0lilagrY4d4Ysg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WnurbI&md5=a00ec9709cb423c06211f89fe05445ae</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-04-742288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-04-742288%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DJAK2%2520Inhibitors%2520for%2520Myeloproliferative%2520Neoplasms%253A%2520What%2520Is%2520Next%253F%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D115%26epage%3D125%26doi%3D10.1182%2Fblood-2017-04-742288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaFave, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">JAK2 the Future: Therapeutic Strategies for JAK-Dependent Malignancies</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">574</span>â <span class="NLM_lpage">582</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2012.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2Fj.tips.2012.08.005" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=574-582&author=L.+M.+LaFaveauthor=R.+L.+Levine&title=JAK2+the+Future%3A+Therapeutic+Strategies+for+JAK-Dependent+Malignancies&doi=10.1016%2Fj.tips.2012.08.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DLaFave%26aufirst%3DL.%2BM.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DJAK2%2520the%2520Future%253A%2520Therapeutic%2520Strategies%2520for%2520JAK-Dependent%2520Malignancies%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D574%26epage%3D582%26doi%3D10.1016%2Fj.tips.2012.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">What Is Next Beyond Janus Kinase 2 Inhibitors for Primary Myelofibrosis?</span>. <i>Curr. Opin. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">123</span>â <span class="NLM_lpage">129</span>, <span class="refDoi">Â DOI: 10.1097/MOH.0b013e32835d8e10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1097%2FMOH.0b013e32835d8e10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=23385614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=123-129&author=F.+P.+Santosauthor=S.+Verstovsek&title=What+Is+Next+Beyond+Janus+Kinase+2+Inhibitors+for+Primary+Myelofibrosis%3F&doi=10.1097%2FMOH.0b013e32835d8e10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?</span></div><div class="casAuthors">Santos, Fabio P. S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-129</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Although the approval of the janus kinase (JAK) inhibitor ruxolitinib for therapy of patients with myelofibrosis represents an important step in the development of targeted therapy for these patients, JAK inhibitors do not eradicate the disease, and a review of novel agents with mechanisms of action complementary to JAK2 enzymic inhibition is timely.  Recent findings: There are several compds. with different mechanisms of action undergoing preclin. and clin. testing in myelofibrosis.  Heat shock protein inhibitors and histone deacetylase inhibitors induce JAK2 degrdn. and downregulation of intracellular oncogenic signalling, and may overcome resistance to JAK2 inhibitors.  Reversal of bone marrow fibrosis is still a therapeutic challenge in this disease, and mAbs targeting transforming growth factor-Î² and lysyl oxidase like-2 may prove efficacious.  Promising compds. inhibiting signal transducer and activator of transcription 5 activity and inducing megakaryocyte polyploidization are in preclin. testing.  Summary: Although none of these new drugs have been approved for therapy of myelofibrosis, their activity is being tested in clin. trials, alone or in combination with JAK2 inhibitors.  Patients with myelofibrosis should be encouraged to participate in clin. trials testing novel compds. for this disorder, particularly if they have failed a trial of JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gqDFCRlvYrVg90H21EOLACvtfcHk0lhNaIMQpGEkWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D&md5=49159c335e02a416c0541d8b92069f4e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e32835d8e10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e32835d8e10%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DF.%2BP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DWhat%2520Is%2520Next%2520Beyond%2520Janus%2520Kinase%25202%2520Inhibitors%2520for%2520Primary%2520Myelofibrosis%253F%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2013%26volume%3D20%26spage%3D123%26epage%3D129%26doi%3D10.1097%2FMOH.0b013e32835d8e10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reuther, G. W.</span></span> <span> </span><span class="NLM_article-title">Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics</span>. <i>Prog. Mol. Biol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">437</span>â <span class="NLM_lpage">484</span>, <span class="refDoi">Â DOI: 10.1016/bs.pmbts.2016.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2Fbs.pmbts.2016.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=27865464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A280%3ADC%252BC2snot1enug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2016&pages=437-484&author=G.+W.+Reuther&title=Myeloproliferative+Neoplasms%3A+Molecular+Drivers+and+Therapeutics&doi=10.1016%2Fbs.pmbts.2016.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics</span></div><div class="casAuthors">Reuther G W</div><div class="citationInfo"><span class="NLM_cas:title">Progress in molecular biology and translational science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">437-484</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Activating mutations in genes that drive neoplastic cell growth are numerous and widespread in cancer, and specific genetic alterations are associated with certain types of cancer.  For example, classic myeloproliferative neoplasms (MPNs) are hematopoietic stem cell disorders that affect cells of the myeloid lineage, including erythrocytes, platelets, and granulocytes.  An activating mutation in the JAK2 tyrosine kinase is prevalent in these diseases.  In MPN patients that lack such a mutation, other genetic changes that lead to activation of the JAK2 signaling pathway are present, indicating deregulation of JAK2 signaling plays an etiological driving role in MPNs, a concept supported by significant evidence from in vivo experimental MPN systems.  Thus, small molecules that inhibit JAK2 activity are ideal drugs to impede the progression of disease in MPN patients.  However, even though JAK inhibitors provide significant symptomatic relief, they have failed as a remission-inducing therapy.  Nonetheless, the progress made understanding the molecular etiology of MPNs since 2005 is significant and has provided insight for the development and testing of novel molecular targeted therapeutic approaches.  The current understanding of driver mutations in MPNs and an overview of current and potential therapeutic strategies for MPN patients will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRi64LuFKtexCO2kE7krGOBfW6udTcc2eYDkaYBn3oua7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snot1enug%253D%253D&md5=9c2c3af37062ca1bbf15a874170ffdb5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmbts.2016.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmbts.2016.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DReuther%26aufirst%3DG.%2BW.%26atitle%3DMyeloproliferative%2520Neoplasms%253A%2520Molecular%2520Drivers%2520and%2520Therapeutics%26jtitle%3DProg.%2520Mol.%2520Biol.%2520Transl.%2520Sci.%26date%3D2016%26volume%3D144%26spage%3D437%26epage%3D484%26doi%3D10.1016%2Fbs.pmbts.2016.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bose, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Myelofibrosis: An Update on Drug Therapy in 2016</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2375</span>â <span class="NLM_lpage">2389</span>, <span class="refDoi">Â DOI: 10.1080/14656566.2016.1252333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1080%2F14656566.2016.1252333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=27774820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKltb%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=2375-2389&author=P.+Boseauthor=S.+Verstovsek&title=Myelofibrosis%3A+An+Update+on+Drug+Therapy+in+2016&doi=10.1080%2F14656566.2016.1252333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Myelofibrosis: an update on drug therapy in 2016</span></div><div class="casAuthors">Bose, Prithviraj; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2375-2389</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Primary myelofibrosis (PMF) is the least common but the most aggressive of the classic Philadelphia chromosome-neg. myeloproliferative neoplasms.  Survival is much shorter in PMF than in polycythemia vera (PV) or essential thrombocythemia (ET).  Post-PV/ET myelofibrosis (MF) is clin. indistinguishable from PMF and approached similarly.: Current pharmacol. therapy of MF revolves around the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, which dramatically improves constitutional symptoms and splenomegaly in the majority of patients, and improves overall survival (OS).  However, allogeneic stem cell transplantation remains the only potential cure.  Other JAK inhibitors continue to be developed for MF, and momelotinib and pacritinib are in phase III clin. trials.  Anemia is common in MF, and initially worsened by ruxolitinib.  Momelotinib and pacritinib may prove advantageous in this regard.  Current strategies for managing anemia of MF include danazol, immunomodulatory drugs and erythroid stimulating agents, either alone or in combination with ruxolitinib.: A no. of other agents, representing diverse drug classes, are in various stages of development for MF.  These include newer JAK inhibitors, other signaling inhibitors, epigenetic modifiers, anti-fibrotic agents, telomerase inhibitors, and activin receptor ligand traps (for anemia).  Hopefully, these novel therapies will further extend the clin. benefits of ruxolitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJrOVEwApIsLVg90H21EOLACvtfcHk0lhNaIMQpGEkWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKltb%252FL&md5=2df28795d127525f62d600d31d1b9a5b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F14656566.2016.1252333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2016.1252333%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DMyelofibrosis%253A%2520An%2520Update%2520on%2520Drug%2520Therapy%2520in%25202016%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2016%26volume%3D17%26spage%3D2375%26epage%3D2389%26doi%3D10.1080%2F14656566.2016.1252333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span>. <i>Clin Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2051</span>â <span class="NLM_lpage">2059</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+Pathways%3A+Molecular+Basis+for+Sensitivity+and+Resistance+to+JAK+Kinase+Inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0ljFV2YxmzmsjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520Pathways%253A%2520Molecular%2520Basis%2520for%2520Sensitivity%2520and%2520Resistance%2520to%2520JAK%2520Kinase%2520Inhibitors%26jtitle%3DClin%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilpivaara, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hricik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullally, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marubayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>489</i></span>,  <span class="NLM_fpage">155</span>â <span class="NLM_lpage">159</span>, <span class="refDoi">Â DOI: 10.1038/nature11303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnature11303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=22820254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=489&publication_year=2012&pages=155-159&author=P.+Koppikarauthor=N.+Bhagwatauthor=O.+Kilpivaaraauthor=T.+Manshouriauthor=M.+Adliauthor=T.+Hricikauthor=F.+Liuauthor=L.+M.+Saundersauthor=A.+Mullallyauthor=O.+Abdel-Wahabauthor=L.+Leungauthor=A.+Weinsteinauthor=S.+Marubayashiauthor=A.+Goelauthor=M.+Gonenauthor=Z.+Estrovauthor=B.+L.+Ebertauthor=G.+L.+Chiosisauthor=S.+D.+Nimerauthor=B.+E.+Bernsteinauthor=S.+Verstovsekauthor=R.+L.+Levine&title=Heterodimeric+JAK-STAT+Activation+As+a+Mechanism+of+Persistence+to+JAK2+Inhibitor+Therapy&doi=10.1038%2Fnature11303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span></div><div class="casAuthors">Koppikar, Priya; Bhagwat, Neha; Kilpivaara, Outi; Manshouri, Taghi; Adli, Mazhar; Hricik, Todd; Liu, Fan; Saunders, Lindsay M.; Mullally, Ann; Abdel-Wahab, Omar; Leung, Laura; Weinstein, Abby; Marubayashi, Sachie; Goel, Aviva; Goenen, Mithat; Estrov, Zeev; Ebert, Benjamin L.; Chiosis, Gabriela; Nimer, Stephen D.; Bernstein, Bradley E.; Verstovsek, Srdan; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">489</span>
        (<span class="NLM_cas:issue">7414</span>),
    <span class="NLM_cas:pages">155-159</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of somatic activating mutations in JAK2 (refs 1-4) and in the thrombopoietin receptor gene (MPL) in most patients with myeloproliferative neoplasm (MPN) led to the clin. development of JAK2 kinase inhibitors.  JAK2 inhibitor therapy improves MPN-assocd. splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN.  We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2.  Here we show that JAK2 inhibitor persistence is assocd. with reactivation of JAK-STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 intrans by other JAK kinases.  Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is assocd. with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression.  We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors.  RNA interference and pharmacol. studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression.  Consequently, therapies that result in JAK2 degrdn. retain efficacy in persistent cells and may provide addnl. benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlKcCqEPMbLLVg90H21EOLACvtfcHk0ljFV2YxmzmsjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI&md5=3289538048859aa236965d985b2ef79f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnature11303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11303%26sid%3Dliteratum%253Aachs%26aulast%3DKoppikar%26aufirst%3DP.%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DKilpivaara%26aufirst%3DO.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DAdli%26aufirst%3DM.%26aulast%3DHricik%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DSaunders%26aufirst%3DL.%2BM.%26aulast%3DMullally%26aufirst%3DA.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DWeinstein%26aufirst%3DA.%26aulast%3DMarubayashi%26aufirst%3DS.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DChiosis%26aufirst%3DG.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DHeterodimeric%2520JAK-STAT%2520Activation%2520As%2520a%2520Mechanism%2520of%2520Persistence%2520to%2520JAK2%2520Inhibitor%2520Therapy%26jtitle%3DNature%26date%3D2012%26volume%3D489%26spage%3D155%26epage%3D159%26doi%3D10.1038%2Fnature11303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellacasa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carobbio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Introna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaldi, A.</span></span> <span> </span><span class="NLM_article-title">The Histone Deacetylase Inhibitor ITF2357 Selectively Targets Cells Bearing Mutated JAK2(V617F)</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">740</span>â <span class="NLM_lpage">747</span>, <span class="refDoi">Â DOI: 10.1038/sj.leu.2405049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fsj.leu.2405049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=18079739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=740-747&author=V.+Gueriniauthor=V.+Barbuiauthor=O.+Spinelliauthor=A.+Salviauthor=C.+Dellacasaauthor=A.+Carobbioauthor=M.+Intronaauthor=T.+Barbuiauthor=J.+Golayauthor=A.+Rambaldi&title=The+Histone+Deacetylase+Inhibitor+ITF2357+Selectively+Targets+Cells+Bearing+Mutated+JAK2%28V617F%29&doi=10.1038%2Fsj.leu.2405049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F</span></div><div class="casAuthors">Guerini, V.; Barbui, V.; Spinelli, O.; Salvi, A.; Dellacasa, C.; Carobbio, A.; Introna, M.; Barbui, T.; Golay, J.; Rambaldi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-747</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors investigated the activity of ITF2357, a novel histone deacetylase inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2V617F mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line.  The clonogenic activity of JAK2V617F mutated cells was inhibited by low concns. of ITF2357 (IC50 0.001-0.01 Î¼), 100- to 250-fold lower than required to inhibit growth of normal or tumor cells lacking this mutation.  Under these conditions, ITF2357 allowed a seven fold increase in the outgrowth of unmutated over mutated colonies.  By western blotting the authors showed that in HEL cells, ITF2357 led to the disappearance of total and phosphorylated JAK2V617F as well as pSTAT5 and pSTAT3, but it did not affect the wild-type JAK2 or STAT proteins in the control K562 cell line.  By real-time PCR, the authors showed that, upon exposure to ITF2357, JAK2V617F mRNA was not modified in granulocytes from PV patients while the expression of the PRV-1 gene, a known target of JAK2, was rapidly downmodulated.  Altogether, the data presented suggest that ITF2357 inhibits proliferation of cells bearing the JAK2V617F mutation through a specific down-modulation of the JAK2V617F protein and inhibition of its downstream signaling.  Leukemia (2008) 22, 740-747; doi:10.1038/sj.leu.2405049; published online 13 Dec. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJVQmHmDb8RLVg90H21EOLACvtfcHk0ljFV2YxmzmsjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D&md5=de59fdaf20ec85e733052c09733b9193</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2405049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2405049%26sid%3Dliteratum%253Aachs%26aulast%3DGuerini%26aufirst%3DV.%26aulast%3DBarbui%26aufirst%3DV.%26aulast%3DSpinelli%26aufirst%3DO.%26aulast%3DSalvi%26aufirst%3DA.%26aulast%3DDellacasa%26aufirst%3DC.%26aulast%3DCarobbio%26aufirst%3DA.%26aulast%3DIntrona%26aufirst%3DM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DGolay%26aufirst%3DJ.%26aulast%3DRambaldi%26aufirst%3DA.%26atitle%3DThe%2520Histone%2520Deacetylase%2520Inhibitor%2520ITF2357%2520Selectively%2520Targets%2520Cells%2520Bearing%2520Mutated%2520JAK2%2528V617F%2529%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D740%26epage%3D747%26doi%3D10.1038%2Fsj.leu.2405049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balusu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jillella, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K. N.</span></span> <span> </span><span class="NLM_article-title">Cotreatment with Panobinostat and JAK2 Inhibitor TG101209 Attenuates JAK2V617F Levels and Signaling and Exerts Synergistic Cytotoxic Effects Against Human Myeloproliferative Neoplastic Cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">5024</span>â <span class="NLM_lpage">5033</span>, <span class="refDoi">Â DOI: 10.1182/blood-2009-05-222133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1182%2Fblood-2009-05-222133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=19828702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2gsb%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=5024-5033&author=Y.+Wangauthor=W.+Fiskusauthor=D.+G.+Chongauthor=K.+M.+Buckleyauthor=K.+Natarajanauthor=R.+Raoauthor=A.+Joshiauthor=R.+Balusuauthor=S.+Koulauthor=J.+Chenauthor=A.+Savoieauthor=C.+Ustunauthor=A.+P.+Jillellaauthor=P.+Atadjaauthor=R.+L.+Levineauthor=K.+N.+Bhalla&title=Cotreatment+with+Panobinostat+and+JAK2+Inhibitor+TG101209+Attenuates+JAK2V617F+Levels+and+Signaling+and+Exerts+Synergistic+Cytotoxic+Effects+Against+Human+Myeloproliferative+Neoplastic+Cells&doi=10.1182%2Fblood-2009-05-222133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells</span></div><div class="casAuthors">Wang, Yongchao; Fiskus, Warren; Chong, Daniel G.; Buckley, Kathleen M.; Natarajan, Kavita; Rao, Rekha; Joshi, Atul; Balusu, Ramesh; Koul, Sanjay; Chen, Jianguang; Savoie, Andrew; Ustun, Celalettin; Jillella, Anand P.; Atadja, Peter; Levine, Ross L.; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5024-5033</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL-neg. myeloproliferative neoplasms (MPNs).  JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3 (PI3)/AKT pathways, conferring proliferative and survival advantages in the MPN hematopoietic progenitor cells (HPCs).  Treatment with the pan-histone deacetylase (HDAC) inhibitor panobinostat (PS) is known to inhibit the chaperone function of heat shock protein 90, as well as induce growth arrest and apoptosis of transformed HPCs.  Here, we demonstrate that PS treatment depletes the autophosphorylation, expression, and downstream signaling of JAK2V617F.  Treatment with PS also disrupted the chaperone assocn. of JAK2V617F with hsp90, promoting proteasomal degrdn. of JAK2V617F.  PS also induced apoptosis of the cultured JAK2V617F-expressing human erythroleukemia HEL92.1.7 and Ba/F3-JAK2V617F cells.  Treatment with the JAK2 TK inhibitor TG101209 attenuated JAK2V617F autophosphorylation and induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells.  Cotreatment with PS and TG101209 further depleted JAK/STAT signaling and synergistically induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells.  Cotreatment with TG101209 and PS exerted greater cytotoxicity against primary CD34+ MPN cells than normal CD34+ HPCs.  These in vitro findings suggest combination therapy with HDAC and JAK2V617F inhibitors is of potential value for the treatment of JAK2V617F-pos. MPN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodK5zBrODMYbVg90H21EOLACvtfcHk0liSY36lv9zT_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2gsb%252FI&md5=061242179d1d48acd664acc8f484f003</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222133%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DChong%26aufirst%3DD.%2BG.%26aulast%3DBuckley%26aufirst%3DK.%2BM.%26aulast%3DNatarajan%26aufirst%3DK.%26aulast%3DRao%26aufirst%3DR.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DBalusu%26aufirst%3DR.%26aulast%3DKoul%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSavoie%26aufirst%3DA.%26aulast%3DUstun%26aufirst%3DC.%26aulast%3DJillella%26aufirst%3DA.%2BP.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DCotreatment%2520with%2520Panobinostat%2520and%2520JAK2%2520Inhibitor%2520TG101209%2520Attenuates%2520JAK2V617F%2520Levels%2520and%2520Signaling%2520and%2520Exerts%2520Synergistic%2520Cytotoxic%2520Effects%2520Against%2520Human%2520Myeloproliferative%2520Neoplastic%2520Cells%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D5024%26epage%3D5033%26doi%3D10.1182%2Fblood-2009-05-222133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">The Oral HDAC Inhibitor Pracinostat (SB939) Is Efficacious and Synergistic with the JAK2 Inhibitor Pacritinib (SB1518) in Preclinical Models of AML</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e69</span> <span class="refDoi">Â DOI: 10.1038/bcj.2012.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fbcj.2012.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=22829971" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&author=V.+Novotny-Diermayrauthor=S.+Hartauthor=K.+C.+Gohauthor=A.+Cheongauthor=L.+C.+Ongauthor=H.+Hentzeauthor=M.+K.+Pashaauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=J.+M.+Wood&title=The+Oral+HDAC+Inhibitor+Pracinostat+%28SB939%29+Is+Efficacious+and+Synergistic+with+the+JAK2+Inhibitor+Pacritinib+%28SB1518%29+in+Preclinical+Models+of+AML&doi=10.1038%2Fbcj.2012.14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2012.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2012.14%26sid%3Dliteratum%253Aachs%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Oral%2520HDAC%2520Inhibitor%2520Pracinostat%2520%2528SB939%2529%2520Is%2520Efficacious%2520and%2520Synergistic%2520with%2520the%2520JAK2%2520Inhibitor%2520Pacritinib%2520%2528SB1518%2529%2520in%2520Preclinical%2520Models%2520of%2520AML%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2012%26volume%3D2%26doi%3D10.1038%2Fbcj.2012.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conneally, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipka, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharyya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribrag, V.</span></span> <span> </span><span class="NLM_article-title">Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">4060</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=4060&author=C.+N.+Harrisonauthor=J.-J.+Kiladjianauthor=F.+H.+Heidelauthor=A.+M.+Vannucchiauthor=F.+Passamontiauthor=A.+Hayatauthor=E.+Conneallyauthor=B.+Martinoauthor=T.+Kindlerauthor=D.+B.+Lipkaauthor=S.+Acharyyaauthor=P.+Gopalakrishnaauthor=S.+Ideauthor=T.+Liuauthor=S.+Muauthor=V.+Ribrag&title=Efficacy%2C+Safety%2C+and+Confirmation+of+the+Recommended+Phase+2+Starting+Dose+of+the+Combination+of+Ruxolitinib+%28RUX%29+and+Panobinostat+%28PAN%29+in+Patients+%28Pts%29+with+Myelofibrosis+%28MF%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DHayat%26aufirst%3DA.%26aulast%3DConneally%26aufirst%3DE.%26aulast%3DMartino%26aufirst%3DB.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DLipka%26aufirst%3DD.%2BB.%26aulast%3DAcharyya%26aufirst%3DS.%26aulast%3DGopalakrishna%26aufirst%3DP.%26aulast%3DIde%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DMu%26aufirst%3DS.%26aulast%3DRibrag%26aufirst%3DV.%26atitle%3DEfficacy%252C%2520Safety%252C%2520and%2520Confirmation%2520of%2520the%2520Recommended%2520Phase%25202%2520Starting%2520Dose%2520of%2520the%2520Combination%2520of%2520Ruxolitinib%2520%2528RUX%2529%2520and%2520Panobinostat%2520%2528PAN%2529%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Myelofibrosis%2520%2528MF%2529%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D4060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a> (NCT01433445, accessed Sep 14, 2011; NCT01693601, accessed Sep 26,
2012; NCT02267278, accessed Oct 17, <span class="NLM_year">2014</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2F+%28NCT01433445%2C+accessed+Sep+14%2C+2011%3B+NCT01693601%2C+accessed+Sep+26%2C%0A2012%3B+NCT02267278%2C+accessed+Oct+17%2C+2014%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zwergel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stazi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mail, A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: Updated Studies in Various Epigenetic-Related Diseases</span>. <i>J. Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">15</span>, <span class="refDoi">Â DOI: 10.21767/2472-1158.100015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.21767%2F2472-1158.100015" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=1-15&author=C.+Zwergelauthor=G.+Staziauthor=S.+Valenteauthor=A.+Mail&title=Histone+Deacetylase+Inhibitors%3A+Updated+Studies+in+Various+Epigenetic-Related+Diseases&doi=10.21767%2F2472-1158.100015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.21767%2F2472-1158.100015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21767%252F2472-1158.100015%26sid%3Dliteratum%253Aachs%26aulast%3DZwergel%26aufirst%3DC.%26aulast%3DStazi%26aufirst%3DG.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DMail%26aufirst%3DA.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520Updated%2520Studies%2520in%2520Various%2520Epigenetic-Related%2520Diseases%26jtitle%3DJ.%2520Clin.%2520Epigenet.%26date%3D2016%26volume%3D2%26spage%3D1%26epage%3D15%26doi%3D10.21767%2F2472-1158.100015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>â <span class="NLM_lpage">691</span>, <span class="refDoi">Â DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+Their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0liDlZQgtSrarQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520Their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monciino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span> <span> </span><span class="NLM_article-title">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1373</span>â <span class="NLM_lpage">1428</span>, <span class="refDoi">Â DOI: 10.1002/med.21437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1002%2Fmed.21437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=28181261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1373-1428&author=C.+Zagniauthor=G.+Florestaauthor=G.+Monciinoauthor=A.+Rescifina&title=The+Search+for+Potent%2C+Small-Molecule+HDACIs+in+Cancer+Treatment%3A+A+Decade+After+Vorinostat&doi=10.1002%2Fmed.21437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span></div><div class="casAuthors">Zagni Chiara; Floresta Giuseppe; Monciino Giulia; Rescifina Antonio; Floresta Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1373-1428</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression.  In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases.  Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma.  This review provides an overview of current knowledge, progress, and molecular mechanisms of HDACIs, covering a period from 2011 until 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPT4s_HXWveWmbXvSEQle5fW6udTcc2eZv8PZDJdQR4bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D&md5=79f4fe123e5ee6ba072e9147536fab67</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fmed.21437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21437%26sid%3Dliteratum%253Aachs%26aulast%3DZagni%26aufirst%3DC.%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DMonciino%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26atitle%3DThe%2520Search%2520for%2520Potent%252C%2520Small-Molecule%2520HDACIs%2520in%2520Cancer%2520Treatment%253A%2520A%2520Decade%2520After%2520Vorinostat%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D1373%26epage%3D1428%26doi%3D10.1002%2Fmed.21437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>â <span class="NLM_lpage">7887</span>, <span class="refDoi">Â DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0liDlZQgtSrarQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - Foe or Friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>â <span class="NLM_lpage">8971</span>, <span class="refDoi">Â DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+Foe+or+Friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lgzk28P2bQodA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands. An Emerging Drug Discovery Paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>â <span class="NLM_lpage">6543</span>, <span class="refDoi">Â DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+Multiple+Ligands.+An+Emerging+Drug+Discovery+Paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lgzk28P2bQodA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520Multiple%2520Ligands.%2520An%2520Emerging%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">950</span>â <span class="NLM_lpage">955</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.6b00247</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyqsr3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=950-955&author=X.+Liangauthor=J.+Zangauthor=M.+Zhuauthor=Q.+Gaoauthor=B.+Wangauthor=W.+Xuauthor=Y.+Zhang&title=Design%2C+Synthesis%2C+and+Antitumor+Evaluation+of+4-Amino-%281H%29-pyrazole+Derivatives+as+JAKs+Inhibitors&doi=10.1021%2Facsmedchemlett.6b00247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors</span></div><div class="casAuthors">Liang, Xuewu; Zang, Jie; Zhu, Mengyuan; Gao, Qianwen; Wang, Binghe; Xu, Wenfang; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">950-955</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abnormalities in the JAK/STAT signaling pathway lead to many diseases such as immunodeficiency, inflammation, and cancer.  Herein, we designed and synthesized a series of 4-amino-(1H)-pyrazole derivs. as potent JAKs inhibitors for cancer treatment.  Results from in vitro protein kinase inhibition expts. indicated that some compds. are potent JAKs inhibitors.  For example, the IC50 values of compd. I against JAK1, JAK2, and JAK3 were 3.4, 2.2, and 3.5 nM, resp.  In cell culture expts., compd. I showed potent antiproliferative activity against various cell lines (PC-3, HEL, K562, MCF-7, and MOLT4) at low micromolar levels, while compd. II showed selective cytotoxicity at submicromolar levels against HEL (IC50: 0.35 Î¼M) and K562 (IC50: 0.37 Î¼M) cell lines.  It is worth noting that both I and II showed more potent antiproliferative activities than the approved JAKs inhibitor Ruxolitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB3anVRvyZ0rVg90H21EOLACvtfcHk0lgzk28P2bQodA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyqsr3P&md5=18dc9a4f862e2607a784fe9a28fbd682</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00247%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Antitumor%2520Evaluation%2520of%25204-Amino-%25281H%2529-pyrazole%2520Derivatives%2520as%2520JAKs%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D950%26epage%3D955%26doi%3D10.1021%2Facsmedchemlett.6b00247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvedere, S.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5097</span>â <span class="NLM_lpage">5116</span>, <span class="refDoi">Â DOI: 10.1021/jm0303094</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0303094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5097-5116&author=T.+A.+Millerauthor=D.+J.+Witterauthor=S.+Belvedere&title=Histone+Deacetylase+Inhibitors&doi=10.1021%2Fjm0303094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors</span></div><div class="casAuthors">Miller, Thomas A.; Witter, David J.; Belvedere, Sandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5097-5116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the medicinal chem. and structure-activity relationships underlying advances in histone deacetylase (HDAC) class I/II inhibitor discovery, design, and optimization.  HDAC structural studies and HDAC inhibitory activity of small-mol. hydroxamic acids, carboxylates, benzamides, electrophilic ketones, and cyclic peptides are described.  Miscellaneousness and selectivity of the class I/II HDACs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU5UlOsBUF7rVg90H21EOLACvtfcHk0liSb-axIeH41w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D&md5=d2d0a95d87d699334c1630df5deda38a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm0303094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0303094%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DT.%2BA.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DBelvedere%26aufirst%3DS.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5097%26epage%3D5116%26doi%3D10.1021%2Fjm0303094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>â <span class="NLM_lpage">8357</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Ligand+Efficient+Dual+Inhibitors+of+Janus+Kinase+%28JAK%29+and+Histone+Deacetylase+%28HDAC%29+Based+on+Ruxolitinib+and+Vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0liSb-axIeH41w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Ligand%2520Efficient%2520Dual%2520Inhibitors%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520and%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Based%2520on%2520Ruxolitinib%2520and%2520Vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>â <span class="NLM_lpage">10846</span>, <span class="refDoi">Â DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+Design+and+Simple+Chemistry+Yield+a+Superior%2C+Neuroprotective+HDAC6+Inhibitor%2C+Tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated Î±-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0liSb-axIeH41w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520Design%2520and%2520Simple%2520Chemistry%2520Yield%2520a%2520Superior%252C%2520Neuroprotective%2520HDAC6%2520Inhibitor%252C%2520Tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senkevitch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durum, S.</span></span> <span> </span><span class="NLM_article-title">The Promise of Janus Kinase Inhibitors in the Treatment of Hematological Malignancies</span>. <i>Cytokine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">33</span>â <span class="NLM_lpage">41</span>, <span class="refDoi">Â DOI: 10.1016/j.cyto.2016.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2Fj.cyto.2016.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=28277287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhtLjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2017&pages=33-41&author=E.+Senkevitchauthor=S.+Durum&title=The+Promise+of+Janus+Kinase+Inhibitors+in+the+Treatment+of+Hematological+Malignancies&doi=10.1016%2Fj.cyto.2016.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The promise of Janus kinase inhibitors in the treatment of hematological malignancies</span></div><div class="casAuthors">Senkevitch, Emilee; Durum, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33-41</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAK) are a family of kinases that play an essential role in cytokine signaling and are implicated in the pathogenesis of autoimmune diseases and hematol. malignancies.  As a result, the JAKs have become attractive therapeutic targets.  The discovery of a JAK2 point mutation (JAK2 V617F) as the main cause of polycythemia vera lead to the development and FDA approval of a JAK1/2 inhibitor, ruxolitinib, in 2011.  This review focuses on the various JAK and assocd. components aberrations implicated in myeloproliferative neoplasms, leukemias, and lymphomas.  In addn. to ruxolitinib, other JAK inhibitors are currently being evaluated in clin. trials for treating hematol. malignancies.  The use of JAK inhibitors alone or in combination therapy should be considered as a way to deliver targeted therapy to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWc9geNHOJcbVg90H21EOLACvtfcHk0ljteNaHg3V9VQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhtLjF&md5=f3f2928b5d421b285d5cbdb76abab65d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2016.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2016.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DSenkevitch%26aufirst%3DE.%26aulast%3DDurum%26aufirst%3DS.%26atitle%3DThe%2520Promise%2520of%2520Janus%2520Kinase%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Hematological%2520Malignancies%26jtitle%3DCytokine%26date%3D2017%26volume%3D98%26spage%3D33%26epage%3D41%26doi%3D10.1016%2Fj.cyto.2016.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maru, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span> <span> </span><span class="NLM_article-title">Action Mechanisms of Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1543</span>â <span class="NLM_lpage">1549</span>, <span class="refDoi">Â DOI: 10.1111/cas.13062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1111%2Fcas.13062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=27554046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlykur3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=1543-1549&author=Y.+Imaiauthor=Y.+Maruauthor=J.+Tanaka&title=Action+Mechanisms+of+Histone+Deacetylase+Inhibitors+in+the+Treatment+of+Hematological+Malignancies&doi=10.1111%2Fcas.13062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies</span></div><div class="casAuthors">Imai, Yoichi; Maru, Yoshiro; Tanaka, Junji</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1543-1549</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Histone deacetylases (HDACs) critically regulate gene expression by detg. the acetylation status of histones.  In addn., studies have increasingly focused on the activities of HDACs, esp. involving non-histone proteins, and their various biol. effects.  Aberrant HDAC expression obsd. in several kinds of human tumors makes HDACs potential targets for cancer treatment.  Several preclin. studies have suggested that HDAC inhibitors exhibit some efficacy in the treatment of acute myelogenous leukemia (AML) with AML1-ETO, which mediates transcriptional repression through its interaction with a complex including HDAC1.  Recurrent mutations in epigenetic regulators are found in T-cell lymphomas (TCLs), and HDAC inhibitors and hypomethylating agents were shown to act cooperatively in the treatment of TCLs.  Preclin. modeling has suggested that persistent activation of the signal transducer and activator of transcription (STAT) signaling pathway could serve as a useful biomarker of resistance to HDAC inhibitor in patients with cutaneous TCL.  Panobinostat, a pan-HDAC inhibitor, in combination with bortezomib and dexamethasone, has achieved longer progression-free survival in patients with relapsed/refractory multiple myeloma (MM) than the placebo in combination with bortezomib and dexamethasone.  Panobinostat inhibited MM cell growth by degrading protein phosphatase 3 catalytic subunit Î± (PPP3CA), a catalytic subunit of calcineurin.  This degrdn. was suggested to be mediated by the blockade of the chaperone function of heat shock protein 90 (HSP90) due to HDAC6 inhibition.  Aberrant PPP3CA expression in advanced MM indicated a possible correlation between high PPP3CA expression and the pathogenesis of MM.  Furthermore, PPP3CA was suggested as a common target of panobinostat and bortezomib.  This article is protected by copyright.  All rights reserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs8mVwuDgQ9LVg90H21EOLACvtfcHk0ljteNaHg3V9VQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlykur3O&md5=d97540b4f33bb4ce6c044717785f9954</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fcas.13062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13062%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DY.%26aulast%3DMaru%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DJ.%26atitle%3DAction%2520Mechanisms%2520of%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Hematological%2520Malignancies%26jtitle%3DCancer%2520Sci.%26date%3D2016%26volume%3D107%26spage%3D1543%26epage%3D1549%26doi%3D10.1111%2Fcas.13062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T.-C.</span></span> <span> </span><span class="NLM_article-title">Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">440</span>â <span class="NLM_lpage">446</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-09-1947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1158%2F0008-5472.CAN-09-1947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=20068163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=440-446&author=T.-C.+Chou&title=Drug+Combination+Studies+and+Their+Synergy+Quantification+Using+the+Chou-Talalay+Method&doi=10.1158%2F0008-5472.CAN-09-1947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method</span></div><div class="casAuthors">Chou, Ting-Chao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">440-446</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  This brief perspective article focuses on the most common errors and pitfalls, as well as the do's and don'ts in drug combination studies, in terms of exptl. design, data acquisition, data interpretation, and computerized simulation.  The Chou-Talalay method for drug combination is based on the median-effect equation, derived from the mass-action law principle, which is the unified theory that provides the common link between single entity and multiple entities, and first order and higher order dynamics.  This general equation encompasses the Michaelis-Menten, Hill, Henderson-Hasselbalch, and Scatchard equations in biochem. and biophysics.  The resulting combination index (CI) theorem of Chou-Talalay offers quant. definition for additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations.  This theory also provides algorithms for automated computer simulation for synergism and/or antagonism at any effect and dose level, as shown in the CI plot and isobologram, resp.  Cancer Res; 70(2); 440-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpECUlVzkYExbVg90H21EOLACvtfcHk0ljteNaHg3V9VQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWksA%253D%253D&md5=d0713e60852fc656bc91719ccb27eb1a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-1947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-1947%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DT.-C.%26atitle%3DDrug%2520Combination%2520Studies%2520and%2520Their%2520Synergy%2520Quantification%2520Using%2520the%2520Chou-Talalay%2520Method%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D440%26epage%3D446%26doi%3D10.1158%2F0008-5472.CAN-09-1947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akeno-Stuart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croyle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauf, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaguarnera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitagliano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosios, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span> <span> </span><span class="NLM_article-title">The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression Through Distinct Mechanisms in Medullary Thyroid Cancer Cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">6956</span>â <span class="NLM_lpage">6964</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-06-4605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1158%2F0008-5472.CAN-06-4605" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6956-6964&author=N.+Akeno-Stuartauthor=M.+Croyleauthor=J.+A.+Knaufauthor=R.+Malaguarneraauthor=D.+Vitaglianoauthor=M.+Santoroauthor=C.+Stephanauthor=K.+Grosiosauthor=M.+Wartmannauthor=R.+Cozensauthor=G.+Caravattiauthor=D.+Fabbroauthor=H.+A.+Laneauthor=J.+A.+Fagin&title=The+RET+Kinase+Inhibitor+NVP-AST487+Blocks+Growth+and+Calcitonin+Gene+Expression+Through+Distinct+Mechanisms+in+Medullary+Thyroid+Cancer+Cells&doi=10.1158%2F0008-5472.CAN-06-4605"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4605%26sid%3Dliteratum%253Aachs%26aulast%3DAkeno-Stuart%26aufirst%3DN.%26aulast%3DCroyle%26aufirst%3DM.%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26aulast%3DMalaguarnera%26aufirst%3DR.%26aulast%3DVitagliano%26aufirst%3DD.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DGrosios%26aufirst%3DK.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520RET%2520Kinase%2520Inhibitor%2520NVP-AST487%2520Blocks%2520Growth%2520and%2520Calcitonin%2520Gene%2520Expression%2520Through%2520Distinct%2520Mechanisms%2520in%2520Medullary%2520Thyroid%2520Cancer%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6956%26epage%3D6964%26doi%3D10.1158%2F0008-5472.CAN-06-4605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komrokji, R. S.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive Review of Pacritinib in Myelofibrosis</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2819</span>â <span class="NLM_lpage">2830</span>, <span class="refDoi">Â DOI: 10.2217/fon.15.200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.2217%2Ffon.15.200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=26367195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Glu7zJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=2819-2830&author=S.+Verstovsekauthor=R.+S.+Komrokji&title=A+Comprehensive+Review+of+Pacritinib+in+Myelofibrosis&doi=10.2217%2Ffon.15.200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of pacritinib in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Komrokji, Rami S.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2819-2830</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling, inducing durable redns. in splenomegaly and constitutional symptoms in patients with myelofibrosis.  However, the assocn. of ruxolitinib therapy with myelosuppression indicates the continued need for optimal treatment choices in myelofibrosis.  Pacritinib, a dual JAK2 and FLT3 inhibitor, improves disease-related symptoms and signs with manageable gastrointestinal toxicity in patients with myelofibrosis with splenomegaly and high-risk features, without causing overt myelosuppression, and therefore may provide an important treatment option for a range of patients with myelofibrosis.  This article examines the role of JAK2 and FLT3 signaling in myelofibrosis and provides an overview of the clin. development of pacritinib as a new therapy for myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_XeeN6LrxrVg90H21EOLACvtfcHk0liK-btx4CgCSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Glu7zJ&md5=7807d824fabe4323f680c388100bd5a0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2217%2Ffon.15.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.15.200%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKomrokji%26aufirst%3DR.%2BS.%26atitle%3DA%2520Comprehensive%2520Review%2520of%2520Pacritinib%2520in%2520Myelofibrosis%26jtitle%3DFuture%2520Oncol.%26date%3D2015%26volume%3D11%26spage%3D2819%26epage%3D2830%26doi%3D10.2217%2Ffon.15.200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamis, A. P.</span></span> <span> </span><span class="NLM_article-title">Ten Years of Anti-Vascular Endothelial Growth Factor Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">385</span>â <span class="NLM_lpage">403</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2015.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnrd.2015.17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=26775688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28XoslSrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=385-403&author=N.+Ferraraauthor=A.+P.+Adamis&title=Ten+Years+of+Anti-Vascular+Endothelial+Growth+Factor+Therapy&doi=10.1038%2Fnrd.2015.17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Ten years of anti-vascular endothelial growth factor therapy</span></div><div class="casAuthors">Ferrara, Napoleone; Adamis, Anthony P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">385-403</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both normal and pathol. angiogenesis, has revealed innovative therapeutic approaches in oncol. and ophthalmol.  The first VEGFA inhibitor, bevacizumab, was approved by the US Food and Drug Administration in 2004 for the first-line treatment of metastatic colorectal cancer, and the first VEGFA inhibitors in ophthalmol., pegaptanib and ranibizumab, were approved in 2004 and 2006, resp.  To mark this tenth anniversary of anti-VEGFA therapy, we discuss the discovery of VEGFA, the successes and challenges in the development of VEGFA inhibitors and the impact of these agents on the treatment of cancers and ophthalmic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDKy9tn09lEbVg90H21EOLACvtfcHk0liK-btx4CgCSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XoslSrtA%253D%253D&md5=f9109ce5719fa70fa7da58d69dde39fc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.17%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DAdamis%26aufirst%3DA.%2BP.%26atitle%3DTen%2520Years%2520of%2520Anti-Vascular%2520Endothelial%2520Growth%2520Factor%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D385%26epage%3D403%26doi%3D10.1038%2Fnrd.2015.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boloor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Ward, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epperly, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkle, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knick, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudeman, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczyk, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-Dimethyl-2H-Indazol-6-yl)Methylamino]-2-Pyrimidinyl]Amino]-2-Methyl-Benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4632</span>â <span class="NLM_lpage">4640</span>, <span class="refDoi">Â DOI: 10.1021/jm800566m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.+Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-Dimethyl-2H-Indazol-6-yl%29Methylamino%5D-2-Pyrimidinyl%5DAmino%5D-2-Methyl-Benzenesulfonamide+%28Pazopanib%29%2C+a+Novel+and+Potent+Vascular+Endothelial+Growth+Factor+Receptor+Inhibitor&doi=10.1021%2Fjm800566m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor</span></div><div class="casAuthors">Harris, Philip A.; Boloor, Amogh; Cheung, Mui; Kumar, Rakesh; Crosby, Renae M.; Davis-Ward, Ronda G.; Epperly, Andrea H.; Hinkle, Kevin W.; Hunter, Robert N., III; Johnson, Jennifer H.; Knick, Victoria B.; Laudeman, Christopher P.; Luttrell, Deirdre K.; Mook, Robert A.; Nolte, Robert T.; Rudolph, Sharon K.; Szewczyk, Jerzy R.; Truesdale, Anne T.; Veal, James M.; Wang, Liping; Stafford, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4632-4640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy.  We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N4-(2,3-dimethyl-2H-indazol-6-yl)-N4-methyl-N2-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clin. development for renal-cell cancer and other solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIb4UT-IbEi7Vg90H21EOLACvtfcHk0liK-btx4CgCSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D&md5=a8737a6e003a3f6002575b4b96712fc9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-Dimethyl-2H-Indazol-6-yl%2529Methylamino%255D-2-Pyrimidinyl%255DAmino%255D-2-Methyl-Benzenesulfonamide%2520%2528Pazopanib%2529%252C%2520a%2520Novel%2520and%2520Potent%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640%26doi%3D10.1021%2Fjm800566m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span> <span> </span><span class="NLM_article-title">A Novel Irreversible FLT3 Inhibitor, FF-10101, Shows Excellent Efficacy against AML cells with FLT3 Mutations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">426</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1182/blood-2017-05-786657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1182%2Fblood-2017-05-786657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=29187377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=426-438&author=T.+Yamauraauthor=T.+Nakataniauthor=K.+Udaauthor=H.+Oguraauthor=W.+Shinauthor=N.+Kurokawaauthor=K.+Saitoauthor=N.+Fujikawaauthor=T.+Dateauthor=M.+Takasakiauthor=D.+Teradaauthor=A.+Hiraiauthor=A.+Akashiauthor=F.+Chenauthor=Y.+Adachiauthor=Y.+Ishikawaauthor=F.+Hayakawaauthor=S.+Hagiwaraauthor=T.+Naoeauthor=H.+Kiyoi&title=A+Novel+Irreversible+FLT3+Inhibitor%2C+FF-10101%2C+Shows+Excellent+Efficacy+against+AML+cells+with+FLT3+Mutations&doi=10.1182%2Fblood-2017-05-786657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span></div><div class="casAuthors">Yamaura, Takeshi; Nakatani, Toshiyuki; Uda, Ken; Ogura, Hayato; Shin, Wigyon; Kurokawa, Naoya; Saito, Koichi; Fujikawa, Norie; Date, Tomomi; Takasaki, Masaru; Terada, Daisuke; Hirai, Atsushi; Akashi, Akimi; Chen, Fangli; Adachi, Yoshiya; Ishikawa, Yuichi; Hayakawa, Fumihiko; Hagiwara, Shinji; Naoe, Tomoki; Kiyoi, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">426-438</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">An activating mutation of Fms-like tyrosine kinase 3 (FLT3) is the most frequent genetic alteration assocd. with poor prognosis in acute myeloid leukemia (AML).  Although many FLT3 inhibitors have been clin. developed, no first-generation inhibitors have demonstrated clin. efficacy by monotherapy, due to poor pharmacokinetics or unfavorable safety profiles possibly assocd. with low selectivity against FLT3 kinase.  Recently, a selective FLT3 inhibitor, quizartinib, demonstrated favorable outcomes in clin. studies.  However, several resistant mutations emerged during the disease progression.  To overcome these problems, we developed a novel FLT3 inhibitor, FF-10101, designed to possess selective and irreversible FLT3 inhibition.  The co-crystal structure of FLT3 protein bound to FF-10101 revealed the formation of a covalent bond between FF-10101 and the cysteine residue at 695 of FLT3.  The unique binding brought high selectivity and inhibitory activity against FLT3 kinase.  FF-10101 showed potent growth inhibitory effects on human AML cell lines harboring FLT3 internal tandem duplication (FLT3-ITD), MOLM-13, MOLM-14, and MV4-11, and all tested types of mutant FLT3-expressing 32D cells including quizartinib-resistant mutations at D835, Y842, and F691 residues in the FLT3 kinase domain.  In mouse s.c. implantation models, orally administered FF-10101 showed significant growth inhibitory effect on FLT3-ITD-D835Y- and FLT3-ITD-F691L-expressing 32D cells.  Furthermore, FF-10101 potently inhibited growth of primary AML cells harboring either FLT3-ITD or FLT3-D835 mutation in vitro and in vivo.  These results indicate that FF-10101 is a promising agent for the treatment of patients with AML with FLT3 mutations, including the activation loop mutations clin. identified as quizartinib-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNdcWgLnPALVg90H21EOLACvtfcHk0lgNLpdsn6X3Hw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE&md5=6812be0253e393c018ad5f7b47b9ec02</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-786657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-786657%26sid%3Dliteratum%253Aachs%26aulast%3DYamaura%26aufirst%3DT.%26aulast%3DNakatani%26aufirst%3DT.%26aulast%3DUda%26aufirst%3DK.%26aulast%3DOgura%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DW.%26aulast%3DKurokawa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DFujikawa%26aufirst%3DN.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DTakasaki%26aufirst%3DM.%26aulast%3DTerada%26aufirst%3DD.%26aulast%3DHirai%26aufirst%3DA.%26aulast%3DAkashi%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DHagiwara%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DA%2520Novel%2520Irreversible%2520FLT3%2520Inhibitor%252C%2520FF-10101%252C%2520Shows%2520Excellent%2520Efficacy%2520against%2520AML%2520cells%2520with%2520FLT3%2520Mutations%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D426%26epage%3D438%26doi%3D10.1182%2Fblood-2017-05-786657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inks, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3324</span>â <span class="NLM_lpage">3341</span>, <span class="refDoi">Â DOI: 10.1021/jm401877m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401877m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3324-3341&author=X.+Liauthor=E.+S.+Inksauthor=X.+Liauthor=J.+Houauthor=C.+J.+Chouauthor=J.+Zhangauthor=Y.+Jiangauthor=Y.+Zhangauthor=W.+Xu&title=Discovery+of+the+First+N-Hydroxycinnamamide-Based+Histone+Deacetylase+1%2F3+Dual+Inhibitors+with+Potent+Oral+Antitumor+Activity&doi=10.1021%2Fjm401877m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity</span></div><div class="casAuthors">Li, Xiaoyang; Inks, Elizabeth S.; Li, Xiaoguang; Hou, Jinning; Chou, C. James; Zhang, Jian; Jiang, Yuqi; Zhang, Yingjie; Xu, Wenfang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3324-3341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our previous study, we designed and synthesized a novel series of N-hydroxycinnamamide-based histone deacetylase inhibitors (HDACIs), among which the representative compd. I exhibited promising HDACs inhibition and antitumor activity.  In this current study, we report the development of a more potent class of N-hydroxycinnamamide-based HDACIs, using I as lead, among which, compd. II gave IC50 values of 11.8, 498.1, 3.9, 2000.8, 5700.4, 308.2, and 900.4 nM for the inhibition of HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, HDAC6, and HDAC11, exhibiting dual HDAC1/3 selectivity.  Several of these compds. showed excellent growth inhibition in multiple tumor cell lines.  In vivo antitumor assay in U937 xenograft model identified compd. II as a potent, orally active HDACI.  To the best of our knowledge, this work constitutes the first report of oral active N-hydroxycinnamamide-based HDACIs with dual HDAC1/3 selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrBGqCPWPO2rVg90H21EOLACvtfcHk0lgNLpdsn6X3Hw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsr4%253D&md5=4e86a4e7c9fda199bdd3cb12730db1da</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm401877m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401877m%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DInks%26aufirst%3DE.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520the%2520First%2520N-Hydroxycinnamamide-Based%2520Histone%2520Deacetylase%25201%252F3%2520Dual%2520Inhibitors%2520with%2520Potent%2520Oral%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3324%26epage%3D3341%26doi%3D10.1021%2Fjm401877m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaopeng Peng, Jingxuan Chen, Ling Li, Zhiqiang Sun, Jin Liu, Yichang Ren, Junli Huang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8447-8473. <a href="https://doi.org/10.1021/acs.jmedchem.1c00413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00413%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEfficient%252BSynthesis%252Band%252BBioevaluation%252Bof%252BNovel%252BDual%252BTubulin%25252FHistone%252BDeacetylase%252B3%252BInhibitors%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D07062021%26volume%3D64%26issue%3D12%26spage%3D8447%26epage%3D8473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuewu Liang, Shuai Tang, Xuyi Liu, Yingluo Liu, Qifu Xu, Xiaomin Wang, Abdusaid Saidahmatov, Chunpu Li, Jiang Wang, Yu Zhou, Yingjie Zhang, Meiyu Geng, Min Huang, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02111%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPyrrolo%25255B2%25252C3-d%25255Dpyrimidine-based%252BDerivatives%252Bas%252BPotent%252BJAK%25252FHDAC%252BDual%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRefractory%252BSolid%252BTumors%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2021%26date%3D2020%26date%3D07122020%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tingting Liu, Yichao Wan, Yuliang Xiao, Chengcai Xia, <span class="NLM_string-name hlFld-ContribAuthor">Guiyun Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 8977-9002. <a href="https://doi.org/10.1021/acs.jmedchem.0c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual-Target%252BInhibitors%252BBased%252Bon%252BHDACs%25253A%252BNovel%252BAntitumor%252BAgents%252Bfor%252BCancer%252BTherapy%26aulast%3DLiu%26aufirst%3DTingting%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D23032020%26date%3D30042020%26date%3D22042020%26volume%3D63%26issue%3D17%26spage%3D8977%26epage%3D9002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yi Zhou, Xiaoting Liu, Junxin Xue, Lulu Liu, Tao Liang, Wen Li, Xinying Yang, Xuben Hou, <span class="NLM_string-name hlFld-ContribAuthor">Hao Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4701-4715. <a href="https://doi.org/10.1021/acs.jmedchem.9b02161" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02161%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPeptide%252BBoronate%252BDerivatives%252Bas%252BHistone%252BDeacetylase%252Band%252BProteasome%252BDual%252BInhibitors%252Bfor%252BOvercoming%252BBortezomib%252BResistance%252Bof%252BMultiple%252BMyeloma%26aulast%3DZhou%26aufirst%3DYi%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D24122019%26date%3D23042020%26date%3D08042020%26volume%3D63%26issue%3D9%26spage%3D4701%26epage%3D4715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, Carina Danchik, Suiyang Liu, Pranav Shah, Amy Q. Wang, Garrett Dunn, Md Kabir, Elias C. Padilha, Xin Xu, Anton Simeonov, Surender Kharbanda, Richard Stone, <span class="NLM_string-name hlFld-ContribAuthor">Gurmit Grewal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4256-4292. <a href="https://doi.org/10.1021/acs.jmedchem.0c00193" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BQuinazolin-4-one-Based%252BHydroxamic%252BAcids%252Bas%252BDual%252BPI3K%25252FHDAC%252BInhibitors%26aulast%3DThakur%26aufirst%3DAshish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03022020%26date%3D08042020%26date%3D26032020%26volume%3D63%26issue%3D8%26spage%3D4256%26epage%3D4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Chao  Duan</span>, <span class="hlFld-ContribAuthor ">Shao-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Jing  Shi</span>, <span class="hlFld-ContribAuthor ">Lin-Feng  Jin</span>, <span class="hlFld-ContribAuthor ">Tong  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Song</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Guan</span>. </span><span class="cited-content_cbyCitation_article-title">Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113588. <a href="https://doi.org/10.1016/j.ejmech.2021.113588" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113588</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113588%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DResearch%252Bprogress%252Bof%252Bdual%252Binhibitors%252Btargeting%252Bcrosstalk%252Bbetween%252Bhistone%252Bepigenetic%252Bmodulators%252Bfor%252Bcancer%252Btherapy%26aulast%3DDuan%26aufirst%3DYing-Chao%26date%3D2021%26volume%3D222%26spage%3D113588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabian  Fischer</span>, <span class="hlFld-ContribAuthor ">Leandro A  Alves Avelar</span>. </span><span class="cited-content_cbyCitation_article-title">A short overview of resistance to approved histone deacetylaseÂ inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (14)
                                     , 1153-1155. <a href="https://doi.org/10.4155/fmc-2021-0102" title="DOI URL">https://doi.org/10.4155/fmc-2021-0102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2021-0102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2021-0102%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DA%252Bshort%252Boverview%252Bof%252Bresistance%252Bto%252Bapproved%252Bhistone%252Bdeacetylase%2525C2%2525A0inhibitors%26aulast%3DFischer%26aufirst%3DFabian%26date%3D2021%26volume%3D13%26issue%3D14%26spage%3D1153%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrey D.  Bondarev</span>, <span class="hlFld-ContribAuthor ">Misty M.  Attwood</span>, <span class="hlFld-ContribAuthor ">JÃ¶rgen  Jonsson</span>, <span class="hlFld-ContribAuthor ">Vladimir N.  Chubarev</span>, <span class="hlFld-ContribAuthor ">Vadim V.  Tarasov</span>, <span class="hlFld-ContribAuthor ">Helgi B.  SchiÃ¶th</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments of HDAC inhibitors: Emerging indications and novel molecules. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Clinical Pharmacology</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1111/bcp.14889" title="DOI URL">https://doi.org/10.1111/bcp.14889</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcp.14889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcp.14889%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DRecent%252Bdevelopments%252Bof%252BHDAC%252Binhibitors%25253A%252BEmerging%252Bindications%252Band%252Bnovel%252Bmolecules%26aulast%3DBondarev%26aufirst%3DAndrey%2BD.%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arshdeep  Singh</span>, <span class="hlFld-ContribAuthor ">Ting-Yu  Chang</span>, <span class="hlFld-ContribAuthor ">Navdeep  Kaur</span>, <span class="hlFld-ContribAuthor ">Kai-Cheng  Hsu</span>, <span class="hlFld-ContribAuthor ">Yun  Yen</span>, <span class="hlFld-ContribAuthor ">Tony Eight  Lin</span>, <span class="hlFld-ContribAuthor ">Mei-Jung  Lai</span>, <span class="hlFld-ContribAuthor ">Sung-Bau  Lee</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>215 </em>, 113169. <a href="https://doi.org/10.1016/j.ejmech.2021.113169" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113169%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCAP%252Brigidification%252Bof%252BMS-275%252Band%252Bchidamide%252Bleads%252Bto%252Benhanced%252Bantiproliferative%252Beffects%252Bmediated%252Bthrough%252BHDAC1%25252C%252B2%252Band%252Btubulin%252Bpolymerization%252Binhibition%26aulast%3DSingh%26aufirst%3DArshdeep%26date%3D2021%26volume%3D215%26spage%3D113169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandria M.  Chan</span>, <span class="hlFld-ContribAuthor ">Steven  Fletcher</span>. </span><span class="cited-content_cbyCitation_article-title">Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (2)
                                     , 178-196. <a href="https://doi.org/10.1039/D0MD00286K" title="DOI URL">https://doi.org/10.1039/D0MD00286K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00286K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00286K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DShifting%252Bthe%252Bparadigm%252Bin%252Btreating%252Bmulti-factorial%252Bdiseases%25253A%252Bpolypharmacological%252Bco-inhibitors%252Bof%252BHDAC6%26aulast%3DChan%26aufirst%3DAlexandria%2BM.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D2%26spage%3D178%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neha  Upadhyay</span>, <span class="hlFld-ContribAuthor ">Kalpana  Tilekar</span>, <span class="hlFld-ContribAuthor ">Fulvio  Loiodice</span>, <span class="hlFld-ContribAuthor ">Natalia Yu.  Anisimova</span>, <span class="hlFld-ContribAuthor ">Tatiana S.  Spirina</span>, <span class="hlFld-ContribAuthor ">Darina V.  Sokolova</span>, <span class="hlFld-ContribAuthor ">Galina B.  Smirnova</span>, <span class="hlFld-ContribAuthor ">Jun-yong  Choe</span>, <span class="hlFld-ContribAuthor ">Franz-Josef  Meyer-Almes</span>, <span class="hlFld-ContribAuthor ">Vadim S.  Pokrovsky</span>, <span class="hlFld-ContribAuthor ">Antonio  Lavecchia</span>, <span class="hlFld-ContribAuthor ">CS  Ramaa</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>107 </em>, 104527. <a href="https://doi.org/10.1016/j.bioorg.2020.104527" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104527%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPharmacophore%252Bhybridization%252Bapproach%252Bto%252Bdiscover%252Bnovel%252Bpyrazoline-based%252Bhydantoin%252Banalogs%252Bwith%252Banti-tumor%252Befficacy%26aulast%3DUpadhyay%26aufirst%3DNeha%26date%3D2021%26volume%3D107%26spage%3D104527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jenna N.  Beyer</span>, <span class="hlFld-ContribAuthor ">Nicole R.  Raniszewski</span>, <span class="hlFld-ContribAuthor ">George M.  Burslem</span>. </span><span class="cited-content_cbyCitation_article-title">Advances and Opportunities in Epigenetic Chemical Biology. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2021,</strong> <em>22 </em>
                                    (1)
                                     , 17-42. <a href="https://doi.org/10.1002/cbic.202000459" title="DOI URL">https://doi.org/10.1002/cbic.202000459</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.202000459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.202000459%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DAdvances%252Band%252BOpportunities%252Bin%252BEpigenetic%252BChemical%252BBiology%26aulast%3DBeyer%26aufirst%3DJenna%2BN.%26date%3D2021%26date%3D2020%26volume%3D22%26issue%3D1%26spage%3D17%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amr K.A.  Bass</span>, <span class="hlFld-ContribAuthor ">Mona S.  El-Zoghbi</span>, <span class="hlFld-ContribAuthor ">El-Shimaa M.  Nageeb</span>, <span class="hlFld-ContribAuthor ">Mamdouh F.A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Mohamed  Badr</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112904. <a href="https://doi.org/10.1016/j.ejmech.2020.112904" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112904%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComprehensive%252Breview%252Bfor%252Banticancer%252Bhybridized%252Bmultitargeting%252BHDAC%252Binhibitors%26aulast%3DBass%26aufirst%3DAmr%2BK.A.%26date%3D2021%26volume%3D209%26spage%3D112904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">You-Guang  Zheng</span>, <span class="hlFld-ContribAuthor ">Jin-An  Wang</span>, <span class="hlFld-ContribAuthor ">Long  Meng</span>, <span class="hlFld-ContribAuthor ">Xin  Pei</span>, <span class="hlFld-ContribAuthor ">Ling  Zhang</span>, <span class="hlFld-ContribAuthor ">Lin  An</span>, <span class="hlFld-ContribAuthor ">Cheng-Lin  Li</span>, <span class="hlFld-ContribAuthor ">Ying-Long  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112934. <a href="https://doi.org/10.1016/j.ejmech.2020.112934" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112934</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112934%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bactivity%252Bevaluation%252Bof%252B3-%2525284-phenyl-1H-imidazol-2-yl%252529-1H-pyrazole%252Bderivatives%252Bas%252Bpotent%252BJAK%252B2%25252F3%252Band%252Baurora%252BA%25252FB%252Bkinases%252Bmulti-targeted%252Binhibitors%26aulast%3DZheng%26aufirst%3DYou-Guang%26date%3D2021%26volume%3D209%26spage%3D112934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Colleen E.  Quaas</span>, <span class="hlFld-ContribAuthor ">David T.  Long</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting (de)acetylation: A Diversity of Mechanism and Disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00076-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00076-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00076-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00076-1%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252B%252528de%252529acetylation%25253A%252BA%252BDiversity%252Bof%252BMechanism%252Band%252BDisease%26aulast%3DQuaas%26aufirst%3DColleen%2BE.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Gao</span>, <span class="hlFld-ContribAuthor ">Hang  Zhang</span>, <span class="hlFld-ContribAuthor ">FrÃ©dÃ©ric  Lirussi</span>, <span class="hlFld-ContribAuthor ">Carmen  Garrido</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>182 </em>, 114224. <a href="https://doi.org/10.1016/j.bcp.2020.114224" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114224%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DDual%252Binhibitors%252Bof%252Bhistone%252Bdeacetylases%252Band%252Bother%252Bcancer-related%252Btargets%25253A%252BA%252Bpharmacological%252Bperspective%26aulast%3DGao%26aufirst%3DYuan%26date%3D2020%26volume%3D182%26spage%3D114224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaopeng  Peng</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Sun</span>, <span class="hlFld-ContribAuthor ">Peihua  Kuang</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112831. <a href="https://doi.org/10.1016/j.ejmech.2020.112831" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112831%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bon%252BHDAC%252Binhibitors%252Bwith%252Bdual%252Btargeting%252Bcapabilities%252Bfor%252Bcancer%252Btreatment%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2020%26volume%3D208%26spage%3D112831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua P.  Smalley</span>, <span class="hlFld-ContribAuthor ">Shaun M.  Cowley</span>, <span class="hlFld-ContribAuthor ">James T.  Hodgkinson</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional HDAC Therapeutics: One Drug to Rule Them All?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (19)
                                     , 4394. <a href="https://doi.org/10.3390/molecules25194394" title="DOI URL">https://doi.org/10.3390/molecules25194394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25194394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25194394%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBifunctional%252BHDAC%252BTherapeutics%25253A%252BOne%252BDrug%252Bto%252BRule%252BThem%252BAll%25253F%26aulast%3DSmalley%26aufirst%3DJoshua%2BP.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D19%26spage%3D4394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoshihide  Usami</span>, <span class="hlFld-ContribAuthor ">Yuya  Tatsui</span>, <span class="hlFld-ContribAuthor ">Hiroki  Yoneyama</span>, <span class="hlFld-ContribAuthor ">Shinya  Harusawa</span>. </span><span class="cited-content_cbyCitation_article-title">C4-Alkylamination of C4-Halo-1H-1-tritylpyrazoles Using Pd(dba)2 or CuI. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (20)
                                     , 4634. <a href="https://doi.org/10.3390/molecules25204634" title="DOI URL">https://doi.org/10.3390/molecules25204634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25204634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25204634%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DC4-Alkylamination%252Bof%252BC4-Halo-1H-1-tritylpyrazoles%252BUsing%252BPd%252528dba%2525292%252Bor%252BCuI%26aulast%3DUsami%26aufirst%3DYoshihide%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D20%26spage%3D4634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yufeng  Xiao</span>, <span class="hlFld-ContribAuthor ">Xuan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in small molecular modulators targeting histone deacetylase 6. </span><span class="cited-content_cbyCitation_journal-name">Future Drug Discovery</span><span> <strong>2020,</strong> <em>2 </em>
                                    (4)
                                     , FDD53. <a href="https://doi.org/10.4155/fdd-2020-0023" title="DOI URL">https://doi.org/10.4155/fdd-2020-0023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fdd-2020-0023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffdd-2020-0023%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Drug%2520Discovery%26atitle%3DRecent%252Badvances%252Bin%252Bsmall%252Bmolecular%252Bmodulators%252Btargeting%252Bhistone%252Bdeacetylase%252B6%26aulast%3DXiao%26aufirst%3DYufeng%26date%3D2020%26volume%3D2%26issue%3D4%26spage%3DFDD53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel R.  de Lera</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Two-hit wonders: The expanding universe of multitargeting epigenetic agents. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>57 </em>, 135-154. <a href="https://doi.org/10.1016/j.cbpa.2020.05.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTwo-hit%252Bwonders%25253A%252BThe%252Bexpanding%252Buniverse%252Bof%252Bmultitargeting%252Bepigenetic%252Bagents%26aulast%3Dde%2BLera%26aufirst%3DAngel%2BR.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qifu  Xu</span>, <span class="hlFld-ContribAuthor ">Chunxi  Liu</span>, <span class="hlFld-ContribAuthor ">Jie  Zang</span>, <span class="hlFld-ContribAuthor ">Shuai  Gao</span>, <span class="hlFld-ContribAuthor ">C. James  Chou</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fcell.2020.00454" title="DOI URL">https://doi.org/10.3389/fcell.2020.00454</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2020.00454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2020.00454%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252BHybrid%252Bof%252BVorinostat%252Band%252BRiluzole%252Bas%252Ba%252BPotent%252BAntitumor%252BAgent%26aulast%3DXu%26aufirst%3DQifu%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seketoulie  Keretsu</span>, <span class="hlFld-ContribAuthor ">Swapnil Pandurang  Bhujbal</span>, <span class="hlFld-ContribAuthor ">Seung Joo  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Study of Pyrimidinâ2âAminopyrazolâHydroxamateâbased
              JAK2
              Inhibitors for the Treatment of Myeloproliferative Neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2020,</strong> <em>41 </em>
                                    (5)
                                     , 542-551. <a href="https://doi.org/10.1002/bkcs.12008" title="DOI URL">https://doi.org/10.1002/bkcs.12008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bkcs.12008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbkcs.12008%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DComputational%252BStudy%252Bof%252BPyrimidin%2525E2%252580%2525902%2525E2%252580%252590Aminopyrazol%2525E2%252580%252590Hydroxamate%2525E2%252580%252590based%252BJAK2%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BMyeloproliferative%252BNeoplasms%26aulast%3DKeretsu%26aufirst%3DSeketoulie%26date%3D2020%26date%3D2020%26volume%3D41%26issue%3D5%26spage%3D542%26epage%3D551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hang  Dong</span>, <span class="hlFld-ContribAuthor ">Qifu  Xu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (4)
                                     , 263-274. <a href="https://doi.org/10.1080/13543776.2020.1725470" title="DOI URL">https://doi.org/10.1080/13543776.2020.1725470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1725470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1725470%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DHistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitors%252Bin%252Bcancer%25253A%252Ba%252Bpatent%252Breview%252B%2525282017-present%252529%26aulast%3DZhao%26aufirst%3DChunlong%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D4%26spage%3D263%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Guoliang  Gong</span>, <span class="hlFld-ContribAuthor ">Xinyang  Chen</span>, <span class="hlFld-ContribAuthor ">Ruihu  Song</span>, <span class="hlFld-ContribAuthor ">Mei  Duan</span>, <span class="hlFld-ContribAuthor ">Ruizhi  Qiao</span>, <span class="hlFld-ContribAuthor ">Yu  Jiao</span>, <span class="hlFld-ContribAuthor ">Jianzhao  Qi</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Yong  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2019,</strong> <em>67 </em>
                                    (10)
                                     , 1116-1122. <a href="https://doi.org/10.1248/cpb.c19-00425" title="DOI URL">https://doi.org/10.1248/cpb.c19-00425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c19-00425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c19-00425%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BBenzoylimidazole%252BDerivatives%252Bas%252BRaf%252Band%252BHistone%252BDeacetylases%252BDual%252BInhibitors%26aulast%3DChen%26aufirst%3DXin%26date%3D2019%26volume%3D67%26issue%3D10%26spage%3D1116%26epage%3D1122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuewu  Liang</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (15)
                                     , 1849-1852. <a href="https://doi.org/10.4155/fmc-2019-0168" title="DOI URL">https://doi.org/10.4155/fmc-2019-0168</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0168%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DNovel-targeted%252Btherapy%252Bfor%252Bhematological%252Bmalignancies%252Bwith%252BJAK%252Band%252BHDAC%252Bdual%252Binhibitors%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2019%26volume%3D11%26issue%3D15%26spage%3D1849%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hang  Dong</span>, <span class="hlFld-ContribAuthor ">Hao  Yin</span>, <span class="hlFld-ContribAuthor ">Chunlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Jiangying  Cao</span>, <span class="hlFld-ContribAuthor ">Wenfang  Xu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (13)
                                     , 2407. <a href="https://doi.org/10.3390/molecules24132407" title="DOI URL">https://doi.org/10.3390/molecules24132407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24132407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24132407%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BOsimertinib-Based%252BHDAC%252Band%252BEGFR%252BDual%252BInhibitors%26aulast%3DDong%26aufirst%3DHang%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D13%26spage%3D2407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the approved JAK inhibitor and HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of JAK and HDAC dual inhibitors based on the HDAC inhibitor pharmacophore. The three parts of the HDAC inhibitor pharmacophore are indicated in three colors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Binding mode of SAHA (<b>3</b>) in the active site of HDAC2 (Protein Data Bank (PDB) code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IWG">5IWG</a>). The hydroxamic acid group of SAHA chelates the Zn<sup>2+</sup> in a bidentate manner and forms multiple hydrogen bonds with the Tyr308 residue and the His145 residue. The aliphatic chain occupies the hydrophobic channel, and the phenylamino group interacts with the Asp104 residue at the entrance of the active site. (B) Binding mode of ruxolitinib (<b>1</b>) in the active site of JAK2 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). The pyrrolopyrimidine ring of compound <b>1</b> forms dual hydrogen bonds with the backbone residues (Leu932 and Glu930) of the hinge region of JAK2. (C) Binding mode of <b>8a</b> in the active site of HDAC2. (D) Binding mode of <b>8a</b> in the ATP pocket of JAK2. Yellow dashed lines represent the hydrogen bonds. Oxygen, nitrogen, chlorine, and polar hydrogen atoms are shown in pink, blue, violet, and white, respectively. The figures were generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediates <b>15a</b>â<b>h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd/C, H<sub>2</sub>, EtOH, room temperature (rt), 1â2 days, 90%; (b) (Boc)<sub>2</sub>O, NaHCO<sub>3</sub>/H<sub>2</sub>O, tetrahydrofuran (THF), rt, 1â2 days, 75%; (c) cesium carbonate, CH<sub>3</sub>CN, 40â50 Â°C, 10 h, 51â82%; (d) HCl/EtOAc, rt, 6â10 h, 63â93%.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0021.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Intermediates <b>17a</b>â<b>o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (e) for <b>17a</b> and <b>17l</b>, corresponding amines, Na<sub>2</sub>CO<sub>3</sub>, EtOH, rt, overnight, 40â44%; for <b>17b</b>, <b>17d</b>â<b>f</b>, corresponding amines, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), dimethylformamide (DMF), rt, overnight, 57â82%; for <b>17c</b>, corresponding amine, DIPEA, <i>N</i>-methylpyrrolidone (NMP), 100 Â°C, overnight, 40%; for <b>17g</b>â<b>k</b>, corresponding amines, EtOH, 0 Â°C, 0.5â3 h, 63â83%; for <b>17m</b>, corresponding amine, H<sub>2</sub>O/CH<sub>3</sub>OH = 3:1, 50 Â°C, 5 h, 68%; for <b>17n</b> and <b>17o</b>, corresponding amines, EtOH, â50 Â°C, 1 h, 25â30%.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Target Compounds <b>8a</b>â<b>z</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (f) TFA, <i>n</i>-BuOH, 130 Â°C, 3 h, 20â70%; (g) NH<sub>2</sub>OK, CH<sub>3</sub>OH (dry), rt, 0.5â1 h, 34â80%.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0010.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SAR summary of JAK and HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) A549 cells were treated with dimethyl sulfoxide (DMSO) or compounds for 6 h. The levels of acetyl-Î±-tubulin (Ac-Tub) and acetyl-histone H4 (Ac-HH4) were determined by immunoblotting. Î²-Actin was used as a loading control. The result is the representative of three independent experiments. (B) ImageJ was used to quantify the Western blot data. At 80 nM, the effects of <b>8a</b> and <b>8k</b> on acetyl-Î±-tubulin were much superior to those of tubastatin A and <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0015.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. MDA-MB-231 cells were treated with DMSO or compounds for 12 h. The levels of phosphorylated STAT3 (p-STAT3-Tyr705), total STAT3, acetyl-Î±-tubulin (Ac-Tub), and acetyl-histone H3 (Ac-HH3) were determined by immunoblotting. GAPDH was used as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Induction of apoptosis in HEL cells after 24 h of treatment. (B) Ability of compounds <b>3</b>, <b>1</b>, <b>8a</b>, and <b>8m</b> to induce apoptosis in HEL cells after 24 h of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0016.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Induction of apoptosis in K562 cells after 24 h of treatment. (B) Ability of compounds <b>3</b>, <b>1</b>, <b>8a</b>, and <b>8m</b> to induce apoptosis in K562 cells after 24 h of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0002.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Growth curve of the implanted HEL xenograft in nude mice. (B) Picture of dissected HEL tumor tissues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0017.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Drug concentrations in tumor. (B) Drug concentrations in plasma. The tumor and plasma concentrations of compounds <b>1</b>, <b>3</b>, and <b>8m</b> in mice were measured after the last of five daily doses (100 mg/(kg day), IP). Mice were sacrificed at 0.5, 1.0, and 4.0 h, respectively, after administration; then, blood and tumor samples were collected.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/medium/jm-2018-01597m_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0018.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Binding mode of <b>8m</b> in the active site of HDAC6 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>). (B) Binding mode of <b>8m</b> in the active site of JAK2 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>). (C) Binding mode of <b>8m</b> in the active site of FLT3 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X02">5X02</a>). (D) Binding mode of <b>8m</b> in the active site of VEGFR2 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3CJG">3CJG</a>). (E) Binding mode of <b>8m</b> in the active site of RET kinase (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVU">2IVU</a>). Yellow dashed lines represent the hydrogen bonds. Oxygen, nitrogen, chlorine, and polar hydrogen atoms are shown in pink, blue, violet, and white, respectively. The figures were generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.8b01597/20190418/images/large/jm-2018-01597m_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01597&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i134">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43247" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43247" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 43 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabner, B. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors in Cancer Therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5459</span>â <span class="NLM_lpage">5468</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2009.22.1291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1200%2FJCO.2009.22.1291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=19826124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKkt7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=5459-5468&author=A.+A.+Laneauthor=B.+A.+Chabner&title=Histone+Deacetylase+Inhibitors+in+Cancer+Therapy&doi=10.1200%2FJCO.2009.22.1291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors in cancer therapy</span></div><div class="casAuthors">Lane, Andrew A.; Chabner, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5459-5468</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose: Epigenetic processes are implicated in cancer causation and progression.  The acetylation status of histones regulates access of transcription factors to DNA and influences levels of gene expression.  Histone deacetylase (HDAC) activity diminishes acetylation of histones, causing compaction of the DNA/histone complex.  This compaction blocks gene transcription and inhibits differentiation, providing a rationale for developing HDAC inhibitors.  Methods: In this review, we explore the biol. of the HDAC enzymes, summarize the pharmacol. properties of HDAC inhibitors, and examine results of selected clin. trials.  We consider the potential of these inhibitors in combination therapy with targeted drugs and with cytotoxic chemotherapy.  Results: HDAC inhibitors promote growth arrest, differentiation, and apoptosis of tumor cells, with minimal effects on normal tissue.  In addn. to decompaction of the histone/DNA complex, HDAC inhibition also affects acetylation status and function of nonhistone proteins.  HDAC inhibitors have demonstrated antitumor activity in clin. trials, and one drug of this class, vorinostat, is US Food and Drug Administration approved for the treatment of cutaneous T-cell lymphoma.  Other inhibitors in advanced stages of clin. development, including depsipeptide and MGCD0103, differ from vorinostat in structure and isoenzyme specificity, and have shown activity against lymphoma, leukemia, and solid tumors.  Promising preclin. activity in combination with cytotoxics, inhibitors of heat shock protein 90, and inhibitors of proteasome function have led to combination therapy trials.  Conclusion: HDAC inhibitors are an important emerging therapy with single-agent activity against multiple cancers, and have significant potential in combination use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVyuJFNi_TFrVg90H21EOLACvtfcHk0lhKA4bXrdFnYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKkt7vE&md5=2752b7df219427b6758b69828f95efb4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.1291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.1291%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DA.%2BA.%26aulast%3DChabner%26aufirst%3DB.%2BA.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520in%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D5459%26epage%3D5468%26doi%3D10.1200%2FJCO.2009.22.1291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Libby, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burwick, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensinger, W. I.</span></span> <span> </span><span class="NLM_article-title">Panobinostat: A Review of Trial Results and Future Prospects in Multiple Myeloma</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">18</span>, <span class="refDoi">Â DOI: 10.1586/17474086.2015.983065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1586%2F17474086.2015.983065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=25410127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvFemsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=9-18&author=E.+N.+Libbyauthor=P.+S.+Beckerauthor=N.+Burwickauthor=D.+J.+Greenauthor=L.+Holmbergauthor=W.+I.+Bensinger&title=Panobinostat%3A+A+Review+of+Trial+Results+and+Future+Prospects+in+Multiple+Myeloma&doi=10.1586%2F17474086.2015.983065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat: a review of trial results and future prospects in multiple myeloma</span></div><div class="casAuthors">Libby, Edward N.; Becker, Pamela S.; Burwick, Nicholas; Green, Damian J.; Holmberg, Leona; Bensinger, William Ira</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Multiple myeloma is an incurable often devastating disease that is responsible for 1-2% of all cancers.  Multiple myeloma is the second most common hematol. malignancy.  Over the past two decades, advances in therapy have doubled life expectancy.  Unfortunately, all patients ultimately relapse.  Novel agents (immunomodulatory drugs and proteasome inhibitors) have changed the outlook for patients, but further breakthroughs are needed.  Epigenetic treatments offer potential for advancing therapy by modifying oncogene responses.  The acetylation status of various proteins can affect the availability of chromatin for transcription.  This response may be modulated epigenetically to advantage using histone deacetylase inhibitors like panobinostat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYo-p3uvsAR7Vg90H21EOLACvtfcHk0lhKA4bXrdFnYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvFemsA%253D%253D&md5=dd585819692a3a7af7b6786041ec6010</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1586%2F17474086.2015.983065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17474086.2015.983065%26sid%3Dliteratum%253Aachs%26aulast%3DLibby%26aufirst%3DE.%2BN.%26aulast%3DBecker%26aufirst%3DP.%2BS.%26aulast%3DBurwick%26aufirst%3DN.%26aulast%3DGreen%26aufirst%3DD.%2BJ.%26aulast%3DHolmberg%26aufirst%3DL.%26aulast%3DBensinger%26aufirst%3DW.%2BI.%26atitle%3DPanobinostat%253A%2520A%2520Review%2520of%2520Trial%2520Results%2520and%2520Future%2520Prospects%2520in%2520Multiple%2520Myeloma%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2015%26volume%3D8%26spage%3D9%26epage%3D18%26doi%3D10.1586%2F17474086.2015.983065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Anticancer Activities of Histone Deacetylase Inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">769</span>â <span class="NLM_lpage">784</span>, <span class="refDoi">Â DOI: 10.1038/nrd2133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+W.+Johnstone&title=Anticancer+Activities+of+Histone+Deacetylase+Inhibitors&doi=10.1038%2Fnrd2133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0lj_D39dxM6qrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DAnticancer%2520Activities%2520of%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784%26doi%3D10.1038%2Fnrd2133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span> <span> </span><span class="NLM_article-title">Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">459</span>â <span class="NLM_lpage">473</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2Fj.ccell.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=27622335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=459-473&author=H.+Zengauthor=J.+Quauthor=N.+Jinauthor=J.+Xuauthor=C.+Linauthor=Y.+Chenauthor=X.+Yangauthor=X.+Heauthor=S.+Tangauthor=X.+Lanauthor=X.+Yangauthor=Z.+Chenauthor=M.+Huangauthor=J.+Dingauthor=M.+Geng&title=Feedback+Activation+of+Leukemia+Inhibitory+Factor+Receptor+Limits+Response+to+Histone+Deacetylase+Inhibitors+in+Breast+Cancer&doi=10.1016%2Fj.ccell.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer</span></div><div class="casAuthors">Zeng, Hanlin; Qu, Jia; Jin, Nan; Xu, Jun; Lin, Chenchu; Chen, Yi; Yang, Xinying; He, Xiang; Tang, Shuai; Lan, Xiaojing; Yang, Xiaotong; Chen, Ziqi; Huang, Min; Ding, Jian; Geng, Meiyu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-473</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have demonstrated clin. benefits in subtypes of hematol. malignancies.  However, the efficacy of HDAC inhibitors in solid tumors remains uncertain.  This study takes breast cancer as a model to understand mechanisms accounting for limited response of HDAC inhibitors in solid tumors and to seek combination solns.  We discover that feedback activation of leukemia inhibitory factor receptor (LIFR) signaling in breast cancer limits the response to HDAC inhibition.  Mechanistically, HDAC inhibition increases histone acetylation at the LIFR gene promoter, which recruits bromodomain protein BRD4, upregulates LIFR expression, and activates JAK1-STAT3 signaling.  Importantly, JAK1 or BRD4 inhibition sensitizes breast cancer to HDAC inhibitors, implicating combination inhibition of HDAC with JAK1 or BRD4 as potential therapies for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL24sYbhFYeLVg90H21EOLACvtfcHk0lj_D39dxM6qrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI&md5=9ce620c7a19519a95edd714f8012518c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DLan%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26atitle%3DFeedback%2520Activation%2520of%2520Leukemia%2520Inhibitory%2520Factor%2520Receptor%2520Limits%2520Response%2520to%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520Breast%2520Cancer%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D459%26epage%3D473%26doi%3D10.1016%2Fj.ccell.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loboda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooden, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span> <span> </span><span class="NLM_article-title">Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-cell Lymphoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">3785</span>â <span class="NLM_lpage">3794</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-07-6091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1158%2F0008-5472.CAN-07-6091" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3785-3794&author=V.+R.+Fantinauthor=A.+Lobodaauthor=C.+P.+Paweletzauthor=R.+C.+Hendricksonauthor=J.+W.+Pierceauthor=J.+A.+Rothauthor=L.+Liauthor=F.+Goodenauthor=S.+Korenchukauthor=X.+S.+Houauthor=E.+A.+Harringtonauthor=S.+Randolphauthor=J.+F.+Reillyauthor=C.+M.+Wareauthor=M.+E.+Kadinauthor=S.+R.+Frankelauthor=V.+M.+Richon&title=Constitutive+Activation+of+Signal+Transducers+and+Activators+of+Transcription+Predicts+Vorinostat+Resistance+in+Cutaneous+T-cell+Lymphoma&doi=10.1158%2F0008-5472.CAN-07-6091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6091%26sid%3Dliteratum%253Aachs%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DLoboda%26aufirst%3DA.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DHendrickson%26aufirst%3DR.%2BC.%26aulast%3DPierce%26aufirst%3DJ.%2BW.%26aulast%3DRoth%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGooden%26aufirst%3DF.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DHou%26aufirst%3DX.%2BS.%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DRandolph%26aufirst%3DS.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DWare%26aufirst%3DC.%2BM.%26aulast%3DKadin%26aufirst%3DM.%2BE.%26aulast%3DFrankel%26aufirst%3DS.%2BR.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26atitle%3DConstitutive%2520Activation%2520of%2520Signal%2520Transducers%2520and%2520Activators%2520of%2520Transcription%2520Predicts%2520Vorinostat%2520Resistance%2520in%2520Cutaneous%2520T-cell%2520Lymphoma%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3785%26epage%3D3794%26doi%3D10.1158%2F0008-5472.CAN-07-6091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">QuintÃ¡s-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Janus Kinase Inhibitors for the Treatment of Myeloproliferative Neoplasias and Beyond</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">140</span>, <span class="refDoi">Â DOI: 10.1038/nrd3264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnrd3264" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=127-140&author=A.+Quint%C3%A1s-Cardamaauthor=H.+Kantarjianauthor=J.+Cortesauthor=S.+Verstovsek&title=Janus+Kinase+Inhibitors+for+the+Treatment+of+Myeloproliferative+Neoplasias+and+Beyond&doi=10.1038%2Fnrd3264"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd3264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3264%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DJanus%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Myeloproliferative%2520Neoplasias%2520and%2520Beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D127%26epage%3D140%26doi%3D10.1038%2Fnrd3264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borie, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">A New Modality for Immunosuppression: Targeting the JAK/STAT Pathway</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">555</span>â <span class="NLM_lpage">564</span>, <span class="refDoi">Â DOI: 10.1038/nrd1441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnrd1441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=15232577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Oru7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=555-564&author=J.+J.+O%E2%80%99Sheaauthor=M.+Pesuauthor=D.+C.+Borieauthor=P.+S.+Changelian&title=A+New+Modality+for+Immunosuppression%3A+Targeting+the+JAK%2FSTAT+Pathway&doi=10.1038%2Fnrd1441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A new modality for immunosuppression: targeting the JAK/STAT pathway</span></div><div class="casAuthors">O'Shea, John J.; Pesu, Marko; Borie, Dominic C.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">555-564</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Thousands of organs are transplanted each year and millions of people suffer from autoimmune diseases, which creates a need for an armamentarium of immunosuppressive drugs.  Unfortunately, immunosuppressants have unwanted side effects owing, in part, to the fact that they have ubiquitous mol. targets.  Cytokines have emerged as important controllers of the immune response, and work during the past decade has identified Janus kinases (JAKs) and signal transducers, and activators of transcription (STATs), as crucial intracellular elements in cytokine signalling.  Here, we discuss the potential of the JAK/STAT pathway as a target for new immunosuppressants.  In particular, the inhibition of JAK3 seems to be an excellent strategy, because of the selective expression and precise functions of this kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhrBmh4tsEibVg90H21EOLACvtfcHk0ljkwya6vgER7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Oru7o%253D&md5=7f09261dbb7c43b4eedb750a35f8e7d5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd1441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1441%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DA%2520New%2520Modality%2520for%2520Immunosuppression%253A%2520Targeting%2520the%2520JAK%252FSTAT%2520Pathway%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D555%26epage%3D564%26doi%3D10.1038%2Fnrd1441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourouclas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassiliou, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bench, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erber, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. R.</span></span> <span> </span><span class="NLM_article-title">Cancer Genome, Project. Acquired Mutation of the Tyrosine Kinase JAK2 in Human Myeloproliferative Disorders</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">1054</span>â <span class="NLM_lpage">1061</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(05)74230-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2FS0140-6736%2805%2974230-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=15781101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFGrs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=1054-1061&author=E.+J.+Baxterauthor=L.+M.+Scottauthor=P.+J.+Campbellauthor=C.+Eastauthor=N.+Fourouclasauthor=S.+Swantonauthor=G.+S.+Vassiliouauthor=A.+J.+Benchauthor=E.+M.+Boydauthor=N.+Curtinauthor=M.+A.+Scottauthor=W.+N.+Erberauthor=A.+R.+Green&title=Cancer+Genome%2C+Project.+Acquired+Mutation+of+the+Tyrosine+Kinase+JAK2+in+Human+Myeloproliferative+Disorders&doi=10.1016%2FS0140-6736%2805%2974230-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</span></div><div class="casAuthors">Baxter, E. Joanna; Scott, Linda M.; Campbell, Peter J.; East, Clare; Fourouclas, Nasios; Swanton, Soheila; Vassiliou, George S.; Bench, Anthony J.; Boyd, Elaine M.; Curtin, Natasha; Scott, Mike A.; Erber, Wendy N.; Green, Anthony R.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">9464</span>),
    <span class="NLM_cas:pages">1054-1061</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Human myeloproliferative disorders form a range of clonal haematol. malignant diseases, the main members of which are polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.  The mol. pathogenesis of these disorders is unknown, but tyrosine kinases have been implicated in several related disorders.  We investigated the role of the cytoplasmic tyrosine kinase JAK2 in patients with a myeloproliferative disorder.  Methods: We obtained DNA samples from patients with polycythemia vera, essential thrombocythemia, or idiopathic myelofibrosis.  The coding exons of JAK2 were bidirectionally sequenced from peripheral-blood granulocytes, T cells, or both.  Allele-specific PCR, mol. cytogenetic studies, microsatellite PCR, Affymetrix single nucleotide polymorphism array analyses, and colony assays were undertaken on subgroups of patients.  Findings: A single point mutation (Val617Phe) was identified in JAK2 in 71 (97%) of 73 patients with polycythemia vera, 29 (57%) of 51 with essential thrombocythemia, and eight (50%) of 16 with idiopathic myelofibrosis.  The mutation is acquired, is present in a variable proportion of granulocytes, alters a highly conserved valine present in the neg. regulatory JH2 domain, and is predicted to dysregulate kinase activity.  It was heterozygous in most patients, homozygous in a subset as a result of mitotic recombination, and arose in a multipotent progenitor capable of giving rise to erythroid and myeloid cells.  The mutation was present in all erythropoietin-independent erythroid colonies.  Interpretation: A single acquired mutation of JAK2 was noted in more than half of patients with a myeloproliferative disorder.  Its presence in all erythropoietin-independent erythroid colonies demonstrates a link with growth factor hypersensitivity, a key biol. feature of these disorders.  Relevance to practice: Identification of the Val617Phe JAK2 mutation lays the foundation for new approaches to the diagnosis, classification, and treatment of myeloproliferative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8cc-kg2leZrVg90H21EOLACvtfcHk0ljnUfbn4eYMkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFGrs7g%253D&md5=3c9dc565a1986a47d12e4bccd8c8cc1a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974230-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974230-6%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26aulast%3DEast%26aufirst%3DC.%26aulast%3DFourouclas%26aufirst%3DN.%26aulast%3DSwanton%26aufirst%3DS.%26aulast%3DVassiliou%26aufirst%3DG.%2BS.%26aulast%3DBench%26aufirst%3DA.%2BJ.%26aulast%3DBoyd%26aufirst%3DE.%2BM.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BA.%26aulast%3DErber%26aufirst%3DW.%2BN.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26atitle%3DCancer%2520Genome%252C%2520Project.%2520Acquired%2520Mutation%2520of%2520the%2520Tyrosine%2520Kinase%2520JAK2%2520in%2520Human%2520Myeloproliferative%2520Disorders%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D1054%26epage%3D1061%26doi%3D10.1016%2FS0140-6736%2805%2974230-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">James, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Couedic, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staerk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delhommeau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacout, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raslova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennaceur-Griscelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeval, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadevall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span> <span> </span><span class="NLM_article-title">A Unique Clonal JAK2 Mutation Leading to Constitutive Signalling Causes Polycythaemia Vera</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span>,  <span class="NLM_fpage">1144</span>â <span class="NLM_lpage">1148</span>, <span class="refDoi">Â DOI: 10.1038/nature03546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnature03546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=15793561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=1144-1148&author=C.+Jamesauthor=V.+Ugoauthor=J.+P.+Le+Couedicauthor=J.+Staerkauthor=F.+Delhommeauauthor=C.+Lacoutauthor=L.+Garconauthor=H.+Raslovaauthor=R.+Bergerauthor=A.+Bennaceur-Griscelliauthor=J.+L.+Villevalauthor=S.+N.+Constantinescuauthor=N.+Casadevallauthor=W.+Vainchenker&title=A+Unique+Clonal+JAK2+Mutation+Leading+to+Constitutive+Signalling+Causes+Polycythaemia+Vera&doi=10.1038%2Fnature03546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span></div><div class="casAuthors">James, Chloe; Ugo, Valerie; Le Couedic, Jean-Pierre; Staerk, Judith; Delhommeau, Francois; Lacout, Catherine; Garcon, Loic; Raslova, Hana; Berger, Roland; Bennaceur-Griscelli, Annelise; Villeval, Jean Luc; Constantinescu, Stefan N.; Casadevall, Nicole; Vainchenker, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7037</span>),
    <span class="NLM_cas:pages">1144-1148</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative disorders are clonal hematopoietic stem cell malignancies characterized by independency or hypersensitivity of hematopoietic progenitors to numerous cytokines.  The mol. basis of most myeloproliferative disorders is unknown.  On the basis of the model of chronic myeloid leukemia, it is expected that a constitutive tyrosine kinase activity could be at the origin of these diseases.  Polycythemia vera is an acquired myeloproliferative disorder, characterized by the presence of polycythemia diversely assocd. with thrombocytosis, leukocytosis and splenomegaly.  Polycythemia vera progenitors are hypersensitive to erythropoietin and other cytokines.  Here, the authors describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (>80%) polycythemia vera patients.  The mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model.  As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new mol. classification of these disorders and novel therapeutical approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-6NigTwc97Vg90H21EOLACvtfcHk0ljnUfbn4eYMkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D&md5=9e9c223dd4e2da2ebf52d14edda85963</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature03546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03546%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DC.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DLe%2BCouedic%26aufirst%3DJ.%2BP.%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DLacout%26aufirst%3DC.%26aulast%3DGarcon%26aufirst%3DL.%26aulast%3DRaslova%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBennaceur-Griscelli%26aufirst%3DA.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26atitle%3DA%2520Unique%2520Clonal%2520JAK2%2520Mutation%2520Leading%2520to%2520Constitutive%2520Signalling%2520Causes%2520Polycythaemia%2520Vera%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D1144%26epage%3D1148%26doi%3D10.1038%2Fnature03546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kralovics, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buser, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiedt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passweg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoda, R. C.</span></span> <span> </span><span class="NLM_article-title">A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1779</span>â <span class="NLM_lpage">1790</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa051113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1056%2FNEJMoa051113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=15858187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1779-1790&author=R.+Kralovicsauthor=F.+Passamontiauthor=A.+S.+Buserauthor=S.+S.+Teoauthor=R.+Tiedtauthor=J.+R.+Passwegauthor=A.+Tichelliauthor=M.+Cazzolaauthor=R.+C.+Skoda&title=A+Gain-of-Function+Mutation+of+JAK2+in+Myeloproliferative+Disorders&doi=10.1056%2FNEJMoa051113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A gain-of-function mutation of JAK2 in myeloproliferative disorders</span></div><div class="casAuthors">Kralovics, Robert; Passamonti, Francesco; Buser, Andreas S.; Teo, Soon-Siong; Tiedt, Ralph; Passweg, Jakob R.; Tichelli, Andre; Cazzola, Mario; Skoda, Radek C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1779-1790</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are clonal myeloproliferative disorders arising from a multi-potent progenitor.  The loss of heterozygosity (LOH) on the short arm of chromosome 9 (9pLOH) in myeloproliferative disorders suggests that 9p harbors a mutation that contributes to the cause of clonal expansion of hematopoietic cells in these diseases.  METHODS We performed microsatellite mapping of the 9pLOH region and DNA sequencing in 244 patients with myeloproliferative disorders (128 with polycythemia vera, 93 with essential thrombocythemia, and 23 with idiopathic myelofibrosis).  RESULTS Microsatellite mapping identified a 9pLOH region that included the Janus kinase 2 (JAK2) gene.  In patients with 9pLOH, JAK2 had a homozygous GâT transversion, causing phenylalanine to be substituted for valine at position 617 of JAK2 (V617F).  All 51 patients with 9pLOH had the V617F mutation.  Of 193 patients without 9pLOH, 66 were heterozygous for V617F and 127 did not have the mutation.  The frequency of V617F was 65 % among patients with polycythemia vera (83 of 128), 57 % among patients with idiopathic myelofibrosis (13 of 23), and 23 % among patients with essential thrombocythemia (21 of 93).  V617F is a somatic mutation present in hematopoietic cells.  Mitotic recombination probably causes both 9pLOH and the transition from heterozygosity to homozygosity for V617F.  Genetic evidence and in vitro functional studies indicate that V617F gives hematopoietic precursors proliferative and survival advantages.  Patients with the V617F mutation had a significantly longer duration of disease and a higher rate of complications (fibrosis, hemorrhage, and thrombosis) and treatment with cytoreductive therapy than patients with wild-type JAK2.  CONCLUSIONS A high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqTe7EsB_527Vg90H21EOLACvtfcHk0ljnUfbn4eYMkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsLw%253D&md5=5dd4bc090ded1c812b61923cad36e77e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa051113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa051113%26sid%3Dliteratum%253Aachs%26aulast%3DKralovics%26aufirst%3DR.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DBuser%26aufirst%3DA.%2BS.%26aulast%3DTeo%26aufirst%3DS.%2BS.%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DPassweg%26aufirst%3DJ.%2BR.%26aulast%3DTichelli%26aufirst%3DA.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26atitle%3DA%2520Gain-of-Function%2520Mutation%2520of%2520JAK2%2520in%2520Myeloproliferative%2520Disorders%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1779%26epage%3D1790%26doi%3D10.1056%2FNEJMoa051113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadleigh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntly, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodarska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelsperger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Activating Mutation in the Tyrosine Kinase JAK2 in Polycythemia Vera, Essential Thrombocythemia, and Myeloid Metaplasia with Myelofibrosis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">387</span>â <span class="NLM_lpage">397</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2005.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2Fj.ccr.2005.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=15837627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=387-397&author=R.+L.+Levineauthor=M.+Wadleighauthor=J.+Coolsauthor=B.+L.+Ebertauthor=G.+Wernigauthor=B.+J.+Huntlyauthor=T.+J.+Boggonauthor=I.+Wlodarskaauthor=J.+J.+Clarkauthor=S.+Mooreauthor=J.+Adelspergerauthor=S.+Kooauthor=J.+C.+Leeauthor=S.+Gabrielauthor=T.+Mercherauthor=A.+D%E2%80%99Andreaauthor=S.+Frohlingauthor=K.+Dohnerauthor=P.+Marynenauthor=P.+Vandenbergheauthor=R.+A.+Mesaauthor=A.+Tefferiauthor=J.+D.+Griffinauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=T.+R.+Golubauthor=S.+J.+Leeauthor=D.+G.+Gilliland&title=Activating+Mutation+in+the+Tyrosine+Kinase+JAK2+in+Polycythemia+Vera%2C+Essential+Thrombocythemia%2C+and+Myeloid+Metaplasia+with+Myelofibrosis&doi=10.1016%2Fj.ccr.2005.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</span></div><div class="casAuthors">Levine, Ross L.; Wadleigh, Martha; Cools, Jan; Ebert, Benjamin L.; Wernig, Gerlinde; Huntly, Brian J. P.; Boggon, Titus J.; Wlodarska, Iwona; Clark, Jennifer J.; Moore, Sandra; Adelsperger, Jennifer; Koo, Sumin; Lee, Jeffrey C.; Gabriel, Stacey; Mercher, Thomas; D'Andrea, Alan; Froehling, Stefan; Doehner, Konstanze; Marynen, Peter; Vandenberghe, Peter; Mesa, Ruben A.; Tefferi, Ayalew; Griffin, James D.; Eck, Michael J.; Sellers, William R.; Meyerson, Matthew; Golub, Todd R.; Lee, Stephanie J.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">387-397</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors.  An internet-based protocol was used to collect clin. information and biol. specimens from patients with these diseases.  High-throughput DNA re-sequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations.  Mol. and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele.  JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not obsd. in 269 normal individuals.  In vitro anal. demonstrated that JAK2V617F is a constitutively active tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJNzUFm3Q3bVg90H21EOLACvtfcHk0ljJhIx-Ni4Axg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D&md5=2a3e893867b114e8749cd6f5e55990b7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DHuntly%26aufirst%3DB.%2BJ.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DAdelsperger%26aufirst%3DJ.%26aulast%3DKoo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DMercher%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DActivating%2520Mutation%2520in%2520the%2520Tyrosine%2520Kinase%2520JAK2%2520in%2520Polycythemia%2520Vera%252C%2520Essential%2520Thrombocythemia%252C%2520and%2520Myeloid%2520Metaplasia%2520with%2520Myelofibrosis%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D387%26epage%3D397%26doi%3D10.1016%2Fj.ccr.2005.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Overcoming Treatment Challenges in Myelofibrosis and Polycythemia Vera: the Role of Ruxolitinib</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1125</span>â <span class="NLM_lpage">1142</span>, <span class="refDoi">Â DOI: 10.1007/s00280-016-3012-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1007%2Fs00280-016-3012-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=27017614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28XltF2rtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2016&pages=1125-1142&author=J.+C.+Bryanauthor=S.+Verstovsek&title=Overcoming+Treatment+Challenges+in+Myelofibrosis+and+Polycythemia+Vera%3A+the+Role+of+Ruxolitinib&doi=10.1007%2Fs00280-016-3012-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib</span></div><div class="casAuthors">Bryan, Jeffrey C.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1125-1142</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Myelofibrosis (MF) and polycythemia vera (PV) are BCR-ABL1-neg. myeloproliferative neoplasms assocd. with somatic hematopoietic stem cell mutations leading to over activation of JAK-STAT signaling.  MF and PV are pathogenically related and share specific clin. features such as splenomegaly and constitutional symptoms.  The MF phenotype is dominated by the effects of progressive bone marrow fibrosis resulting in shortened survival.  In contrast, elevated thrombosis risk due to erythrocytosis is the primary clin. concern in PV.  Ruxolitinib, an oral JAK1/JAK2 inhibitor, is approved in the USA for the treatment of patients with intermediate- or high-risk MF and patients with PV who have had an inadequate response to or are intolerant of hydroxyurea.  For MF, results of two phase III studies demonstrated that ruxolitinib therapy reduced spleen vol. and MF-related symptom burden, improved quality-of-life measures, and was assocd. with prolonged overall survival.  Treatment benefits were generally sustained with continued therapy.  Dose-dependent cytopenias were common but generally manageable with transfusions (for anemia), dose redn., or treatment interruption.  Optimal dosing management is crit. to maintain long-term treatment benefit, because cessation of therapy resulted in rapid return of symptoms to baseline levels.  Results of the phase III PV trial showed that ruxolitinib was significantly more effective than std. therapy in controlling hematocrit levels and improving splenomegaly and PV-related symptoms.  Only 1 of 110 patients in the ruxolitinib arm compared with 6 of 112 patients in the control arm experienced a thromboembolic event through week 32.  Grade â¥3 cytopenias were uncommon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJdrGniqBGrVg90H21EOLACvtfcHk0ljJhIx-Ni4Axg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltF2rtrY%253D&md5=8e24890058631f83b5fd157d7d6f2b0f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3012-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3012-z%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DJ.%2BC.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DOvercoming%2520Treatment%2520Challenges%2520in%2520Myelofibrosis%2520and%2520Polycythemia%2520Vera%253A%2520the%2520Role%2520of%2520Ruxolitinib%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D77%26spage%3D1125%26epage%3D1142%26doi%3D10.1007%2Fs00280-016-3012-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bose, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">JAK2 Inhibitors for Myeloproliferative Neoplasms: What Is Next?</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">115</span>â <span class="NLM_lpage">125</span>, <span class="refDoi">Â DOI: 10.1182/blood-2017-04-742288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1182%2Fblood-2017-04-742288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=28500170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WnurbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=115-125&author=P.+Boseauthor=S.+Verstovsek&title=JAK2+Inhibitors+for+Myeloproliferative+Neoplasms%3A+What+Is+Next%3F&doi=10.1182%2Fblood-2017-04-742288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2 inhibitors for myeloproliferative neoplasms: what is next?</span></div><div class="casAuthors">Bose, Prithviraj; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-126</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing.  Several other JAK2 inhibitors have entered clin. testing, but none have been approved and many have been discontinued.  Importantly, the activity of these agents is not restricted to patients with JAK2 V617F or exon 12 mutations.  Although JAK2 inhibitors provide substantial clin. benefit, their disease-modifying activity is limited, and rational combinations with other targeted agents are needed, particularly in MF, in which survival is short.  Many such combinations are being explored, as are other novel agents, some of which could successfully be combined with JAK2 inhibitors in the future.  In addn., new JAK2 inhibitors with the potential for less myelosuppression continue to be investigated.  Given the proven safety and efficacy of ruxolitinib, it is likely that ruxolitinib-based combinations will be a major way forward in drug development for MF.  If approved, less myelosuppressive JAK2 inhibitors such as pacritinib or NS-018 could prove to be very useful addns. to the therapeutic armamentarium in MF.  In PV, inhibitors of histone deacetylases and human double minute 2 have activity, but their role, if any, in the future treatment algorithm is uncertain, given the availability of ruxolitinib and renewed interest in interferons.  Ruxolitinib is in late-phase clin. trials in essential thrombocythemia, in which it could fill an important void for patients with troublesome symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr05BKuhh_JNLVg90H21EOLACvtfcHk0liXPy_AzAL_PQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WnurbI&md5=a00ec9709cb423c06211f89fe05445ae</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-04-742288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-04-742288%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DJAK2%2520Inhibitors%2520for%2520Myeloproliferative%2520Neoplasms%253A%2520What%2520Is%2520Next%253F%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D115%26epage%3D125%26doi%3D10.1182%2Fblood-2017-04-742288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaFave, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">JAK2 the Future: Therapeutic Strategies for JAK-Dependent Malignancies</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">574</span>â <span class="NLM_lpage">582</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2012.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2Fj.tips.2012.08.005" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=574-582&author=L.+M.+LaFaveauthor=R.+L.+Levine&title=JAK2+the+Future%3A+Therapeutic+Strategies+for+JAK-Dependent+Malignancies&doi=10.1016%2Fj.tips.2012.08.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DLaFave%26aufirst%3DL.%2BM.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DJAK2%2520the%2520Future%253A%2520Therapeutic%2520Strategies%2520for%2520JAK-Dependent%2520Malignancies%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D574%26epage%3D582%26doi%3D10.1016%2Fj.tips.2012.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">What Is Next Beyond Janus Kinase 2 Inhibitors for Primary Myelofibrosis?</span>. <i>Curr. Opin. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">123</span>â <span class="NLM_lpage">129</span>, <span class="refDoi">Â DOI: 10.1097/MOH.0b013e32835d8e10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1097%2FMOH.0b013e32835d8e10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=23385614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=123-129&author=F.+P.+Santosauthor=S.+Verstovsek&title=What+Is+Next+Beyond+Janus+Kinase+2+Inhibitors+for+Primary+Myelofibrosis%3F&doi=10.1097%2FMOH.0b013e32835d8e10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?</span></div><div class="casAuthors">Santos, Fabio P. S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-129</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Although the approval of the janus kinase (JAK) inhibitor ruxolitinib for therapy of patients with myelofibrosis represents an important step in the development of targeted therapy for these patients, JAK inhibitors do not eradicate the disease, and a review of novel agents with mechanisms of action complementary to JAK2 enzymic inhibition is timely.  Recent findings: There are several compds. with different mechanisms of action undergoing preclin. and clin. testing in myelofibrosis.  Heat shock protein inhibitors and histone deacetylase inhibitors induce JAK2 degrdn. and downregulation of intracellular oncogenic signalling, and may overcome resistance to JAK2 inhibitors.  Reversal of bone marrow fibrosis is still a therapeutic challenge in this disease, and mAbs targeting transforming growth factor-Î² and lysyl oxidase like-2 may prove efficacious.  Promising compds. inhibiting signal transducer and activator of transcription 5 activity and inducing megakaryocyte polyploidization are in preclin. testing.  Summary: Although none of these new drugs have been approved for therapy of myelofibrosis, their activity is being tested in clin. trials, alone or in combination with JAK2 inhibitors.  Patients with myelofibrosis should be encouraged to participate in clin. trials testing novel compds. for this disorder, particularly if they have failed a trial of JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gqDFCRlvYrVg90H21EOLACvtfcHk0liXPy_AzAL_PQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D&md5=49159c335e02a416c0541d8b92069f4e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e32835d8e10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e32835d8e10%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DF.%2BP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DWhat%2520Is%2520Next%2520Beyond%2520Janus%2520Kinase%25202%2520Inhibitors%2520for%2520Primary%2520Myelofibrosis%253F%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2013%26volume%3D20%26spage%3D123%26epage%3D129%26doi%3D10.1097%2FMOH.0b013e32835d8e10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reuther, G. W.</span></span> <span> </span><span class="NLM_article-title">Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics</span>. <i>Prog. Mol. Biol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">437</span>â <span class="NLM_lpage">484</span>, <span class="refDoi">Â DOI: 10.1016/bs.pmbts.2016.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2Fbs.pmbts.2016.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=27865464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A280%3ADC%252BC2snot1enug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2016&pages=437-484&author=G.+W.+Reuther&title=Myeloproliferative+Neoplasms%3A+Molecular+Drivers+and+Therapeutics&doi=10.1016%2Fbs.pmbts.2016.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics</span></div><div class="casAuthors">Reuther G W</div><div class="citationInfo"><span class="NLM_cas:title">Progress in molecular biology and translational science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">437-484</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Activating mutations in genes that drive neoplastic cell growth are numerous and widespread in cancer, and specific genetic alterations are associated with certain types of cancer.  For example, classic myeloproliferative neoplasms (MPNs) are hematopoietic stem cell disorders that affect cells of the myeloid lineage, including erythrocytes, platelets, and granulocytes.  An activating mutation in the JAK2 tyrosine kinase is prevalent in these diseases.  In MPN patients that lack such a mutation, other genetic changes that lead to activation of the JAK2 signaling pathway are present, indicating deregulation of JAK2 signaling plays an etiological driving role in MPNs, a concept supported by significant evidence from in vivo experimental MPN systems.  Thus, small molecules that inhibit JAK2 activity are ideal drugs to impede the progression of disease in MPN patients.  However, even though JAK inhibitors provide significant symptomatic relief, they have failed as a remission-inducing therapy.  Nonetheless, the progress made understanding the molecular etiology of MPNs since 2005 is significant and has provided insight for the development and testing of novel molecular targeted therapeutic approaches.  The current understanding of driver mutations in MPNs and an overview of current and potential therapeutic strategies for MPN patients will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRi64LuFKtexCO2kE7krGOBfW6udTcc2ea2jhD3vnh5ZLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snot1enug%253D%253D&md5=9c2c3af37062ca1bbf15a874170ffdb5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmbts.2016.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmbts.2016.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DReuther%26aufirst%3DG.%2BW.%26atitle%3DMyeloproliferative%2520Neoplasms%253A%2520Molecular%2520Drivers%2520and%2520Therapeutics%26jtitle%3DProg.%2520Mol.%2520Biol.%2520Transl.%2520Sci.%26date%3D2016%26volume%3D144%26spage%3D437%26epage%3D484%26doi%3D10.1016%2Fbs.pmbts.2016.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bose, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Myelofibrosis: An Update on Drug Therapy in 2016</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2375</span>â <span class="NLM_lpage">2389</span>, <span class="refDoi">Â DOI: 10.1080/14656566.2016.1252333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1080%2F14656566.2016.1252333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=27774820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKltb%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=2375-2389&author=P.+Boseauthor=S.+Verstovsek&title=Myelofibrosis%3A+An+Update+on+Drug+Therapy+in+2016&doi=10.1080%2F14656566.2016.1252333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Myelofibrosis: an update on drug therapy in 2016</span></div><div class="casAuthors">Bose, Prithviraj; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2375-2389</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Primary myelofibrosis (PMF) is the least common but the most aggressive of the classic Philadelphia chromosome-neg. myeloproliferative neoplasms.  Survival is much shorter in PMF than in polycythemia vera (PV) or essential thrombocythemia (ET).  Post-PV/ET myelofibrosis (MF) is clin. indistinguishable from PMF and approached similarly.: Current pharmacol. therapy of MF revolves around the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, which dramatically improves constitutional symptoms and splenomegaly in the majority of patients, and improves overall survival (OS).  However, allogeneic stem cell transplantation remains the only potential cure.  Other JAK inhibitors continue to be developed for MF, and momelotinib and pacritinib are in phase III clin. trials.  Anemia is common in MF, and initially worsened by ruxolitinib.  Momelotinib and pacritinib may prove advantageous in this regard.  Current strategies for managing anemia of MF include danazol, immunomodulatory drugs and erythroid stimulating agents, either alone or in combination with ruxolitinib.: A no. of other agents, representing diverse drug classes, are in various stages of development for MF.  These include newer JAK inhibitors, other signaling inhibitors, epigenetic modifiers, anti-fibrotic agents, telomerase inhibitors, and activin receptor ligand traps (for anemia).  Hopefully, these novel therapies will further extend the clin. benefits of ruxolitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJrOVEwApIsLVg90H21EOLACvtfcHk0lhpF4hHcM91fg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKltb%252FL&md5=2df28795d127525f62d600d31d1b9a5b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F14656566.2016.1252333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2016.1252333%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DMyelofibrosis%253A%2520An%2520Update%2520on%2520Drug%2520Therapy%2520in%25202016%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2016%26volume%3D17%26spage%3D2375%26epage%3D2389%26doi%3D10.1080%2F14656566.2016.1252333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span>. <i>Clin Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2051</span>â <span class="NLM_lpage">2059</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+Pathways%3A+Molecular+Basis+for+Sensitivity+and+Resistance+to+JAK+Kinase+Inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0lhpF4hHcM91fg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520Pathways%253A%2520Molecular%2520Basis%2520for%2520Sensitivity%2520and%2520Resistance%2520to%2520JAK%2520Kinase%2520Inhibitors%26jtitle%3DClin%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilpivaara, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hricik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullally, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Wahab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marubayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>489</i></span>,  <span class="NLM_fpage">155</span>â <span class="NLM_lpage">159</span>, <span class="refDoi">Â DOI: 10.1038/nature11303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnature11303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=22820254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=489&publication_year=2012&pages=155-159&author=P.+Koppikarauthor=N.+Bhagwatauthor=O.+Kilpivaaraauthor=T.+Manshouriauthor=M.+Adliauthor=T.+Hricikauthor=F.+Liuauthor=L.+M.+Saundersauthor=A.+Mullallyauthor=O.+Abdel-Wahabauthor=L.+Leungauthor=A.+Weinsteinauthor=S.+Marubayashiauthor=A.+Goelauthor=M.+Gonenauthor=Z.+Estrovauthor=B.+L.+Ebertauthor=G.+L.+Chiosisauthor=S.+D.+Nimerauthor=B.+E.+Bernsteinauthor=S.+Verstovsekauthor=R.+L.+Levine&title=Heterodimeric+JAK-STAT+Activation+As+a+Mechanism+of+Persistence+to+JAK2+Inhibitor+Therapy&doi=10.1038%2Fnature11303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span></div><div class="casAuthors">Koppikar, Priya; Bhagwat, Neha; Kilpivaara, Outi; Manshouri, Taghi; Adli, Mazhar; Hricik, Todd; Liu, Fan; Saunders, Lindsay M.; Mullally, Ann; Abdel-Wahab, Omar; Leung, Laura; Weinstein, Abby; Marubayashi, Sachie; Goel, Aviva; Goenen, Mithat; Estrov, Zeev; Ebert, Benjamin L.; Chiosis, Gabriela; Nimer, Stephen D.; Bernstein, Bradley E.; Verstovsek, Srdan; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">489</span>
        (<span class="NLM_cas:issue">7414</span>),
    <span class="NLM_cas:pages">155-159</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of somatic activating mutations in JAK2 (refs 1-4) and in the thrombopoietin receptor gene (MPL) in most patients with myeloproliferative neoplasm (MPN) led to the clin. development of JAK2 kinase inhibitors.  JAK2 inhibitor therapy improves MPN-assocd. splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN.  We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2.  Here we show that JAK2 inhibitor persistence is assocd. with reactivation of JAK-STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 intrans by other JAK kinases.  Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is assocd. with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression.  We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors.  RNA interference and pharmacol. studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression.  Consequently, therapies that result in JAK2 degrdn. retain efficacy in persistent cells and may provide addnl. benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlKcCqEPMbLLVg90H21EOLACvtfcHk0lhpF4hHcM91fg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI&md5=3289538048859aa236965d985b2ef79f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnature11303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11303%26sid%3Dliteratum%253Aachs%26aulast%3DKoppikar%26aufirst%3DP.%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DKilpivaara%26aufirst%3DO.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DAdli%26aufirst%3DM.%26aulast%3DHricik%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DSaunders%26aufirst%3DL.%2BM.%26aulast%3DMullally%26aufirst%3DA.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DWeinstein%26aufirst%3DA.%26aulast%3DMarubayashi%26aufirst%3DS.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DChiosis%26aufirst%3DG.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DHeterodimeric%2520JAK-STAT%2520Activation%2520As%2520a%2520Mechanism%2520of%2520Persistence%2520to%2520JAK2%2520Inhibitor%2520Therapy%26jtitle%3DNature%26date%3D2012%26volume%3D489%26spage%3D155%26epage%3D159%26doi%3D10.1038%2Fnature11303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellacasa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carobbio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Introna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaldi, A.</span></span> <span> </span><span class="NLM_article-title">The Histone Deacetylase Inhibitor ITF2357 Selectively Targets Cells Bearing Mutated JAK2(V617F)</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">740</span>â <span class="NLM_lpage">747</span>, <span class="refDoi">Â DOI: 10.1038/sj.leu.2405049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fsj.leu.2405049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=18079739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=740-747&author=V.+Gueriniauthor=V.+Barbuiauthor=O.+Spinelliauthor=A.+Salviauthor=C.+Dellacasaauthor=A.+Carobbioauthor=M.+Intronaauthor=T.+Barbuiauthor=J.+Golayauthor=A.+Rambaldi&title=The+Histone+Deacetylase+Inhibitor+ITF2357+Selectively+Targets+Cells+Bearing+Mutated+JAK2%28V617F%29&doi=10.1038%2Fsj.leu.2405049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F</span></div><div class="casAuthors">Guerini, V.; Barbui, V.; Spinelli, O.; Salvi, A.; Dellacasa, C.; Carobbio, A.; Introna, M.; Barbui, T.; Golay, J.; Rambaldi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-747</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors investigated the activity of ITF2357, a novel histone deacetylase inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2V617F mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line.  The clonogenic activity of JAK2V617F mutated cells was inhibited by low concns. of ITF2357 (IC50 0.001-0.01 Î¼), 100- to 250-fold lower than required to inhibit growth of normal or tumor cells lacking this mutation.  Under these conditions, ITF2357 allowed a seven fold increase in the outgrowth of unmutated over mutated colonies.  By western blotting the authors showed that in HEL cells, ITF2357 led to the disappearance of total and phosphorylated JAK2V617F as well as pSTAT5 and pSTAT3, but it did not affect the wild-type JAK2 or STAT proteins in the control K562 cell line.  By real-time PCR, the authors showed that, upon exposure to ITF2357, JAK2V617F mRNA was not modified in granulocytes from PV patients while the expression of the PRV-1 gene, a known target of JAK2, was rapidly downmodulated.  Altogether, the data presented suggest that ITF2357 inhibits proliferation of cells bearing the JAK2V617F mutation through a specific down-modulation of the JAK2V617F protein and inhibition of its downstream signaling.  Leukemia (2008) 22, 740-747; doi:10.1038/sj.leu.2405049; published online 13 Dec. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJVQmHmDb8RLVg90H21EOLACvtfcHk0ljQ2cI0_8Ehfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D&md5=de59fdaf20ec85e733052c09733b9193</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2405049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2405049%26sid%3Dliteratum%253Aachs%26aulast%3DGuerini%26aufirst%3DV.%26aulast%3DBarbui%26aufirst%3DV.%26aulast%3DSpinelli%26aufirst%3DO.%26aulast%3DSalvi%26aufirst%3DA.%26aulast%3DDellacasa%26aufirst%3DC.%26aulast%3DCarobbio%26aufirst%3DA.%26aulast%3DIntrona%26aufirst%3DM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DGolay%26aufirst%3DJ.%26aulast%3DRambaldi%26aufirst%3DA.%26atitle%3DThe%2520Histone%2520Deacetylase%2520Inhibitor%2520ITF2357%2520Selectively%2520Targets%2520Cells%2520Bearing%2520Mutated%2520JAK2%2528V617F%2529%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D740%26epage%3D747%26doi%3D10.1038%2Fsj.leu.2405049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balusu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jillella, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K. N.</span></span> <span> </span><span class="NLM_article-title">Cotreatment with Panobinostat and JAK2 Inhibitor TG101209 Attenuates JAK2V617F Levels and Signaling and Exerts Synergistic Cytotoxic Effects Against Human Myeloproliferative Neoplastic Cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">5024</span>â <span class="NLM_lpage">5033</span>, <span class="refDoi">Â DOI: 10.1182/blood-2009-05-222133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1182%2Fblood-2009-05-222133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=19828702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2gsb%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=5024-5033&author=Y.+Wangauthor=W.+Fiskusauthor=D.+G.+Chongauthor=K.+M.+Buckleyauthor=K.+Natarajanauthor=R.+Raoauthor=A.+Joshiauthor=R.+Balusuauthor=S.+Koulauthor=J.+Chenauthor=A.+Savoieauthor=C.+Ustunauthor=A.+P.+Jillellaauthor=P.+Atadjaauthor=R.+L.+Levineauthor=K.+N.+Bhalla&title=Cotreatment+with+Panobinostat+and+JAK2+Inhibitor+TG101209+Attenuates+JAK2V617F+Levels+and+Signaling+and+Exerts+Synergistic+Cytotoxic+Effects+Against+Human+Myeloproliferative+Neoplastic+Cells&doi=10.1182%2Fblood-2009-05-222133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells</span></div><div class="casAuthors">Wang, Yongchao; Fiskus, Warren; Chong, Daniel G.; Buckley, Kathleen M.; Natarajan, Kavita; Rao, Rekha; Joshi, Atul; Balusu, Ramesh; Koul, Sanjay; Chen, Jianguang; Savoie, Andrew; Ustun, Celalettin; Jillella, Anand P.; Atadja, Peter; Levine, Ross L.; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5024-5033</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL-neg. myeloproliferative neoplasms (MPNs).  JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3 (PI3)/AKT pathways, conferring proliferative and survival advantages in the MPN hematopoietic progenitor cells (HPCs).  Treatment with the pan-histone deacetylase (HDAC) inhibitor panobinostat (PS) is known to inhibit the chaperone function of heat shock protein 90, as well as induce growth arrest and apoptosis of transformed HPCs.  Here, we demonstrate that PS treatment depletes the autophosphorylation, expression, and downstream signaling of JAK2V617F.  Treatment with PS also disrupted the chaperone assocn. of JAK2V617F with hsp90, promoting proteasomal degrdn. of JAK2V617F.  PS also induced apoptosis of the cultured JAK2V617F-expressing human erythroleukemia HEL92.1.7 and Ba/F3-JAK2V617F cells.  Treatment with the JAK2 TK inhibitor TG101209 attenuated JAK2V617F autophosphorylation and induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells.  Cotreatment with PS and TG101209 further depleted JAK/STAT signaling and synergistically induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells.  Cotreatment with TG101209 and PS exerted greater cytotoxicity against primary CD34+ MPN cells than normal CD34+ HPCs.  These in vitro findings suggest combination therapy with HDAC and JAK2V617F inhibitors is of potential value for the treatment of JAK2V617F-pos. MPN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodK5zBrODMYbVg90H21EOLACvtfcHk0ljQ2cI0_8Ehfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2gsb%252FI&md5=061242179d1d48acd664acc8f484f003</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222133%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DChong%26aufirst%3DD.%2BG.%26aulast%3DBuckley%26aufirst%3DK.%2BM.%26aulast%3DNatarajan%26aufirst%3DK.%26aulast%3DRao%26aufirst%3DR.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DBalusu%26aufirst%3DR.%26aulast%3DKoul%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSavoie%26aufirst%3DA.%26aulast%3DUstun%26aufirst%3DC.%26aulast%3DJillella%26aufirst%3DA.%2BP.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DCotreatment%2520with%2520Panobinostat%2520and%2520JAK2%2520Inhibitor%2520TG101209%2520Attenuates%2520JAK2V617F%2520Levels%2520and%2520Signaling%2520and%2520Exerts%2520Synergistic%2520Cytotoxic%2520Effects%2520Against%2520Human%2520Myeloproliferative%2520Neoplastic%2520Cells%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D5024%26epage%3D5033%26doi%3D10.1182%2Fblood-2009-05-222133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">The Oral HDAC Inhibitor Pracinostat (SB939) Is Efficacious and Synergistic with the JAK2 Inhibitor Pacritinib (SB1518) in Preclinical Models of AML</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e69</span> <span class="refDoi">Â DOI: 10.1038/bcj.2012.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fbcj.2012.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=22829971" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&author=V.+Novotny-Diermayrauthor=S.+Hartauthor=K.+C.+Gohauthor=A.+Cheongauthor=L.+C.+Ongauthor=H.+Hentzeauthor=M.+K.+Pashaauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=J.+M.+Wood&title=The+Oral+HDAC+Inhibitor+Pracinostat+%28SB939%29+Is+Efficacious+and+Synergistic+with+the+JAK2+Inhibitor+Pacritinib+%28SB1518%29+in+Preclinical+Models+of+AML&doi=10.1038%2Fbcj.2012.14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2012.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2012.14%26sid%3Dliteratum%253Aachs%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Oral%2520HDAC%2520Inhibitor%2520Pracinostat%2520%2528SB939%2529%2520Is%2520Efficacious%2520and%2520Synergistic%2520with%2520the%2520JAK2%2520Inhibitor%2520Pacritinib%2520%2528SB1518%2529%2520in%2520Preclinical%2520Models%2520of%2520AML%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2012%26volume%3D2%26doi%3D10.1038%2Fbcj.2012.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conneally, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipka, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharyya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribrag, V.</span></span> <span> </span><span class="NLM_article-title">Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">4060</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=4060&author=C.+N.+Harrisonauthor=J.-J.+Kiladjianauthor=F.+H.+Heidelauthor=A.+M.+Vannucchiauthor=F.+Passamontiauthor=A.+Hayatauthor=E.+Conneallyauthor=B.+Martinoauthor=T.+Kindlerauthor=D.+B.+Lipkaauthor=S.+Acharyyaauthor=P.+Gopalakrishnaauthor=S.+Ideauthor=T.+Liuauthor=S.+Muauthor=V.+Ribrag&title=Efficacy%2C+Safety%2C+and+Confirmation+of+the+Recommended+Phase+2+Starting+Dose+of+the+Combination+of+Ruxolitinib+%28RUX%29+and+Panobinostat+%28PAN%29+in+Patients+%28Pts%29+with+Myelofibrosis+%28MF%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DHayat%26aufirst%3DA.%26aulast%3DConneally%26aufirst%3DE.%26aulast%3DMartino%26aufirst%3DB.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DLipka%26aufirst%3DD.%2BB.%26aulast%3DAcharyya%26aufirst%3DS.%26aulast%3DGopalakrishna%26aufirst%3DP.%26aulast%3DIde%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DMu%26aufirst%3DS.%26aulast%3DRibrag%26aufirst%3DV.%26atitle%3DEfficacy%252C%2520Safety%252C%2520and%2520Confirmation%2520of%2520the%2520Recommended%2520Phase%25202%2520Starting%2520Dose%2520of%2520the%2520Combination%2520of%2520Ruxolitinib%2520%2528RUX%2529%2520and%2520Panobinostat%2520%2528PAN%2529%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Myelofibrosis%2520%2528MF%2529%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D4060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a> (NCT01433445, accessed Sep 14, 2011; NCT01693601, accessed Sep 26,
2012; NCT02267278, accessed Oct 17, <span class="NLM_year">2014</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2F+%28NCT01433445%2C+accessed+Sep+14%2C+2011%3B+NCT01693601%2C+accessed+Sep+26%2C%0A2012%3B+NCT02267278%2C+accessed+Oct+17%2C+2014%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zwergel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stazi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mail, A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: Updated Studies in Various Epigenetic-Related Diseases</span>. <i>J. Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">15</span>, <span class="refDoi">Â DOI: 10.21767/2472-1158.100015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.21767%2F2472-1158.100015" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=1-15&author=C.+Zwergelauthor=G.+Staziauthor=S.+Valenteauthor=A.+Mail&title=Histone+Deacetylase+Inhibitors%3A+Updated+Studies+in+Various+Epigenetic-Related+Diseases&doi=10.21767%2F2472-1158.100015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.21767%2F2472-1158.100015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21767%252F2472-1158.100015%26sid%3Dliteratum%253Aachs%26aulast%3DZwergel%26aufirst%3DC.%26aulast%3DStazi%26aufirst%3DG.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DMail%26aufirst%3DA.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520Updated%2520Studies%2520in%2520Various%2520Epigenetic-Related%2520Diseases%26jtitle%3DJ.%2520Clin.%2520Epigenet.%26date%3D2016%26volume%3D2%26spage%3D1%26epage%3D15%26doi%3D10.21767%2F2472-1158.100015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>â <span class="NLM_lpage">691</span>, <span class="refDoi">Â DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+Their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0lh6Uz4Q0tGbyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520Their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monciino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span> <span> </span><span class="NLM_article-title">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1373</span>â <span class="NLM_lpage">1428</span>, <span class="refDoi">Â DOI: 10.1002/med.21437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1002%2Fmed.21437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=28181261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1373-1428&author=C.+Zagniauthor=G.+Florestaauthor=G.+Monciinoauthor=A.+Rescifina&title=The+Search+for+Potent%2C+Small-Molecule+HDACIs+in+Cancer+Treatment%3A+A+Decade+After+Vorinostat&doi=10.1002%2Fmed.21437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span></div><div class="casAuthors">Zagni Chiara; Floresta Giuseppe; Monciino Giulia; Rescifina Antonio; Floresta Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1373-1428</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression.  In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases.  Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma.  This review provides an overview of current knowledge, progress, and molecular mechanisms of HDACIs, covering a period from 2011 until 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPT4s_HXWveWmbXvSEQle5fW6udTcc2ebtAHiTJy9AcLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D&md5=79f4fe123e5ee6ba072e9147536fab67</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fmed.21437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21437%26sid%3Dliteratum%253Aachs%26aulast%3DZagni%26aufirst%3DC.%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DMonciino%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26atitle%3DThe%2520Search%2520for%2520Potent%252C%2520Small-Molecule%2520HDACIs%2520in%2520Cancer%2520Treatment%253A%2520A%2520Decade%2520After%2520Vorinostat%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D1373%26epage%3D1428%26doi%3D10.1002%2Fmed.21437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>â <span class="NLM_lpage">7887</span>, <span class="refDoi">Â DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0liEDXk_X5FQpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - Foe or Friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>â <span class="NLM_lpage">8971</span>, <span class="refDoi">Â DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+Foe+or+Friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0liEDXk_X5FQpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands. An Emerging Drug Discovery Paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>â <span class="NLM_lpage">6543</span>, <span class="refDoi">Â DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+Multiple+Ligands.+An+Emerging+Drug+Discovery+Paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0liEDXk_X5FQpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520Multiple%2520Ligands.%2520An%2520Emerging%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">950</span>â <span class="NLM_lpage">955</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.6b00247</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyqsr3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=950-955&author=X.+Liangauthor=J.+Zangauthor=M.+Zhuauthor=Q.+Gaoauthor=B.+Wangauthor=W.+Xuauthor=Y.+Zhang&title=Design%2C+Synthesis%2C+and+Antitumor+Evaluation+of+4-Amino-%281H%29-pyrazole+Derivatives+as+JAKs+Inhibitors&doi=10.1021%2Facsmedchemlett.6b00247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors</span></div><div class="casAuthors">Liang, Xuewu; Zang, Jie; Zhu, Mengyuan; Gao, Qianwen; Wang, Binghe; Xu, Wenfang; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">950-955</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abnormalities in the JAK/STAT signaling pathway lead to many diseases such as immunodeficiency, inflammation, and cancer.  Herein, we designed and synthesized a series of 4-amino-(1H)-pyrazole derivs. as potent JAKs inhibitors for cancer treatment.  Results from in vitro protein kinase inhibition expts. indicated that some compds. are potent JAKs inhibitors.  For example, the IC50 values of compd. I against JAK1, JAK2, and JAK3 were 3.4, 2.2, and 3.5 nM, resp.  In cell culture expts., compd. I showed potent antiproliferative activity against various cell lines (PC-3, HEL, K562, MCF-7, and MOLT4) at low micromolar levels, while compd. II showed selective cytotoxicity at submicromolar levels against HEL (IC50: 0.35 Î¼M) and K562 (IC50: 0.37 Î¼M) cell lines.  It is worth noting that both I and II showed more potent antiproliferative activities than the approved JAKs inhibitor Ruxolitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB3anVRvyZ0rVg90H21EOLACvtfcHk0liEDXk_X5FQpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyqsr3P&md5=18dc9a4f862e2607a784fe9a28fbd682</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00247%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Antitumor%2520Evaluation%2520of%25204-Amino-%25281H%2529-pyrazole%2520Derivatives%2520as%2520JAKs%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D950%26epage%3D955%26doi%3D10.1021%2Facsmedchemlett.6b00247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvedere, S.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5097</span>â <span class="NLM_lpage">5116</span>, <span class="refDoi">Â DOI: 10.1021/jm0303094</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0303094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5097-5116&author=T.+A.+Millerauthor=D.+J.+Witterauthor=S.+Belvedere&title=Histone+Deacetylase+Inhibitors&doi=10.1021%2Fjm0303094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors</span></div><div class="casAuthors">Miller, Thomas A.; Witter, David J.; Belvedere, Sandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5097-5116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the medicinal chem. and structure-activity relationships underlying advances in histone deacetylase (HDAC) class I/II inhibitor discovery, design, and optimization.  HDAC structural studies and HDAC inhibitory activity of small-mol. hydroxamic acids, carboxylates, benzamides, electrophilic ketones, and cyclic peptides are described.  Miscellaneousness and selectivity of the class I/II HDACs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU5UlOsBUF7rVg90H21EOLACvtfcHk0ljE_X4PI4TUaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D&md5=d2d0a95d87d699334c1630df5deda38a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm0303094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0303094%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DT.%2BA.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DBelvedere%26aufirst%3DS.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5097%26epage%3D5116%26doi%3D10.1021%2Fjm0303094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>â <span class="NLM_lpage">8357</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Ligand+Efficient+Dual+Inhibitors+of+Janus+Kinase+%28JAK%29+and+Histone+Deacetylase+%28HDAC%29+Based+on+Ruxolitinib+and+Vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0ljE_X4PI4TUaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Ligand%2520Efficient%2520Dual%2520Inhibitors%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520and%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Based%2520on%2520Ruxolitinib%2520and%2520Vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>â <span class="NLM_lpage">10846</span>, <span class="refDoi">Â DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+Design+and+Simple+Chemistry+Yield+a+Superior%2C+Neuroprotective+HDAC6+Inhibitor%2C+Tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated Î±-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0ljE_X4PI4TUaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520Design%2520and%2520Simple%2520Chemistry%2520Yield%2520a%2520Superior%252C%2520Neuroprotective%2520HDAC6%2520Inhibitor%252C%2520Tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senkevitch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durum, S.</span></span> <span> </span><span class="NLM_article-title">The Promise of Janus Kinase Inhibitors in the Treatment of Hematological Malignancies</span>. <i>Cytokine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">33</span>â <span class="NLM_lpage">41</span>, <span class="refDoi">Â DOI: 10.1016/j.cyto.2016.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1016%2Fj.cyto.2016.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=28277287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhtLjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2017&pages=33-41&author=E.+Senkevitchauthor=S.+Durum&title=The+Promise+of+Janus+Kinase+Inhibitors+in+the+Treatment+of+Hematological+Malignancies&doi=10.1016%2Fj.cyto.2016.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The promise of Janus kinase inhibitors in the treatment of hematological malignancies</span></div><div class="casAuthors">Senkevitch, Emilee; Durum, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33-41</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAK) are a family of kinases that play an essential role in cytokine signaling and are implicated in the pathogenesis of autoimmune diseases and hematol. malignancies.  As a result, the JAKs have become attractive therapeutic targets.  The discovery of a JAK2 point mutation (JAK2 V617F) as the main cause of polycythemia vera lead to the development and FDA approval of a JAK1/2 inhibitor, ruxolitinib, in 2011.  This review focuses on the various JAK and assocd. components aberrations implicated in myeloproliferative neoplasms, leukemias, and lymphomas.  In addn. to ruxolitinib, other JAK inhibitors are currently being evaluated in clin. trials for treating hematol. malignancies.  The use of JAK inhibitors alone or in combination therapy should be considered as a way to deliver targeted therapy to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWc9geNHOJcbVg90H21EOLACvtfcHk0li6KpoOGAjosg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhtLjF&md5=f3f2928b5d421b285d5cbdb76abab65d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2016.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2016.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DSenkevitch%26aufirst%3DE.%26aulast%3DDurum%26aufirst%3DS.%26atitle%3DThe%2520Promise%2520of%2520Janus%2520Kinase%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Hematological%2520Malignancies%26jtitle%3DCytokine%26date%3D2017%26volume%3D98%26spage%3D33%26epage%3D41%26doi%3D10.1016%2Fj.cyto.2016.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maru, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span> <span> </span><span class="NLM_article-title">Action Mechanisms of Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1543</span>â <span class="NLM_lpage">1549</span>, <span class="refDoi">Â DOI: 10.1111/cas.13062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1111%2Fcas.13062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=27554046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlykur3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=1543-1549&author=Y.+Imaiauthor=Y.+Maruauthor=J.+Tanaka&title=Action+Mechanisms+of+Histone+Deacetylase+Inhibitors+in+the+Treatment+of+Hematological+Malignancies&doi=10.1111%2Fcas.13062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies</span></div><div class="casAuthors">Imai, Yoichi; Maru, Yoshiro; Tanaka, Junji</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1543-1549</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Histone deacetylases (HDACs) critically regulate gene expression by detg. the acetylation status of histones.  In addn., studies have increasingly focused on the activities of HDACs, esp. involving non-histone proteins, and their various biol. effects.  Aberrant HDAC expression obsd. in several kinds of human tumors makes HDACs potential targets for cancer treatment.  Several preclin. studies have suggested that HDAC inhibitors exhibit some efficacy in the treatment of acute myelogenous leukemia (AML) with AML1-ETO, which mediates transcriptional repression through its interaction with a complex including HDAC1.  Recurrent mutations in epigenetic regulators are found in T-cell lymphomas (TCLs), and HDAC inhibitors and hypomethylating agents were shown to act cooperatively in the treatment of TCLs.  Preclin. modeling has suggested that persistent activation of the signal transducer and activator of transcription (STAT) signaling pathway could serve as a useful biomarker of resistance to HDAC inhibitor in patients with cutaneous TCL.  Panobinostat, a pan-HDAC inhibitor, in combination with bortezomib and dexamethasone, has achieved longer progression-free survival in patients with relapsed/refractory multiple myeloma (MM) than the placebo in combination with bortezomib and dexamethasone.  Panobinostat inhibited MM cell growth by degrading protein phosphatase 3 catalytic subunit Î± (PPP3CA), a catalytic subunit of calcineurin.  This degrdn. was suggested to be mediated by the blockade of the chaperone function of heat shock protein 90 (HSP90) due to HDAC6 inhibition.  Aberrant PPP3CA expression in advanced MM indicated a possible correlation between high PPP3CA expression and the pathogenesis of MM.  Furthermore, PPP3CA was suggested as a common target of panobinostat and bortezomib.  This article is protected by copyright.  All rights reserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs8mVwuDgQ9LVg90H21EOLACvtfcHk0li6KpoOGAjosg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlykur3O&md5=d97540b4f33bb4ce6c044717785f9954</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fcas.13062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13062%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DY.%26aulast%3DMaru%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DJ.%26atitle%3DAction%2520Mechanisms%2520of%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Hematological%2520Malignancies%26jtitle%3DCancer%2520Sci.%26date%3D2016%26volume%3D107%26spage%3D1543%26epage%3D1549%26doi%3D10.1111%2Fcas.13062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T.-C.</span></span> <span> </span><span class="NLM_article-title">Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">440</span>â <span class="NLM_lpage">446</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-09-1947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1158%2F0008-5472.CAN-09-1947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=20068163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=440-446&author=T.-C.+Chou&title=Drug+Combination+Studies+and+Their+Synergy+Quantification+Using+the+Chou-Talalay+Method&doi=10.1158%2F0008-5472.CAN-09-1947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method</span></div><div class="casAuthors">Chou, Ting-Chao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">440-446</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  This brief perspective article focuses on the most common errors and pitfalls, as well as the do's and don'ts in drug combination studies, in terms of exptl. design, data acquisition, data interpretation, and computerized simulation.  The Chou-Talalay method for drug combination is based on the median-effect equation, derived from the mass-action law principle, which is the unified theory that provides the common link between single entity and multiple entities, and first order and higher order dynamics.  This general equation encompasses the Michaelis-Menten, Hill, Henderson-Hasselbalch, and Scatchard equations in biochem. and biophysics.  The resulting combination index (CI) theorem of Chou-Talalay offers quant. definition for additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations.  This theory also provides algorithms for automated computer simulation for synergism and/or antagonism at any effect and dose level, as shown in the CI plot and isobologram, resp.  Cancer Res; 70(2); 440-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpECUlVzkYExbVg90H21EOLACvtfcHk0li6KpoOGAjosg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWksA%253D%253D&md5=d0713e60852fc656bc91719ccb27eb1a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-1947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-1947%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DT.-C.%26atitle%3DDrug%2520Combination%2520Studies%2520and%2520Their%2520Synergy%2520Quantification%2520Using%2520the%2520Chou-Talalay%2520Method%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D440%26epage%3D446%26doi%3D10.1158%2F0008-5472.CAN-09-1947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akeno-Stuart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croyle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauf, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaguarnera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitagliano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosios, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span> <span> </span><span class="NLM_article-title">The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression Through Distinct Mechanisms in Medullary Thyroid Cancer Cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">6956</span>â <span class="NLM_lpage">6964</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-06-4605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1158%2F0008-5472.CAN-06-4605" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6956-6964&author=N.+Akeno-Stuartauthor=M.+Croyleauthor=J.+A.+Knaufauthor=R.+Malaguarneraauthor=D.+Vitaglianoauthor=M.+Santoroauthor=C.+Stephanauthor=K.+Grosiosauthor=M.+Wartmannauthor=R.+Cozensauthor=G.+Caravattiauthor=D.+Fabbroauthor=H.+A.+Laneauthor=J.+A.+Fagin&title=The+RET+Kinase+Inhibitor+NVP-AST487+Blocks+Growth+and+Calcitonin+Gene+Expression+Through+Distinct+Mechanisms+in+Medullary+Thyroid+Cancer+Cells&doi=10.1158%2F0008-5472.CAN-06-4605"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4605%26sid%3Dliteratum%253Aachs%26aulast%3DAkeno-Stuart%26aufirst%3DN.%26aulast%3DCroyle%26aufirst%3DM.%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26aulast%3DMalaguarnera%26aufirst%3DR.%26aulast%3DVitagliano%26aufirst%3DD.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DGrosios%26aufirst%3DK.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520RET%2520Kinase%2520Inhibitor%2520NVP-AST487%2520Blocks%2520Growth%2520and%2520Calcitonin%2520Gene%2520Expression%2520Through%2520Distinct%2520Mechanisms%2520in%2520Medullary%2520Thyroid%2520Cancer%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6956%26epage%3D6964%26doi%3D10.1158%2F0008-5472.CAN-06-4605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komrokji, R. S.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive Review of Pacritinib in Myelofibrosis</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2819</span>â <span class="NLM_lpage">2830</span>, <span class="refDoi">Â DOI: 10.2217/fon.15.200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.2217%2Ffon.15.200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=26367195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Glu7zJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=2819-2830&author=S.+Verstovsekauthor=R.+S.+Komrokji&title=A+Comprehensive+Review+of+Pacritinib+in+Myelofibrosis&doi=10.2217%2Ffon.15.200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of pacritinib in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Komrokji, Rami S.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2819-2830</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling, inducing durable redns. in splenomegaly and constitutional symptoms in patients with myelofibrosis.  However, the assocn. of ruxolitinib therapy with myelosuppression indicates the continued need for optimal treatment choices in myelofibrosis.  Pacritinib, a dual JAK2 and FLT3 inhibitor, improves disease-related symptoms and signs with manageable gastrointestinal toxicity in patients with myelofibrosis with splenomegaly and high-risk features, without causing overt myelosuppression, and therefore may provide an important treatment option for a range of patients with myelofibrosis.  This article examines the role of JAK2 and FLT3 signaling in myelofibrosis and provides an overview of the clin. development of pacritinib as a new therapy for myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_XeeN6LrxrVg90H21EOLACvtfcHk0ligGnRIxv4f3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Glu7zJ&md5=7807d824fabe4323f680c388100bd5a0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2217%2Ffon.15.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.15.200%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKomrokji%26aufirst%3DR.%2BS.%26atitle%3DA%2520Comprehensive%2520Review%2520of%2520Pacritinib%2520in%2520Myelofibrosis%26jtitle%3DFuture%2520Oncol.%26date%3D2015%26volume%3D11%26spage%3D2819%26epage%3D2830%26doi%3D10.2217%2Ffon.15.200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamis, A. P.</span></span> <span> </span><span class="NLM_article-title">Ten Years of Anti-Vascular Endothelial Growth Factor Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">385</span>â <span class="NLM_lpage">403</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2015.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1038%2Fnrd.2015.17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=26775688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC28XoslSrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=385-403&author=N.+Ferraraauthor=A.+P.+Adamis&title=Ten+Years+of+Anti-Vascular+Endothelial+Growth+Factor+Therapy&doi=10.1038%2Fnrd.2015.17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Ten years of anti-vascular endothelial growth factor therapy</span></div><div class="casAuthors">Ferrara, Napoleone; Adamis, Anthony P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">385-403</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both normal and pathol. angiogenesis, has revealed innovative therapeutic approaches in oncol. and ophthalmol.  The first VEGFA inhibitor, bevacizumab, was approved by the US Food and Drug Administration in 2004 for the first-line treatment of metastatic colorectal cancer, and the first VEGFA inhibitors in ophthalmol., pegaptanib and ranibizumab, were approved in 2004 and 2006, resp.  To mark this tenth anniversary of anti-VEGFA therapy, we discuss the discovery of VEGFA, the successes and challenges in the development of VEGFA inhibitors and the impact of these agents on the treatment of cancers and ophthalmic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDKy9tn09lEbVg90H21EOLACvtfcHk0ligGnRIxv4f3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XoslSrtA%253D%253D&md5=f9109ce5719fa70fa7da58d69dde39fc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.17%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DAdamis%26aufirst%3DA.%2BP.%26atitle%3DTen%2520Years%2520of%2520Anti-Vascular%2520Endothelial%2520Growth%2520Factor%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D385%26epage%3D403%26doi%3D10.1038%2Fnrd.2015.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boloor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis-Ward, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epperly, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkle, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knick, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudeman, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczyk, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-Dimethyl-2H-Indazol-6-yl)Methylamino]-2-Pyrimidinyl]Amino]-2-Methyl-Benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4632</span>â <span class="NLM_lpage">4640</span>, <span class="refDoi">Â DOI: 10.1021/jm800566m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.+Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-Dimethyl-2H-Indazol-6-yl%29Methylamino%5D-2-Pyrimidinyl%5DAmino%5D-2-Methyl-Benzenesulfonamide+%28Pazopanib%29%2C+a+Novel+and+Potent+Vascular+Endothelial+Growth+Factor+Receptor+Inhibitor&doi=10.1021%2Fjm800566m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor</span></div><div class="casAuthors">Harris, Philip A.; Boloor, Amogh; Cheung, Mui; Kumar, Rakesh; Crosby, Renae M.; Davis-Ward, Ronda G.; Epperly, Andrea H.; Hinkle, Kevin W.; Hunter, Robert N., III; Johnson, Jennifer H.; Knick, Victoria B.; Laudeman, Christopher P.; Luttrell, Deirdre K.; Mook, Robert A.; Nolte, Robert T.; Rudolph, Sharon K.; Szewczyk, Jerzy R.; Truesdale, Anne T.; Veal, James M.; Wang, Liping; Stafford, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4632-4640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy.  We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N4-(2,3-dimethyl-2H-indazol-6-yl)-N4-methyl-N2-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clin. development for renal-cell cancer and other solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIb4UT-IbEi7Vg90H21EOLACvtfcHk0ligGnRIxv4f3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVGrtL4%253D&md5=a8737a6e003a3f6002575b4b96712fc9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-Dimethyl-2H-Indazol-6-yl%2529Methylamino%255D-2-Pyrimidinyl%255DAmino%255D-2-Methyl-Benzenesulfonamide%2520%2528Pazopanib%2529%252C%2520a%2520Novel%2520and%2520Potent%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640%26doi%3D10.1021%2Fjm800566m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span> <span> </span><span class="NLM_article-title">A Novel Irreversible FLT3 Inhibitor, FF-10101, Shows Excellent Efficacy against AML cells with FLT3 Mutations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">426</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1182/blood-2017-05-786657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=10.1182%2Fblood-2017-05-786657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=29187377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=426-438&author=T.+Yamauraauthor=T.+Nakataniauthor=K.+Udaauthor=H.+Oguraauthor=W.+Shinauthor=N.+Kurokawaauthor=K.+Saitoauthor=N.+Fujikawaauthor=T.+Dateauthor=M.+Takasakiauthor=D.+Teradaauthor=A.+Hiraiauthor=A.+Akashiauthor=F.+Chenauthor=Y.+Adachiauthor=Y.+Ishikawaauthor=F.+Hayakawaauthor=S.+Hagiwaraauthor=T.+Naoeauthor=H.+Kiyoi&title=A+Novel+Irreversible+FLT3+Inhibitor%2C+FF-10101%2C+Shows+Excellent+Efficacy+against+AML+cells+with+FLT3+Mutations&doi=10.1182%2Fblood-2017-05-786657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span></div><div class="casAuthors">Yamaura, Takeshi; Nakatani, Toshiyuki; Uda, Ken; Ogura, Hayato; Shin, Wigyon; Kurokawa, Naoya; Saito, Koichi; Fujikawa, Norie; Date, Tomomi; Takasaki, Masaru; Terada, Daisuke; Hirai, Atsushi; Akashi, Akimi; Chen, Fangli; Adachi, Yoshiya; Ishikawa, Yuichi; Hayakawa, Fumihiko; Hagiwara, Shinji; Naoe, Tomoki; Kiyoi, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">426-438</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">An activating mutation of Fms-like tyrosine kinase 3 (FLT3) is the most frequent genetic alteration assocd. with poor prognosis in acute myeloid leukemia (AML).  Although many FLT3 inhibitors have been clin. developed, no first-generation inhibitors have demonstrated clin. efficacy by monotherapy, due to poor pharmacokinetics or unfavorable safety profiles possibly assocd. with low selectivity against FLT3 kinase.  Recently, a selective FLT3 inhibitor, quizartinib, demonstrated favorable outcomes in clin. studies.  However, several resistant mutations emerged during the disease progression.  To overcome these problems, we developed a novel FLT3 inhibitor, FF-10101, designed to possess selective and irreversible FLT3 inhibition.  The co-crystal structure of FLT3 protein bound to FF-10101 revealed the formation of a covalent bond between FF-10101 and the cysteine residue at 695 of FLT3.  The unique binding brought high selectivity and inhibitory activity against FLT3 kinase.  FF-10101 showed potent growth inhibitory effects on human AML cell lines harboring FLT3 internal tandem duplication (FLT3-ITD), MOLM-13, MOLM-14, and MV4-11, and all tested types of mutant FLT3-expressing 32D cells including quizartinib-resistant mutations at D835, Y842, and F691 residues in the FLT3 kinase domain.  In mouse s.c. implantation models, orally administered FF-10101 showed significant growth inhibitory effect on FLT3-ITD-D835Y- and FLT3-ITD-F691L-expressing 32D cells.  Furthermore, FF-10101 potently inhibited growth of primary AML cells harboring either FLT3-ITD or FLT3-D835 mutation in vitro and in vivo.  These results indicate that FF-10101 is a promising agent for the treatment of patients with AML with FLT3 mutations, including the activation loop mutations clin. identified as quizartinib-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNdcWgLnPALVg90H21EOLACvtfcHk0liMajL7hJ68XQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE&md5=6812be0253e393c018ad5f7b47b9ec02</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-786657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-786657%26sid%3Dliteratum%253Aachs%26aulast%3DYamaura%26aufirst%3DT.%26aulast%3DNakatani%26aufirst%3DT.%26aulast%3DUda%26aufirst%3DK.%26aulast%3DOgura%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DW.%26aulast%3DKurokawa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DFujikawa%26aufirst%3DN.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DTakasaki%26aufirst%3DM.%26aulast%3DTerada%26aufirst%3DD.%26aulast%3DHirai%26aufirst%3DA.%26aulast%3DAkashi%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DHagiwara%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DA%2520Novel%2520Irreversible%2520FLT3%2520Inhibitor%252C%2520FF-10101%252C%2520Shows%2520Excellent%2520Efficacy%2520against%2520AML%2520cells%2520with%2520FLT3%2520Mutations%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D426%26epage%3D438%26doi%3D10.1182%2Fblood-2017-05-786657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inks, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3324</span>â <span class="NLM_lpage">3341</span>, <span class="refDoi">Â DOI: 10.1021/jm401877m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401877m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3324-3341&author=X.+Liauthor=E.+S.+Inksauthor=X.+Liauthor=J.+Houauthor=C.+J.+Chouauthor=J.+Zhangauthor=Y.+Jiangauthor=Y.+Zhangauthor=W.+Xu&title=Discovery+of+the+First+N-Hydroxycinnamamide-Based+Histone+Deacetylase+1%2F3+Dual+Inhibitors+with+Potent+Oral+Antitumor+Activity&doi=10.1021%2Fjm401877m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity</span></div><div class="casAuthors">Li, Xiaoyang; Inks, Elizabeth S.; Li, Xiaoguang; Hou, Jinning; Chou, C. James; Zhang, Jian; Jiang, Yuqi; Zhang, Yingjie; Xu, Wenfang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3324-3341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our previous study, we designed and synthesized a novel series of N-hydroxycinnamamide-based histone deacetylase inhibitors (HDACIs), among which the representative compd. I exhibited promising HDACs inhibition and antitumor activity.  In this current study, we report the development of a more potent class of N-hydroxycinnamamide-based HDACIs, using I as lead, among which, compd. II gave IC50 values of 11.8, 498.1, 3.9, 2000.8, 5700.4, 308.2, and 900.4 nM for the inhibition of HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, HDAC6, and HDAC11, exhibiting dual HDAC1/3 selectivity.  Several of these compds. showed excellent growth inhibition in multiple tumor cell lines.  In vivo antitumor assay in U937 xenograft model identified compd. II as a potent, orally active HDACI.  To the best of our knowledge, this work constitutes the first report of oral active N-hydroxycinnamamide-based HDACIs with dual HDAC1/3 selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrBGqCPWPO2rVg90H21EOLACvtfcHk0liMajL7hJ68XQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsr4%253D&md5=4e86a4e7c9fda199bdd3cb12730db1da</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm401877m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401877m%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DInks%26aufirst%3DE.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520the%2520First%2520N-Hydroxycinnamamide-Based%2520Histone%2520Deacetylase%25201%252F3%2520Dual%2520Inhibitors%2520with%2520Potent%2520Oral%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3324%26epage%3D3341%26doi%3D10.1021%2Fjm401877m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IWG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IWG','PDB','5IWG'); return false;">PDB: 5IWG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP','PDB','3FUP'); return false;">PDB: 3FUP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI','PDB','5EEI'); return false;">PDB: 5EEI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X02" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X02','PDB','5X02'); return false;">PDB: 5X02</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3CJG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3CJG','PDB','3CJG'); return false;">PDB: 3CJG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVU','PDB','2IVU'); return false;">PDB: 2IVU</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i131"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01597">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_67582"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01597">10.1021/acs.jmedchem.8b01597</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H NMR, <sup>13</sup>C NMR, and HPLC spectra of all target compounds and supporting figures and tables (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01597/suppl_file/jm8b01597_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula stings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01597/suppl_file/jm8b01597_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01597/suppl_file/jm8b01597_si_001.pdf">jm8b01597_si_001.pdf (3.84 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01597/suppl_file/jm8b01597_si_002.csv">jm8b01597_si_002.csv (3.15 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01597&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01597%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-8" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01597" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                15MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0b87258d22374","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
